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Two roads diverged in a yellow wood,  
And sorry I could not travel both  
And be one traveler, long I stood  
And looked down one as far as I could  
To where it bent in the undergrowth;  
Then took the other, as just as fair,  
And having perhaps the better claim,  
Because it was grassy and wanted wear;  
Though as for that the passing there  
Had worn them really about the same,  
And both that morning equally lay  
In leaves no step had trodden black.  
Oh, I kept the first for another day!  
Yet knowing how way leads on to way,  
I doubted if I should ever come back.  
I shall be telling this with a sigh  
Somewhere ages and ages hence:  
Two roads diverged in a wood, and I—  
I took the one less traveled by,  
And that has made all the difference.  
Robert Frost, The road not taken. 
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CHAPTER 1
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Chapter 1 
INTRODUCTION
 
Phenomenology of schizophrenia 
Schizophrenia is one of the most severe mental illnesses affecting about one percent of the population 
worldwide (Jablensky et al., 1992). The DSM-IV diagnostic criteria include psychotic and negative 
symptomatology severe enough to cause social and occupational dysfunction over a period of at least 
6 months (American Psychiatric Association, 1994). Although psychotic (hallucinations, delusions, 
disorganized speech and behavior) and negative symptoms (eg flattened affect, avolition, social 
withdrawal) are widely recognized as core symptoms of schizophrenia, there also is consensus on the 
marked heterogeneity in clinical presentation of patients diagnosed with schizophrenia (McCormick 
and Flaum, 2005). In psychiatric literature, the clinical manifestations of schizophrenia were usefully 
divided into two main forms first suggested by Robins and Guze (Robins and Guze, 1970), which 
were variably modified in later efforts at subtyping (Carpenter et al., 1999; Crow, 1980; DeQuardo et 
al., 1994; Murray et al., 1992; Sham et al., 1996). These two main forms represent the extremes of the 
‘schizophrenia spectrum’ encountered in clinical settings: an episodic, reactive, non-progressive good 
outcome form with mainly positive symptoms and a chronic, neurodevelopmental form characterized 
by high levels of negative symptoms and cognitive impairments.  
Whereas increased sensitivity to stress is hypothesized to be at the core of the clinical manifestation of 
the first subtype, cognitive impairments represent a major part of the clinical manifestation of the 
latter. Evidence confirmed that sensitivity to stress and cognitive impairments are not correlated in 
patients with psychosis and may even be mutually exclusive (Myin-Germeys et al., 2002; Morrens et 
al., 2007). In line with these findings, a recent Experience Sampling study found significant 
associations between negative symptoms and cognitive impairments and between psychotic symptoms 
and increased stress-sensitivity (Lataster et al., submitted).  
 
The hunt for schizophrenia genes 
Although the heritability of schizophrenia is high (Gottesman, 1991), and promising candidate genes 
involved in neurodevelopment (eg DISC-1, neuregulin, BDNF) and the dopamine system (eg COMT) 
have been identified, genetic association studies have yet to produce consistent results. Reasons for 
these inconsistent results may be found in the heterogeneity of the disorder and in the importance of 
environmental factors in the development of a psychotic disorder in at-risk persons.  
The failure to identify schizophrenia genes through genetic association studies have lead to alternative 
approaches such as studies taking into account gene-environment interaction (Caspi et al., 2005; 
Henquet et al., 2006) and replacement of the dichotomous disorder-outcome with continuous, 
‘endophenotypic’ outcomes. Endophenotypes are quantifiable intermediate factors in the genes-to-
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behaviors pathways which make genetic and biological studies for disease categories more 
manageable (Gottesman and Gould, 2003; Gould and Gottesman, 2005). Five criteria distinguish 
endophenotypes from biological markers: 1. they are associated with the illness in the population, 2. 
they are heritable, 3. they are state independent, 4. they cosegregate with the ilness within families and 
5. an endophenotype identified in probands is found in their unaffected relatives at a higher rate than 
in the general population. Markers that have been put forward as endophenotypes for schizophrenia 
include cognitive impairments, deficits in sensory motor gating, glial cell abnormalities, eye-tracking 
dysfunctions, metabolic disturbances, stress-sensitivity, and others (Gottesman and Gould, 2003; 
Lataster et al., 2007; Thakore, 2007; Turetsky et al., 2007). Possible areas of endophenotypic research 
are 1. the identification of possible endophenotypic markers, 2. the characterization and 
phenomenology of identified endophenotypic markers and 3. the genetic underpinning of identified 
endophenotypic markers. Some of the candidate endophenotypes are already fairly well established (ie 
cognitive impairments, deficits in sensory motor gating, eye-tracking dysfunctions), whereas others 
have been put forward more recently (ie metabolic disturbances, stress-sensitivity).  
This thesis will focus on cognitive impairments, stress-sensitivity and metabolic disturbances, and 
more specifically their characterization, phenomenology and genetic underpinning, as these are 
endophenotypic markers with large and direct impact on treatment and outcome compared to other, 
more subtle endophenotypic markers such as deficits in sensory motor gating and eye-tracking 
dysfunctions.  
 
Cognitive impairment as an endophenotype and its relation to functional outcome 
Cognitive impairments are widely recognized as core features of schizophrenia. A meta-analysis of 
204 studies found relatively large cognitive impairments in memory, attention and executive 
functioning and moderate impairments in vocabulary and visual perceptive skills in 7420 patients with 
schizophrenia compared to 5865 controls (Heinrichs and Zakzanis, 1998). These cognitive 
impairments were also found, to a lesser degree, in first-degree relatives of patients with schizophrenia 
(Finkelstein et al., 1997; Gold, 2004). Given these findings, there is a general consensus that cognitive 
impairment is a useful endophenotype for studying schizophrenia (Gottesman and Gould, 2003; Gould 
and Gottesman, 2005).  
The presence of cognitive impairments in schizophrenia is also reflected in the global intelligence 
measure IQ (Intelligence Quotient), with patients with schizophrenia functioning at a lower intellectual 
level than matched controls (Rabinowitz et al., 2000; Caspi et al., 2003).  
It is accepted that intellectual decline is present long before disease onset (Amminger et al., 2000; 
Caspi et al., 2003; Fuller et al., 2002; Gunnell et al., 2002) and may further progress nearer to disease 
onset (Rabinowitz et al., 2000). However, next to further research into the genetic underpinning of 
cognitive impairments, perhaps the most important area of research currently is whether in 
schizophrenia these impairments further decline or remain relatively stable after disease onset. This 
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discussion was fueled by recent reports showing progressive brain tissue loss (van Haren et al., 2007; 
Cahn et al., 2006), suggesting further decline in intellectual capacities after disease onset. These 
findings seem in line with earlier, cross-sectional studies that found evidence for a progressive decline 
in intellectual abilities (Bilder et al., 1992; Zampera, 1999), but in contrast with recent longitudinal 
studies that showed no further decline (Heaton et al., 2001; Russell et al., 1997) or even a modest 
improvement of (performance) IQ (Gold et al., 1999) or other cognitive measures (Bryson et al., 
2002). Other studies reported a decline in cognitive measures in older schizophrenia patients 
(Friedman et al., 2001; Friedman et al., 2002) whereas cognitive measures in younger patients 
remained stable (Friedman et al., 2001; Hoff et al., 1999; Hoff et al., 2005).  
Part of the explanation for these apparently contrasting findings may be found in the heterogeneity of 
the disorder, with evidence for functional deterioration in some patients, but stability or improvement 
in others (Rabinowitz et al., 2007). These findings are also relevant for the course of cognition in 
schizophrenia, as cognitive impairments were found to strongly correlate with different domains of 
functional outcome and to predict future functional outcomes in a review of studies with a minimum 
follow-up period of 6 months (Green et al, 2004). Remarkably, first episode studies have found little 
evidence for such a prospective association (Bilder et al., 2000; Stirling et al., 2003; Verdoux et al., 
2002).   
 
Stress-sensitivity as an endophenotype for schizophrenia 
A hallmark of studies have provided evidence for the role of stressors such as life events (Bebbington 
et al., 1993; Bebbington et al., 1996; Carr et al., 2000), critical family environments (Bebbington and 
Kuipers, 1994; Butzlaff and Hooley, 1998; Brown et al., 1972), urbanicity (Krabbendam and van Os, 
2005b; van Os et al., 2003) and victimization and childhood trauma (Read et al., 2005; Bebbington et 
al., 2004; Janssen et al., 2004) in the formation of psychotic symptoms.  
Despite highlighting the role of stress in the formation of psychosis, these studies were unable to 
assess stress-sensitivity as a possible endophenotype, as they did not provide quantifiable data on 
individuals’ capacities to cope with stressors, or on the stressors-individual interplay. An interesting 
approach that did allow to quantify moment-to-moment interactions between daily life stressors and 
the individual is the Experience Sampling Method (ESM), which is a structured self-assessment diary 
technique that is used to assess current context, thoughts, mood and symptoms in the flow of daily life 
(Myin-Germeys et al., 2002; Myin-Germeys et al., 2005a; Myin-Germeys et al., 2005b; Myin-
Germeys et al., 2001; Delespaul, 1995). Based on these ESM studies, ‘stress-sensitivity’ was defined 
as the symptomatic response to self-reported daily life stressors, in terms of affective as well as 
psychotic symptoms. As this approach allowed to quantify stressors-individual interplay, it paved the 
way to study stress-sensitivity as a possible endophenotype for schizophrenia.  
These studies have shown that stress-sensitivity is higher in patients with psychosis than in controls, 
with first-degree relatives scoring intermediate (Myin-Germeys et al., 2001; Myin-Germeys et al., 
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2005a). These studies also found evidence for state-independency, as they investigated stress-
sensitivity in remitted patients. Furthermore, evidence was found for cosegregation within families 
(Lataster et al., submitted). Based on these findings, stress-sensitivity has recently been suggested as 
an endophenotype for schizophrenia (Lataster et al., 2007).  
 
Stress-sensitivity, dopamine and COMT 
Whereas there is fairly good evidence that stress-sensitivity is a useful endophenotype for 
schizophrenia, research into the genetic underpinning is lacking. Interestingly, in an ESM study in 
first-degree relatives, increased stress-sensitivity was associated with greater dopaminergic 
responsivity, defined as elevations in plasma homovanillic acid following metabolic perturbation by 2-
deoxy-D-glucose administration, which leads to mild glucoprivation (Myin-Germeys et al., 2005b). As 
these results suggest that increased stress-sensitivity is related to dopaminergic reactivity, an obvious 
candidate gene to investigate the genetic underpinning of stress-sensitivity is the Catechol-O-
Methyltransferase (COMT) gene, since it encodes an enzyme that is critical in the breakdown of 
dopamine, especially in the prefrontal cortex. COMT contains a functional polymorphism that results 
in a change from Valine (Val) to Methionine (Met) (COMTVal158Met) which directly affects enzyme 
function: individuals with the Val/Val genotype have a 40% higher brain COMT enzyme activity than 
individuals with the Met/Met genotype (Chen et al., 2004).  
Evidence suggesting a possible role of COMTVal158Met in increased stress-sensitivity comes from a 
number of general population studies, suggesting that carriers of the Met allele may react stronger to 
stress, by showing that Met/Met subjects display greater stress hormone response to a physical stressor 
(Oswald et al., 2004); greater brain activation in the limbic region to unpleasant (but not pleasant) 
stimuli (Smolka et al., 2005) and greater limbic, hippocampal and prefrontal cortex reactivity to an 
emotional face processing task (Drabant et al., 2006), which suggests that Met carriers may have 
greater reactivity to situations that provoke negative affective states (Drabant et al., 2006). This is in 
keeping with findings from the general population that the Met allele is associated with propensity to 
anxiety (Enoch et al., 2003; Olsson et al., 2005; Stein et al., 2005; Mathew et al., 1980), reduced 
extraversion (Reuter and Hennig, 2005; Stein et al., 2005) and reduced novelty seeking (Reuter and 
Hennig, 2005; Tsai et al., 2004; Benjamin et al., 2000). These findings provide a rationale to study the 
possible role of COMTVal158Met in stress-sensitivity in schizophrenia, especially given its genomic 
localization in the 22q11 region. This region has been identified as one of three loci that had the 
highest likelihood of harbouring schizophrenia-risk genes in a meta-analysis of genome-wide linkage 
scans (Badner and Gershon, 2002) and is deleted in the velo-cardial-facial syndrome, of which the 
psychiatric presentation resembles the clinical syndrome of schizophrenia (Shprintzen et al., 1992; 
Bassett et al., 2003). 
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Metabolic disturbances in schizophrenia: another endophenotype? 
Next to cognitive impairments and stress-sensitivity, the increased vulnerability to develop metabolic 
disturbances such as diabetes and the metabolic syndrome, which comprises abnormalities in glucose 
metabolism, lipid metabolism, obesity and blood pressure, is a third domain of major clinical 
importance in patients with schizophrenia (Newcomer, 2006). Increased central obesity (Thakore et 
al., 2002), decreased insulin sensitivity (Cohn et al., 2006), impaired fasting glucose (Ryan et al., 
2003) and impaired glucose tolerance (Spelman et al., 2007) were shown at increased rates in 
unmedicated first-episode subjects compared to matched controls. Furthermore, high prevalences of 
diabetes and cardiovascular morbidity were reported in unaffected first-degree relatives (Mukherjee et 
al., 1989; De Hert et al., 2006a; Lamberti et al., 2004). A recent study in unmedicated first-episode 
patients, their first-degree relatives and patient-matched controls found impaired glucose tolerance in 
10.5 and 18.2 % in patients and first-degree relatives respectively, compared to 0.0% in controls 
(Spelman et al., 2007). These findings have lead to the identification of the vulnerability for metabolic 
disturbances as another possible endophenotype for schizophrenia (Thakore, 2007), as it is unlikely 
that shared familial environmental factors solely explain the increased rate of metabolic disturbances 
in patients and first-degree relatives.   
Despite these promising findings, it is currently still unclear whether metabolic abnormalities indeed 
are a useful endophenotype for schizophrenia, as the identification as an endophenotype has been 
troubled by the large influence of environmental risk factors. Especially evidence linking the new-
generation, ‘atypical’ antipsychotics with an increased liability to induce diabetes and the metabolic 
syndrome when compared to older, ‘typical’ antipsychotics (Newcomer and Haupt, 2006) has been a 
limiting factor. Furthermore, differences in general risk factors for metabolic disturbances such as age 
and weight have troubled a clear identification of metabolic abnormalities as an endophenotype for 
schizophrenia.  
Much of the research has focused on mapping metabolic disturbances in terms of prevalence and 
incidence and differential effects of antipsychotics and other risk factors, with olanzapine and 
clozapine commonly implicated as most deleterious (Newcomer et al., 2002; Newcomer and Haupt, 
2006). Researchers were prompted to focus on these topics because of the major importance of 
metabolic abnormalities for treatment and outcome, with evidence suggesting a large impact on 
medication adherence (Weiden et al., 2004), quality of  life (Dixon et al., 1999; De Hert et al., 2006b) 
and physical health, with a cardiovascular mortality rate twice as high as in the general population 
(Osby et al., 2000), and a ten-fold higher incidence of diabetic ketoacidosis (Henderson et al., 2007) in 
patients with schizophrenia.  
Despite studies showing the large clinical impact of these abnormalities, the increased scientific 
interest may have lead to increased awaraness among caregivers, but not yet to major changes in 
treatment, with high rates of non-treatment for hypertension, hyperlipidemia and diabetes (Frayne et 
al., 2005; Nasrallah et al., 2006). Furthermore, several guidelines for screening and monitoring 
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metabolic abnormalities were published in recent years, but they have yet to make their way to clinical 
psychiatrists (Wampers et al., 2004; Hanssens et al., 2006). These findings suggest that mapping the 
influence of medications and other risk factors, and investigation and publication of guidelines (ie 
characterization and phenomenology of the candidate endophenotype) can be seen as the most urgent 
topics for research in this area, because of their great clinical relevance. Furthermore, knowledge of 
the influence of medications and other risk factors is also mandatory for the identification, or rejection, 
of metabolic abnormalities as another endophenotype for schizophrenia. For example, within-person 
assessment of the influence of symptomatology on the prevalence of metabolic disturbances (ie 
assessment of ‘state-independency’) is difficult, if not impossible, without knowledge about the 
influence of treatment itself. 
 
Aims of the thesis 
The overall aim of this thesis was to assess the usefulness of 3 candidate endophenotypes for 
schizophrenia: cognitive impairments, stress-sensitivity and metabolic disturbances. This was done by 
evaluating the criteria put forward by Gottesman and Gould (Gottesman and Gould, 2003) and 
subsequently delineating areas of research for each candidate endophenotype with insufficient current 
knowledge in order to evaluate a specific criterion. This lead to the following specific research 
questions: 
 
For cognitive impairments, the aim was to evaluate the course of the global cognitive measure IQ in 
patients who presented with a first episode of psychosis. As the existing data on the course of IQ in 
these patients did not show a clear picture and in part even appeared contradictory as a possible result 
of underlying heterogeneity, a second aim was to investigate possible differences in course of IQ 
resulting from this underlying heterogeneity, with premorbid IQ differentiating between cognitively 
impaired patients and cognitively preserved patients. A third aim was to investigate the relationship 
between IQ measures and functional outcome in this sample of first-episode patients, and especially 
whether underlying heterogeneity, reflected in a differential course of IQ, could also explain the 
intriguing finding in the literature that no clear association was found between cognition at the first 
episode and functional outcome years later, whereas cognition and functional outcome are consistently 
associated in chronic patients. 
 
For stress-sensitivity, the aim was to evaluate whether COMTVal158Met would moderate the psychotic 
and affective reaction to daily life stressors in a sample of patients with psychosis and controls, with 
the anticipation that the Met allele would moderate the effects of stress on negative affect in controls, 
and on negative affect and psychosis in patients with a psychotic disorder. A second aim was to 
evaluate if this possible COMTVal158Met moderation could also be a causal mechanism in the 
development of psychosis, by evaluating whether unaffected first-degree relatives of patients with 
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schizophrenia who share a Met allele have greater concordance of subclinical symptomatology than 
relatives not sharing a Met allele.  
 
For metabolic abnormalities, aims were to assess the comparative adequacy of the widely used 
American Psychiatric Association/American Diabetes Association (APA/ADA) screening guidelines 
for detecting diabetes versus a screening guideline derived from the guidelines of the World Health 
Organization (WHO) in a sample of patients with schizophrenia who were on stable medication for 
more than three months and who were not known with diabetes prior to study entry. By doing so, the 
incidence of new-onset diabetes in this sample could also be evaluated. In a second study, 3-month 
incidence rates of new-onset diabetes and early changes in glucose metabolism were evaluated, 
including differential effects of individual antipsychotics, in a sample of patients who were newly 
initiated on antipsychotic medication. Furthermore, given the genetic overlap between schizophrenia 
and bipolar disorder and the analogous use of atypical antipsychotics as antimanic and mood-
stabilizing medication, the prevalence of diabetes and metabolic syndrome was also assessed in a 
sample of patients diagnosed with bipolar disorder. 
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Abstract 
The aim of the present study was to examine the longitudinal course of IQ and its heterogeneity in 
patients with schizophrenia, from the perspective of the two main “subtypes” of schizophrenia 
described in the literature: progressive cognitive deficit versus cognitive stabilisation or recovery.  
Premorbid IQ scores and WAIS IQ scores of 100 first onset patients were obtained at first 
hospitalization (T1) and after ten years (T2). Significant changes in IQ over time were found, 
representing i) at T1, a deterioration compared to premorbid intelligence (B= -6.3, 95% CI –9.5-  -3.0, 
p<0.0001), followed by ii) a recovery at T2 where IQ matched premorbid intelligence again (B= 0.5, 
95% CI –3.1- 4.0, p=0.79). In addition, a significant interaction was found between course of IQ over 
time and estimated premorbid IQ, demonstrating that subjects with lower premorbid IQ levels 
remained stable over time whereas in individuals with higher premorbid IQ levels a pattern of 
deterioration was evident at T1, followed by a recovery up to premorbid level at T2. The data confirm 
the importance of estimated premorbid IQ as an indicator of the longitudinal course of cognitive 
functioning in patients with schizophrenia and add evidence to the hypothesis of heterogeneity or 
“subtypes” of schizophrenia. The data, however, do not confirm the existence of progressive 
deterioration of cognitive functioning. Rather, catching up of cognitive function later in the course of 
the illness may take place in those whose deficits become apparent in the early phases of illness, 
whereas those with the most severe premorbid impairments remain stable. 
 
Keywords: Schizophrenia, Subtypes, Intelligence, Premorbid 
 
 27
Introduction 
Cognitive symptoms have been recognized as core symptoms of schizophrenia since the times of 
Kraepelin (Kraepelin, 1919) and Bleuler (Bleuler, 1950). There is a general consensus that patients 
diagnosed with schizophrenia function at a lower intellectual level than matched control persons 
(Caspi et al., 2003; David, 1998; Rabinowitz et al., 2000). Several longitudinal studies have shown 
that intellectual decline is present long before disease onset (Amminger et al., 2000; Caspi et al., 2003; 
Fuller et al., 2002; Gunnell et al., 2002). Moreover, this intellectual impairment may further decline 
nearer to disease onset (Rabinowitz et al., 2000). The course after disease onset, however, is much 
debated. Earlier, cross-sectional studies suggested a progressive decline in intellectual abilities (Bilder 
et al., 1992; Zampera, 1999), but this view was not supported in recent longitudinal studies on the 
course of IQ in schizophrenia, showing no further decline in IQ after onset  (Heaton et al., 2001; 
Russell et al., 1997) or even a modest improvement of (performance) IQ (Gold et al., 1999) or other 
cognitive measures (Bryson et al., 2002). In addition, some studies reported a decline in cognitive 
measures in older schizophrenia patients (Friedman et al., 2001; Friedman et al., 2002) whereas 
cognitive measures in younger patients remained stable (Friedman et al., 2001; Hoff et al., 1999; Hoff 
et al., 2005). Apart from methodological issues, diagnostic issues may underlie the controversy 
regarding course of IQ in patients diagnosed with schizophrenia. Although the clinical utility of the 
concept of schizophrenia is generally considered satisfactory, there is a broad consensus that there is 
underlying heterogeneity in etiology and pathophysiology in patients diagnosed with schizophrenia, 
complicating data collection and interpretation of IQ scores and other measures (McCormick and 
Flaum, 2005). As first suggested by Robins and Guze (Robins and Guze, 1970), and later variably 
modified in later efforts at subtyping (Carpenter et al., 1999; Crow, 1980; DeQuardo et al., 1994; 
Murray et al., 1992; Sham et al., 1996), the clinical manifestations of schizophrenia can be usefully 
divided into two main forms, that represent the extremes of the ‘schizophrenia spectrum’ encountered 
in clinical settings: an episodic, reactive, non-progressive good outcome form with mainly positive 
symptoms and a chronic, neurodevelopmental form characterized by high levels of negative 
symptoms, cognitive impairments and progression. Because intellectual functioning is hypothesized to 
be (progressively) impaired in the poor outcome group but not necessarily in the other, the analytical 
strategy of using the two subtypes as a starting point in the investigation of the course of IQ may be 
productive. The validity for this approach is suggested by recent research providing evidence that in 
clinical psychotic syndromes, different underlying mechanisms may result in different clinical 
manifestations (Myin-Germeys et al., 2002; Myin-Germeys et al., 2003; Myin-Germeys et al., 2004). 
For example, the episodic subtype may be characterized by hyperdopaminergic reactivity reflected in 
good responses to antipsychotics (Garver et al., 2000) and increased stress-sensitivity (Myin-Germeys 
et al., 2005). Interestingly, excessive mesocortical dopaminergic stimulation has been associated with 
increased long-term potentiation (LTP) of hippocampal-prefrontal synapses, a classic measure of 
neuroplasticity (Jay et al., 2004). Therefore, it is attractive to hypothesize that there is a possibility for 
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recovery or change of IQ, as a consequence of increased neuroplasticity in this group. The underlying 
pathology of the neurodevelopmental subtype, on the other hand, is thought to be represented in 
particular in structural brain abnormalities (Garver et al., 2000; Lieberman et al., 1996) secondary to 
alterations already present in early life (Murray et al., 1992). According to this view, neurocognitive 
impairments are present long before the clinical characteristics of the disorder become apparent, and 
show a stable or deteriorating course of IQ over time.  
Classifying patient in subtypes early in the course of the illness is a challenging task. A classification 
based on symptomatology is problematic, because of the interrelationship of positive and negative 
symptoms in the acute phase of the illness (Lieberman et al., 1996). Premorbid IQ, on the other hand, 
can be reliably determined and there is strong evidence that low premorbid IQ is associated with 
structural brain abnormalities, cognitive impairments and negative symptoms, all features of the 
neurodevelopmental type (Antonova et al., 2004; Antonova et al., 2005; Tamminga et al., 1998).  
The current study investigated the course of IQ in a 10-year follow-up study in a sample of 100 first 
episode patients with a psychotic disorder. In addition, given the evidence for two different subtypes 
representing the extremes of the spectrum seen in clinical settings, it was hypothesized that estimated 
premorbid IQ would moderate the course of IQ in patients with schizophrenia.  
 
Methods 
Subjects  
One hundred consecutive first episode patients admitted with a psychotic disorder, recruited at the 
university psychiatric hospital St. Jozef in Kortenberg (Belgium), which serves a catchment area of 
approximately 250 000, were followed for an average period of 10.7 years (range 6-14 years; SD=1.6). 
Of these 100 patients, 70 were male and 30 were female. They were informed about the purpose of the 
study and provided written informed consent according to local ethical directives.  
 
Assessment of premorbid intellectual functioning (T0) 
Several methods to estimate premorbid IQ are available, and are typically based on 1) demographic 
characteristics (such as educational achievement) or on 2) current reading ability. Both perspectives 
have proven their value in the general population (Russell et al., 2000). For the population of patients 
diagnosed with schizophrenia, however, demographic characteristics such as educational achievement 
are likely to be influenced by the developmental impairments and prodromal phase of the illness, 
resulting in an underestimation of premorbid IQ. Evidence suggests that an assessment of premorbid 
IQ in patients with schizophrenia using a method that uses reading ability is less sensitive to such 
underestimation, as reading ability is usually well maintained in schizophrenia (Nelson et al., 1990) 
and is not affected by the acute phase of the illness (O'Carroll et al., 1992). Therefore, the ‘Vragenlijst 
voor Intellectuele Status’ (VIS), an algorithm to assess premorbid IQ based on reading ability, was 
chosen as the indicator for premorbid IQ (Mas, 1979). 
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Premorbid IQ based on Highest Attained Educational Level (HAEL IQ) was also assessed, as a 
significant difference between VIS IQ, based on reading ability, and the HAEL IQ estimate of 
premorbid IQ, based on educational achievement, may serve as evidence for a deterioration in 
intellectual functioning during adolescence (Stinissen, 1987).  
 
Because VIS IQ was considered to be the most reliable assessment of premorbid IQ, it was chosen as 
the indicator for premorbid level in all analyses. Since VIS IQ is a single value, it was used as the 
premorbid value of both Total, Verbal and Performal IQ. HAEL IQ was only computed for the 
comparison with VIS IQ, in order to assess the possibility of deterioration of intellectual functioning 
during adolescence.  
 
Assessment of intellectual functioning at first hospitalisation (T1) and follow-up (T2) 
Intellectual functioning of the patients was assessed during their first hospitalization (T1) for 
psychosis, as soon as patients had achieved clinical stability. After a mean follow-up period of 10.7 
years (range 6-14 years; SD=1.6), patients were invited again for a new assessment of intellectual 
functioning (T2). The Flemish translation and norms of the Wechsler Adult Intelligence Score (WAIS) 
were used to assess Total IQ, Verbal IQ and Performance IQ (Stinissen et al., 1970a). None of the 
patients had a WAIS IQ testing between T1 and T2.
Study time line and assessment of diagnosis 
At T1, WAIS IQ was assessed. After a mean follow-up period of 10.7 years (T2; range 6-14 years), 
patients were invited to be interviewed for a formal assessment of diagnosis according to DSM-IV 
criteria, a WAIS IQ assessment, a VIS premorbid IQ assessment and a PANSS rating. All assessments 
were conducted by a trained psychologist.  
The patients who were interviewed at T2 (n=53) had diagnoses of schizophrenia (n=43), 
schizoaffective disorder (n=8) and schizophreniform disorder (n=2). For the remainder of the patients, 
diagnoses were assessed by contacting their psychiatrist (n=15), their family (n=14) or by chart review 
(n=18). These patients had clinical diagnoses of schizophrenia (n=36), schizoaffective (n=6) or 
schizophreniform (n=4) disorder and unspecified psychosis (n=1). As the present study focussed on 
etiological specificity, patients with a T2 diagnosis of schizophreniform disorder or psychosis not 
otherwise specified were excluded from the analyses. 
Analysis 
The IQ data are hierarchically structured: multiple assessments of IQ (level 1) are nested within 
subjects (level 2). Since observations from the same subject are more similar than observations from 
different subjects, conventional regression techniques are not suited for analyzing these data. 
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Therefore, multilevel linear random regression analyses were conducted, taking into account the 
variance components at two levels (time-point level and subject level)(Goldstein, 1987). Data were 
analyzed with the XTREG module in Stata.  
In order to investigate statistically significant changes in IQ over time, regression analyses were 
conducted with a categorical variable time (with T0 as reference category) as independent variable and 
IQ as dependent variable. Separate analyses were conducted for Total IQ, Verbal IQ and Performance 
IQ.  
Secondly, IQ was regressed on the interaction “time*VIS IQ” in order to investigate whether 
premorbid IQ moderated the IQ changes over time.  
Finally, the association between VIS IQ and HAEL IQ was estimated using multilevel regression 
analysis.  
Main effects and interactions were assessed with Wald test (Clayton and Hills, 1993).  
 
Results 
Subjects
The mean age of the patients was 23.2 years (SD=4.0) at the start of their first hospitalization  and 33.8 
years (SD=4.9) at follow-up. At T1 some (n=20) patients could not be tested with a WAIS IQ 
assessment because they remained floridly psychotic or left the hospital unplanned. No large or 
significant differences in gender or premorbid IQ were found between these patients and those who 
could be tested at T1. For age, a suggestive difference was found (table 1).  
At T2, 52 patients could not be retested with a WAIS IQ assessment. Of this group, 11 patients had 
committed suicide. The remaining patients (n=41) could not be reached at the time of follow-up or did 
not consent to be tested again. No large or significant differences in gender, age or premorbid IQ were 
found between the patients who could be retested at T2 and those lost to follow-up (table 2).  
Fifty-three patients were interviewed at T2. They had a mean total PANSS score of 71.5 (SD=17.3), a 
mean positive PANSS score of 17.5 (SD=6.1) and a mean negative PANSS score of 17.4 (SD=5.9). Of 
these 53, 48 also consented to do a WAIS IQ testing, which could be completed in 45 patients. In 5 of 
the 45 patients with a formal diagnostic assessment and a complete T2 WAIS testing, no VIS data 
could be obtained, yielding a sample of 40 patients with a VIS IQ and a T2 WAIS assessment. 
Another 19 patients were willing to fill in questionnaires on demographic variables and do a VIS 
testing, but refused a formal interview with a diagnostic assessment, a PANSS rating and WAIS IQ 
testing, so that for 59 patients a VIS IQ assessment was obtained. Of the 40 patients with complete 
VIS and T2 WAIS IQ data, there were no T1 WAIS IQ data for 10 patients, yielding a sample of 30 
patients with complete T0, T1, T2 IQ data and a formal diagnostic assessment. An overview of the 
characteristics of the available IQ measures is presented in table 3.  
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 Course of IQ 
The multilevel regression analysis revealed significant differences over time for Total IQ. At T1, there 
was a significant deterioration compared to T0 (B= -6.3, 95% CI –9.5-  -3.0, p<0.0001), which was no 
longer present at T2 (B= 0.5, 95% CI –3.1- 4.0, p=0.79). A similar pattern was found for Verbal IQ 
(T0-T1: B= -3.7, 95% CI –6.9- -0.6, p=0.02; T0-T2: B= -0.03, 95% CI –3.4- 3.3, p=0.99), and for 
Performance IQ (T0-T1: B= -9.1, 95% CI –12.9- -5.2, p<0.0001; T0-T2: B= -1.2, 95% CI –5.4- 3.0, 
p=0.57).  
Furthermore, a significant interaction was found between course of Total IQ and VIS IQ (Ȥ2=7.6, 
p=0.02). To clarify the nature of the interaction between course of IQ and VIS IQ, stratified analyses 
were conducted with a low and high VIS IQ subgroup (dichotomized at the 50th percentile). Patients in 
the low IQ group (VIS IQ<108) were considered to be more likely neurodevelopmentally 
compromised (compatible with the ‘neurodevelopmental subtype’), whereas the patients in the high IQ 
group (VIS IQ108) were considered to have a preserved premorbid IQ (compatible with the ‘episodic 
subtype’).  
In the low IQ subgroup (mean=98, SD=2.2),  no significant differences over time were found in Total 
IQ (T0-T1: B= -2.2, 95% CI –7.2- 2.8, p=0.39; T0-T2: B= 3.1, 95% CI –2.5- 8.7, p=0.28), Verbal IQ 
(T0-T1: B= -0.7, 95% CI –5.6- 4.1, p=0.77; T0-T2: B= 3.0, 95% CI –2.3- 8.4, p=0.27), and 
Performance IQ (T0-T1: B= -3.3, 95% CI –8.9- 2.2, p=0.23; T0-T2: B= 2.4, 95% CI –3.6- 8.4, 
p=0.44).  
In the high IQ subgroup (mean=119, SD=1.8), multilevel regression revealed significant differences 
over time, consisting of a deterioration from premorbid level followed by a restoration of IQ up to 
premorbid level for Total IQ (T0-T1: B= -10.3, 95% CI –14.3- -6.2, p<0.0001; T0-T2: B= -1.1, 95% 
CI –5.2- 3.0, p=0.61), Verbal IQ (T0-T1: B= -7.2, 95% CI –11.0- -3.3, p<0.0001; T0-T2: B= -1.1, 
95% CI –4.9- 2.8, p=0.59) and Performance IQ (T0-T1: B= -14.5, 95% CI –19.9- -9.1, p<0.0001; T0-
T2: B= -4.2, 95% CI –9.6- 1.3, p=0.14). An overview of mean IQ scores for the low and high IQ 
subgroups at T0, T1 and T2 is given in table 4. 
 Assessments of premorbid IQ 
For the whole patient group, HAEL IQ scores were significantly lower than VIS IQ scores (B= -4.8, 
95% CI –7.1- 2.4, p<0.0001). This finding was confirmed in the high IQ group (B= -9.8, 95% CI –
12.1- -7.5, p<0.0001), but not in the low IQ group (B= 1.2, 95% CI –2.0- 4.4, p=0.48).   
 
Discussion 
This paper described the longitudinal course of IQ in first episode patients diagnosed with 
schizophrenia. After ten years follow-up, there was no evidence for a deterioration of IQ. The 
hypothesis that estimated premorbid IQ would moderate the course of IQ was confirmed. 
Dichotomization revealed that in the high IQ group, which was hypothesized to reflect the ‘episodic 
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subtype’, IQ measures did not remain stable over the follow-up period. A significant deterioration at 
the first hospitalization was seen, followed by an improvement up to premorbid level. In the low IQ 
group, which was hypothesized to reflect the ‘neurodevelopmental subtype’ a stable course of IQ was 
found. 
 
Findings
 To our knowledge, this paper is the first study to include both measures of premorbid IQ, IQ at first 
hospitalization and at ten years follow-up. The deterioration preceding the first hospitalization is in 
line with previous research (Amminger et al., 2000; Caspi et al., 2003; Fuller et al., 2002; Gunnell et 
al., 2002; Rabinowitz et al., 2000; Reichenberg et al., 2005), as is the global stability of cognitive 
measures over the course of the illness (Rund, 1998; Kurtz, 2005). The possibility of improvement 
following the first episode, however, has not received much attention so far. Several studies reported a 
modest improvement in cognitive measures, typically in first episode patients (Addington et al., 2005; 
Gold et al., 1999; Hoff et al., 1999). Likewise, in the study of Heaton et al (Heaton et al., 2001), 
patients with a long duration of illness (mean, 24 years at baseline) showed an improvement of 
neurocognition that was as large as controls, possibly due to learning effects. Patients with a short 
duration of illness (mean, 2 years at baseline), however, showed a significantly larger improvement. 
These findings support the notion that there is an actual improvement of cognition after the first 
episode, that is not just due to learning effects. In the present study, an improvement was only seen in 
the high IQ group. These findings suggest that patients with higher premorbid IQ levels are likely to 
display higher levels of neuroplasticity than patients with lower premorbid IQ levels.  
There was no significant improvement in the low IQ group after the first hospitalization, as there was 
also no deterioration from premorbid level. The absence of significant differences in VIS IQ, HAEL 
IQ and WAIS IQ scores at the first hospitalization and at follow-up suggest that in this group, 
cognitive deficits are present long before illness onset and remain stable in the years preceding the first 
psychotic episode, and afterwards. This indeed suggests a ‘neurodevelopmental’ type of illness, 
although there was no suggestion of progression over the first ten years of the illness.  
 
Moderation of course of IQ by VIS IQ: evidence for ‘subtypes’? 
The finding that the course of IQ was moderated by VIS IQ, with a stable course in the low VIS IQ 
group and a typical pattern of deterioration and subsequent recovery in the high VIS IQ group is 
interesting, and could be compatible with a more neurodevelopmental type of illness in the low VIS 
IQ group and a more episodic type of illness in the high VIS IQ group. Nevertheless, some remarks 
concerning this interpretation can be made. 
First, it could be argued that the lack of intellectual deterioration of the low IQ group is the 
consequence of an error in the operationalization of the ‘neurodevelopmental subtype’, and that when 
conceptualized differently, there would have been a progressive intellectual deterioration. However, 
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neither in the overall sample, nor in the low or high IQ subsamples was there any suggestion of 
intellectual deterioration, which argues against this explanation. 
Second, the reliability of the classification in ‘subtypes’ largely depends on the reliability of the VIS 
estimate of premorbid IQ. The VIS IQ score, taken at T2, did not differ significantly from the T2 
WAIS Verbal IQ score. Furthermore, the VIS IQ score, although statistically significantly different, 
was only moderately higher than the T1 WAIS Verbal IQ score (3.7 IQ points), in contrast to the T1 
WAIS Total (6.3 IQ points) and Performance IQ (9.1 IQ points) scores. This underscores the 
reliability of verbal IQ measures such as the VIS to estimate premorbid IQ, which is supported by the 
findings of Russell and colleagues  (Russell et al., 2000), who showed that in schizophrenia the 
Vocubulary subscale of the WAIS was even a more reliable estimate of premorbid IQ than the NART.  
Third, one could argue that the obtained VIS IQ scores are relatively high and that subjects scoring 
well below the 50th percentile may have intellectual capacities that are too high to be considered 
neurodevelopmentally comprised. However, the standardization of the WAIS for Belgium was done in 
1970. Since then, no restandardization was done until 1997, with the introduction of WAIS-III 
(Wechsler, 1997), meaning that for the WAIS IQ scores of the current sample, the Flynn-effect was 
not taken into account. This phenomenon consists of a mean estimated rise in IQ scores of 15 IQ 
points per generation (30 years) (Flynn, 1987). This effect was present in every country for which IQ 
follow-up data were available, including Belgium. Therefore, at the time this cohort had their first-
episode WAIS IQ assessment (1985-1989), the average IQ in the general population in Belgium can 
be estimated at around 108 (15 to 19 years since standardization in 1970, times 0.5 IQ points gained 
per year), suggesting that the VIS IQ score of 108 actually represents an average score that can be used 
to differentiate between low and high IQ subjects. It is important to notice that the Flynn effect 
concerns a rise in average IQ when comparing generations, but does not apply to within-subject test-
retest reliability. 
  
Regression to the mean and bottom effect 
Alternative explanations for the distinct courses of IQ in subgroups can be postulated. It could be 
argued that the decrease in the high IQ group results from a regression to the mean. However, the 
recovery at T2 in the high IQ group cannot be explained by this mechanism. In addition, the 
significant difference between VIS IQ and HAEL IQ in the high IQ group provides evidence that a 
functional and intellectual deterioration takes place in the years preceding the first hospitalization in 
the high IQ group. These findings, together with the possibility of increased neuroplasticity in this 
group, strengthen the hypothesis that the difference in rate of deterioration between the high and the 
low VIS IQ subgroups is not solely due to the statistical effect of a regression to the mean in the high 
IQ group. An alternative explanation could be that the low IQ group showed no deterioration of IQ at 
T1 due to a bottom effect. This, however, seems unlikely since the mean VIS IQ in the low IQ group 
was still 98, leaving enough range to measure a possible deterioration in this group.  
 34 
The differential improvement of Total and Performance IQ scores depending on estimated premorbid 
IQ could also reflect differences in learning potential. Patients with a higher premorbid IQ may gain 
more from practice, resulting in a larger improvement in IQ from T1 to T2. However, the relative 
stability of verbal IQ measures over the course of the follow-up period (VIS IQ, WAIS Verbal IQ at 
T1 and T2) argue against the simple attribution of the improvement of Total and Performance IQ at T2 
to practice effects. This is strengthened by the finding that the VIS IQ scores did not differ 
significantly from the T2 WAIS IQ scores. As the VIS was taken only once, at T2, this equivalence 
argues against the presence of differential learning effects. Furthermore, WAIS IQ scores have been 
shown to have a good test-retest stability (Shatz, 1981). 
Methodological issues 
The present study has some limitations. First, not all patients could be tested at their first 
hospitalization (T1) because they left the hospital unplanned or were too psychotic for an IQ test. 
Furthermore, a substantial group were lost to follow-up after ten years (T2). However, no large or 
significant differences in gender, age or premorbid IQ were found between the study patients and the 
patients who could not be tested, both at T1 and at T2. Second, the mean premorbid and follow-up IQ 
scores of 109 suggest that the current sample of first onset patients with schizophrenia may not be 
representative for patients with schizophrenia in general, since patients diagnosed with schizophrenia 
were reported to function at a below-average intellectual level in several studies (Caspi et al., 2003; 
David, 1998; Rabinowitz et al., 2000). However, the high premorbid IQ scores can probably be 
explained by the Flynn effect. In addition, the high premorbid IQ scores probably also reflect the 
particular demographic characteristics of the catchment area, as this catchment area mainly serves the 
area around the city of Leuven. This is a small city with approximately 90 000 inhabitants, that 
harbours the largest university of Belgium with around 30 000 students. As a result, 47 of the 100 
first-episode patients were students, thus considerably raising the mean IQ of our cohort. In line with 
this explanation is the observation that the VIS IQ score was equivalent to the T2 WAIS IQ scores. 
This argues against the explanation that the VIS IQ score is high because it is a single test, since it was 
equivalent to the WAIS estimate of IQ that is based on a wider variety of subtests. Fourth, premorbid 
IQ scores were estimated using VIS IQ scores. The use of VIS IQ to estimate premorbid IQ could be 
less reliable than actually measured WAIS IQ scores. However, as the collection of actually measured 
premorbid WAIS IQ scores would require extremely large cohorts because of the low incidence of 
schizophrenia, the current approach provides an attractive alternative to gather insight into the course 
of cognition in this very important phase. Furthermore, the WAIS IQ scores after ten years follow-up 
add to the credibility of the VIS premorbid IQ estimate; no large or significant differences were found 
between premorbid IQ scores and assessments of IQ at ten year follow-up, both for the low and the 
high premorbid IQ group. Fifth, the current study only included IQ measures, but did not assess 
measures of executive functioning and episodic memory.  
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Conclusion
In conclusion, the distinct trajectories of IQ in our patient sample could be compatible with the general 
notion of an episodic and a neurodevelopmental subtype in schizophrenia patients, as first proposed by 
Robins and Guze (Robins and Guze, 1970). Our data highlight the importance and clinical relevance 
of estimated premorbid IQ as an indicator for the subsequent course of IQ and thus, the distinction 
between ‘subtypes’. The possibility of improvement of cognitive measures after the first episode, and 
the factors determining this recovery, certainly need further investigation.  
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Table 1. Characteristics of patients tested and not tested at first hospitalisation (T1). 
 
 Patients tested Patients not tested Comparison 
Gender (M/F) 57/23 13/7 p=0.59 
Age 22.8 (0.4) 
N=80 
24.7 (1.1) 
N=20 
p=0.06 
Premorbid IQ 108.2 (1.8) 
N=49 
111.7 (3.9) 
N=10 
p=0.41 
 
 
Table 2. Characteristics of patients tested and not tested at follow-up (T2). 
 
 Patients tested Patients not tested Comparison 
Gender (M/F) 30/15 40/15 p=0.51 
Age 23.6 (0.6) 
N=45 
22.9 (0.5) 
N=55 
p=0.35 
Premorbid IQ 110.2 (1.9) 
N=40 
105.7 (2.8) 
N=19 
p=0.19 
 
 
Table 3. Overview of premorbid intelligence and WAIS Total, Verbal and Performance IQ at first hospitalization 
and at follow up. 
 
Variable N Mean SD Min Max 
Premorbid IQ (T0)      
Educational 99 103.19 9.38 77 115 
VIS 59 108.76 12.23 82 134 
First hospitalization (T1)      
Verbal 80 103.95 13.98 57 133 
Performance 80 99.10 16.59 60 136 
Total 80 101.59 15.06 54 132 
Follow-Up (T2)      
Verbal 47 107.65 18.29 58 141 
Performance 48 107.57 17.83 66 140 
Total 45 109.33 17.18 66 141 
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Table 4. Mean IQ scores for the low and high IQ subgroups at T0, T1 and T2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 T0 T1 T2 
Total IQ 
high IQ subgroup 
119.0 109.0 118.7 
Total IQ 
low IQ subgroup 
98.3 96.4 101.7 
Verbal IQ  
high IQ subgroup 
119.0 111.8 118.0 
Verbal IQ  
low IQ subgroup 
98.3 98.2 101.8 
Performance IQ  
high IQ subgroup 
119.9 104.8 115.4 
Performance IQ  
low IQ subgroup 
99.0 95.8 100.7 
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Abstract 
Introduction: The presence of a prospective association between cognition and functional outcome 
in first episode patients with schizophrenia is much debated. Method: Associations between 
Intelligence Quotient (IQ) measures and functional outcome were assessed at the first hospitalization 
and after ten years follow-up. Results: Functional outcome was associated with estimated premorbid 
IQ and IQ at ten-year follow-up, but not with IQ assessed at first hospitalization. Conclusion: The 
presence of a prospective as well as a cross-sectional relationship of the global cognitive measure IQ 
with 10-year functional outcome could be established. However, assessing associations between 
cognitive measures assessed at first hospitalization and subsequent functional outcome, can give 
inconclusive results due to non-uniform intellectual deterioration from premorbid level in the period 
preceding the first hospitalization.  
 
Keywords: Intelligence, Schizophrenia, Outcomes Research 
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Introduction 
It is generally accepted that cognitive measures are associated with functional outcome in patients 
diagnosed with schizophrenia (Green et al., 2000). However, the evidence regarding the direction of 
effects over time remains conflicting. Although there is considerable evidence suggesting that baseline 
cognitive functioning predicts later functional outcome in chronic patients (Green et al., 2004), first 
episode studies have found no evidence for such a prospective association (Bilder et al., 2000; Stirling 
et al., 2003; Verdoux et al., 2002). The reason first episode studies failed to confirm an association 
between cognitive measures and outcome may be related to evidence suggesting that premorbid 
cognition deteriorates in the period prior to the first episode (Rabinowitz et al., 2000a; Reichenberg et 
al., 2005; Jones et al., 1994; Fuller et al., 2002), but that the level of deterioration is not the same for 
high and low premorbid IQ patients. Thus, a recent ten-year follow-up study (van Winkel et al., 2006), 
suggested that the decline in cognition prior to the first episode, expressed as IQ, was particularly 
noticeable in individuals with high estimated premorbid IQ, with subsequent recovery of IQ over the 
next ten years. In individuals with low estimated premorbid IQ, however, IQ levels were stable in the 
period prior to the first episode and at ten-year follow-up (see figure 1). As depicted in figure 1, the 
contrast in IQ between individuals with low and high estimated premorbid IQ is less informative at the 
first episode than it is in the premorbid period and at long-term follow-up, so that the power to detect 
associated differences in outcome is reduced.  
Given this heterogeneity in course of IQ, it is attractive to hypothesize that premorbid IQ and IQ at 
long-term follow-up may be better predictors of functional outcome than IQ assessed at the first 
hospitalization. 
The current study investigated the association between estimated premorbid IQ, IQ at first 
hospitalization and IQ at ten year follow-up on the one hand, and subsequent functional outcome on 
the other in a 10-year follow-up study of a sample of 100 first episode patients diagnosed with 
schizophrenia.  
Methods 
Measures
One-hundred consecutive first-episode patients from the university psychiatric hospital in Kortenberg 
were followed for an average period of 10.7 years (SD=1.6). Of these 100 patients, 70 were male and 
30 were female. Since a diagnosis of schizophrenia implicates a certain duration and a certain severity, 
it is not always possible to diagnose patients accurately at their first episode of psychosis, as is widely 
recognised. It was chosen not to include only patients who could already be diagnosed with 
schizophrenia at their first episode of psychosis, since this approach would predominantly include 
patients with early negative and/or deficitary symptoms. Instead, the recruited subjects were 
consecutively admitted patients from the rehabilitation ward for first-episode patients with psychosis. 
As an admission on the rehabilitation ward was considered necessary for recruited patients, it was 
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ascertained that their first episode of psychosis had relatively large implications for psychosocial 
functioning (severity criterion), over a time-period of at least several months (time criterion), 
indicating that over time, the vast majority of these patients was assumed to be diagnosed with 
schizophrenia. Diagnoses were evaluated at follow-up, and all patients that did not meet DSM-IV 
criteria of schizophrenia or schizoaffective disorder at this assessment were excluded from the 
analyses. All patients were informed about the purpose of the study and provided written informed 
consent. 
Intellectual functioning was assessed at the first hospitalization (T1) using the Flemish translation and 
norms of the full scale Wechsler Adult Intelligence Score (WAIS) (Stinissen et al., 1970). The T1 IQ 
was assessed when patients achieved clinical stability, indicating i) that patients had had an adequate 
treatment for their psychotic symptoms, meaning that they had a remission of psychotic symptoms, or 
in case of non-remission, that large improvements in psychotic symptoms were no longer anticipated, 
and ii) that patients were able to leave the hospital independently without danger (for example during 
the weekends). After a mean follow-up period of 10.7 years (T2; range 6-14 years; SD=1.6), patients 
were invited to be interviewed for a formal assessment of (lifetime) diagnosis according to DSM-IV 
criteria, a WAIS IQ assessment and an assessment of estimated premorbid IQ. All assessments were 
conducted by a trained psychologist. None of the patients had a WAIS IQ testing between T1 and T2.
Premorbid IQ (T0) was assessed using the Vragenlijst voor Intellectuele Status (VIS), an algorithm to 
assess premorbid IQ based on reading ability (Mas, 1979). The use and validity of the VIS, as well as 
an extensive description of the methodology of the study are discussed in an earlier paper on the same 
sample (van Winkel et al., 2006). The patients who were interviewed at T2 (n=53) had diagnoses of 
schizophrenia (n=43), schizoaffective disorder (n=8) and schizophreniform disorder (n=2). For the 
remainder of the patients, diagnoses were assessed by contacting their psychiatrist and/or family, or by 
chart review. These patients had clinical diagnoses of schizophrenia (n=36), schizoaffective (n=6) or 
schizophreniform (n=4) disorder and unspecified psychosis (n=1). The patients with diagnoses of 
schizophreniform disorder (n=6) and unspecified psychosis (n=1) were excluded from the analyses. 
Both at T1 and at T2, the WHO Life Chart was used to rate functional outcome (WHO, 1992). 
Functional outcome was the composite score of living situation, working situation, relational status, 
and social contacts at T2, based on information from the Life Chart. Each outcome area received a 
score ranging from 0 to 2, with 0 being the worst and 2 being the best outcome. Area scores were then 
added up, resulting in a eight-point scale (table 1). Likewise, functional status at T1 was the composite 
score of living situation, working situation and relational status on a six-point scale, since there was 
insufficient information on the status of social contacts at T1.  
 
Sample 
At T1, 20 patients did not have their IQ tested because they remained floridly psychotic or left the 
hospital against medical advice before they could be tested. At T2, 11 patients had died. All other 
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patients (n=89) were contacted. Fifty-three agreed to be interviewed for a WHO Life Chart 
assessment. Two of these patients were diagnosed with schizophreniform disorder and were excluded 
from the analyses. Of the remaining 51 patients, 47 also consented to do a WAIS IQ testing, which 
could be completed in 44 patients. In 4 of these 44 patients with a WHO Life Chart and a complete T2 
WAIS testing, no VIS data could be obtained, yielding a sample of 40 patients with a VIS IQ 
assessment, a T2 WAIS assessment and the WHO Life Chart. Another 19 patients were willing to fill 
in questionnaires on demographic variables and do a VIS testing, but refused a formal interview with a 
WAIS IQ testing, so that for 59 patients a VIS IQ assessment was obtained. Of the 40 patients with 
complete VIS and T2 WAIS IQ data, there were no T1 WAIS IQ data for 10 patients, yielding a 
sample of 30 patients with complete T0, T1, T2 IQ data and a WHO Life Chart assessment. For the 
assessment of functional outcome at T2 for the patients that could not be interviewed directly, 
information was obtained from questionnaires that were sent to them by mail (for 7 patients), from the 
medical file (for 17 patients), or from their parents and/or treating doctor (for 12 patients). Five of the 
patients that could not be interviewed directly were excluded from the analyses because they had 
clinical diagnoses of schizophreniform disorder (n=4) or unspecified psychosis (n=1). For 70 patients, 
sufficient information was available to assess functional outcome at T2, of whom 66 patients had a 
diagnosis of schizophrenia or schizoaffective disorder (table 2). This resulted in a risk set of 51 
patients at T0, 53 patients at T1 and 43 patients at T2 with a diagnosis of schizophrenia or 
schizoaffective disorder for whom both an IQ assessment at this given time-point and functional 
outcome at T2 was available; the associations between IQ and functional outcome were assessed using 
these risk sets.  
 
Analysis
Associations between IQ measures and functional outcome at T2 were determined using linear 
regression analysis, with functional outcome as dependent variable and premorbid IQ, IQ at T1 and IQ 
at T2 as independent variables. Standardized regression coefficients (ȕ) are displayed. The models 
were adjusted for the following a priori selected possible confounding variables: duration of untreated 
psychosis, gender, age at onset and functional status at T1. Duration of untreated psychosis was 
conceptualized as the elapsed time between the first experienced psychotic symptom and the first 
administration of antipsychotic medication. This was assessed by asking the patient, or in case the 
patient was not able to answer, by asking the family.  
Given the unequal availability of IQ measures at T0, T1 and T2, a sensitivity analysis was done with a 
stable risk set consisting of the 30 patients with complete T0, T1, T2 IQ data and a WHO Life Chart 
assessment. The aim of this analysis was to determine whether the unequal availability of IQ measures 
at T0, T1 and T2 would affect the association with the T2 functional outcome measure, and thus, to 
investigate the robustness of the possible associations. 
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Results 
The mean age of the patients at T1 was 23.2 years (SD=4.0). No large or significant differences in 
gender, age or estimated premorbid IQ (assessed at T2) were found between patients who could be 
tested for IQ at T1 and those who could not (van Winkel et al., 2006b). Similarly, no large or 
significant differences were found between patients that could and could not be tested at T2. The mean 
IQ scores were 108.8 at T0 (SD=12.2), 101.6 at T1 (SD=15.1) and 109.3 at T2 (SD=17.2). The 
functional outcome at T2 is shown in table 2. A suggestive association was found between estimated 
premorbid IQ and functional outcome after 10 years (ȕ= 0.24, 95% CI: -0.02-0.50, p=0.07), which was 
significant after adjustment (ȕ= 0.30, 95% CI: 0.02-0.59, p=0.04). However, no significant or large 
association, although directionally similar, was found between IQ at T1 and functional outcome at T2 
(ȕ= 0.08, 95% CI: -0.17-0.33, p=0.52). At T2, IQ again was associated with outcome (ȕ= 0.28, 95% 
CI: 0.02-0.55, p=0.04), also after adjustment for confounders (ȕ= 0.33, 95% CI: 0.02-0.63, p=0.04) 
(figure 2). A sensitivity analysis on a stable risk set of the 30 patients with non-missing data on IQ 
measures at T0, T1 and T2, and on functional outcome at T2, confirmed these findings (estimated 
premorbid IQ: ȕ= 0.31, 95% CI: -0.03-0.65, p=0.07; IQ at T1: ȕ= 0.19, 95% CI: -0.20-0.57, p=0.33; 
IQ at T2: ȕ= 0.34, 95% CI: 0.02-0.69, p=0.06).   
 
Discussion 
The current data show a consistent association between both estimated premorbid IQ and IQ at follow-
up on the one hand and functional outcome on the other after a mean illness duration of ten years. IQ 
assessed at the first hospitalization, however, was not associated with functional outcome at ten years 
follow-up.  
These findings are in line with our hypothesis and confirm the existence of a prospective as well as a 
cross-sectional relationship of the global cognitive measure IQ with functional outcome, and may help 
to explain the controversy in the literature regarding the prospective relationship between cognitive 
measures and subsequent functional outcome between chronic and first episode patients. They also 
support the hypothesis that the use of cognitive measures taken at first hospitalization for the 
prediction of subsequent functional outcome is less informative, due to a non-uniform rate of 
deterioration of premorbid IQ preceding the first hospitalization (van Winkel et al., 2006), although 
other approaches to explain the apparently contradictory findings have also been formulated. 
Addington and colleagues stressed the importance of taking symptoms into account, as the relationship 
between cognition and outcome no longer existed, when it was (cross-sectionally) controlled for 
symptoms (Addington et al., 2005). However, it may not be meaningful to control for symptoms when 
investigating a possible predictive relationship, because symptoms tend to change considerably over 
the course of the illness and their evolution cannot be reliably predicted. An additional problem is the 
interrelationship of negative, depressive and positive symptoms in the presence of a psychotic episode, 
which makes the assessment of negative symptoms at the first hospitalisation problematic (Lieberman 
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et al., 1996). Nevertheless, the finding that the relationship between cognition and outcome no longer 
existed when it was controlled for symptoms (Addington et al., 2005), points to the importance of 
symptomatology for the functional outcome of patients with schizophrenia. The design of the current 
study did not allow to investigate the possibility that the lack of association of the T1 WAIS IQ 
measure with functional outcome at T2 could be due to the presence of psychotic symptomatology and 
the accompanying stress and use of sedative medication at the first hospitalization, as symptomatology 
was not assessed at T1. However, patients were only tested after they achieved clinical stability, as is 
the case in most studies on first-episode patients. This implicates that, given the good response to 
antipsychotic medication in first-episode patients, the vast majority of patients thus had little or no 
remaining psychotic symptoms at the time when they were tested at T1, making it unlikely that the 
presence of psychotic symptomatology at T1 in these patients would solely explain the lack of 
association between IQ at T1 and later functional outcome.  
Despite the fact that the underlying reason for the lack of association between IQ at T1 and subsequent 
functional outcome thus could not be directly tested, the current study is important as it shows that the 
reliability of the assessment of cognition at the first episode of psychosis is questionable and not very 
indicative for the prognosis of patients, whereas estimated premorbid IQ may be a more reliable 
reflection of future cognitive abilities and functional outcome. The possible replication of this finding 
would have important implications to the assessment of prognosis and treatment for future patients 
who present with a first episode of psychosis.  
One could argue that the association between estimated premorbid IQ and subsequent functional 
outcome could be confounded by functional status at first hospitalization, given the expectation that 
high premorbid IQ would be associated with a better functional status at first hospitalization. Recent 
research supports this claim, showing the importance of functional status prior to the first 
hospitalization for psychosis for later outcome (Meng et al., 2006). A recent study on first-episode 
patients with psychosis who did find an association between full scale WAIS IQ assessed at the first 
hospitalization and functional outcome after 3 years (measured by the Global Assessment of 
Functioning), failed to control for this possibly confounding factor (Carlsson et al., 2006). In the 
current study, the association between estimated premorbid IQ and functional outcome remained 
significant, even after controlling for the possible confounding effect of functional status at first 
hospitalization, and other possible confounders. This is in line with findings reported by Munro and 
colleagues, who found an association between measured childhood IQ and outcome after a mean 
period of 21 years in subjects who attended psychiatric services as a child and were later diagnosed 
with schizophrenia  (Munro et al., 2002), which underscores the importance of estimated premorbid 
IQ for the long-term functional outcome in patients with schizophrenia. 
The present study also has some limitations. First, not all patients could be tested at their first 
hospitalization (T1) because they left the hospital unplanned or were clinically unstable. Furthermore, 
a substantial group were lost to follow-up after ten years (T2). However, no large or significant 
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differences in gender, age or premorbid IQ were found between the study patients and the patients who 
could not be tested, both at T1 and at T2. Second, functional status at T1 consisted of the sumscore of 
living situation, work situation and relational status, but we failed to include information on social 
status. Third, the mean estimated premorbid and T2 WAIS IQ scores of 109 suggest that the current 
sample of first onset patients with schizophrenia may not be representative for patients with 
schizophrenia in general, since patients diagnosed with schizophrenia were reported to function at a 
below-average intellectual level in several studies (Caspi et al., 2003; Rabinowitz et al., 2000b). 
However, the standardization of the WAIS for Belgium was done in 1970. Since then, no 
restandardization was done until 1997, with the introduction of WAIS-III (Wechsler, 1997), meaning 
that for the WAIS IQ scores of the current sample, the Flynn-effect was not taken into account. This 
phenomenon consists of a mean estimated rise in IQ scores of 15 IQ points per generation (30 years) 
(Flynn, 1987). This effect was present in every country for which IQ follow-up data were available, 
including Belgium. Therefore, at the time this cohort had their first-episode WAIS IQ assessment 
(1985-1989), the average IQ in the general population in Belgium can be estimated at around 108 (15 
to 19 years since standardization in 1970, times 0.5 IQ points gained per year), suggesting that the 
mean T2 WAIS IQ score of 109 actually represents an average score. In addition, the high T2 WAIS 
IQ scores probably also reflect the particular demographic characteristics of the catchment area, as this 
catchment area mainly serves the area around the city of Leuven. This is a small city with 
approximately 90 000 inhabitants, that harbours the largest university of Belgium with around 30 000 
students. As a result, 47 of the 100 first-episode patients were students, thus considerably raising the 
mean IQ of our cohort. Fourth, the cognitive assessment only included IQ measures, but no measures 
of executive functioning and episodic memory.  
In conclusion, the current data show a consistent association between both estimated premorbid IQ 
and IQ at follow-up on the one hand and functional outcome on the other after a mean illness duration 
of ten years. IQ assessed at the first hospitalization, however, was not associated with functional 
outcome at ten years follow-up. Clearly, these findings need replication, but they may shed light on 
the apparently conflicting evidence regarding the prospective relationship between cognition and 
subsequent functional outcome in first episode patients.  
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Table 1. Conceptualization of the T2 functional outcome measure.* 
 0 1 2 
Living 
situation 
 
Address in psychiatric 
hospital 
With family or sheltered housing Alone or with partner 
Working 
situation 
 
No job Voluntary or sheltered work Paid work or student° 
Relational 
status 
 
No relationship Relationship for more than 6 months but no 
contractual engagement 
Married or living as 
married# 
Social 
contacts 
Almost none Only with family and/or colleagues at work Large network of 
social contacts 
 
*The T2 functional outcome measure is the sumscore of the scores on living situation, working situation, 
relational status and social contacts. 
°Or gratuated less than six months prior to T2. 
#With contractual engagement. 
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Table 2. Functional outcome at T2. 
 
*The T2 functional outcome measure is the sumscore of the scores on living situation, working situation, 
relational status and social contacts. 
°Or gratuated less than six months prior to T2. 
#With contractual engagement. 
SCZ/SA: patients with diagnoses of schizophrenia or schizoaffective disorder at T2 
 All patients 
(N) 
Mean  
(SD) 
SCZ/SA 
 (N) 
Mean 
(SD) 
Living situation 
Address in psychiatric hospital 
With family 
Sheltered housing 
Alone 
With partner 
80 
22 
15 
11 
17 
15 
1.13 
(0.8) 
74 
22 
15 
11 
16 
10 
1.05 
(0.8) 
Working situation 
No job 
Voluntary work 
Sheltered work 
Paid work parttime 
Paid work fulltime 
Student° 
80 
49 
9 
5 
1 
16 
0 
0.60 
(0.8) 
74 
48 
9 
4 
1 
12 
0 
0.53 
(0.8) 
Relational status 
None 
Without contractual engagement, >6 months 
Married or living as married# 
76 
53 
14 
9 
0.42 
(0.7) 
70 
53 
12 
5 
0.31 
(0.6) 
Social contacts 
Almost none 
Only with family and/or colleagues at work 
Large network of social contacts 
70 
22 
32 
16 
0.91 
(0.7) 
66 
22 
29 
15 
0.89 
(0.7) 
Functional outcome* 70 3.01 
(2.2) 
66 2.83 
(0.8) 
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Figure 1. Course of IQ in patients with high and low premorbid IQ, as found in a recent ten-year follow-up study 
on the same sample (van Winkel et al., 2006), suggesting that the decline in cognition prior to the first episode, 
expressed as IQ, was particularly noticeable in individuals with high estimated premorbid IQ, with subsequent 
recovery of IQ over the next ten years. In individuals with low estimated premorbid IQ, however, IQ levels were 
stable in the period prior to the first episode and at ten-year follow-up. 
 
 
 
T0: estimated premorbid IQ 
T1: IQ at first hospitalization 
T2: IQ at ten-years follow-up 
Pairwise comparisons T0-T1 and T1-T2: *p<0.01, **p<0.001 
90
95
100
105
110
115
120
125
T0 T1 T2
High premorbid IQ Low premorbid IQ
** 
  *
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Figure 2. Associations between functional outcome at T2 and IQ measures at T0 (estimated premorbid IQ), T1 
(at first hospitalization) and T2 (at ten-years follow-up). The standardized regression coefficients are displayed. 
 
*p<0.05 
# duration of untreated psychosis, gender, age at onset and functional status at T1 
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
T0 T1 T2
not adjusted adjusted for confounders#
*
*
*
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Abstract 
Background: Gene-environment interactions involving the Catechol-O-Methyltransferase  Val158Met 
polymorphism (COMTVal158Met) have been implicated in the causation of psychosis. Evidence from 
general population studies suggests that Met/Met subjects are sensitive to stress, a trait associated with 
psychosis. We hypothesized that the Met allele would moderate the effects of stress on negative affect 
(NA) in controls, and on NA and psychosis in patients with a psychotic disorder. Methods: Thirty-
one patients with a psychotic disorder and comorbid cannabis misuse and 25 healthy cannabis users 
were studied with the Experience Sampling Method (ESM), a structured diary technique assessing 
current context and emotional and psychotic experiences in daily life. Results : A significant 
interaction between COMTVal158Met genotype and ESM stress in the model of NA was found for 
patients (interaction Ȥ2=7.4, p=0.02), but not for controls (interaction Ȥ2=3.8, p=0.15). In the model of 
ESM psychosis, a significant interaction between COMTVal158Met genotype and ESM stress was also 
apparent (interaction Ȥ2=11.6, p<0.01), with Met/Met patients showing the largest increase in 
psychotic experiences as well as NA in reaction to ESM stress. Conclusion: The findings suggest 
that the COMTVal158Met polymorphism moderates affective and psychotic responses to stress in patients 
with psychosis, providing evidence for gene-environment interaction mechanisms in the formation of 
psychotic symptoms.  
 
Key words: COMT, Schizophrenia, Psychosis, Gene-Environment Interaction, Stress, Experience 
Sampling Method 
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Introduction 
The Catechol-O-Methyltransferase gene (COMT) has received much attention as a candidate gene in 
recent psychosis research, because of its function in inactivating catecholamines at postsynaptic sites 
in the human brain. COMT contains a functional polymorphism that results in a change from Valine 
(Val) to Methionine (Met) (COMTVal158Met). The amino acid change affects the function of the enzyme: 
individuals with the Val/Val genotype have a 40% higher COMT enzyme activity in the brain than 
individuals with the Met/Met genotype (Chen et al., 2004a). However, the results from association 
studies attempting to examine the COMTVal158Met polymorphism as a specific risk gene for 
schizophrenia have shown great inconsistency. Earlier studies found an association of schizophrenia 
with the Met allele (Park et al., 2002; Ohmori et al., 1998; Kotler et al., 1999), whereas later evidence 
favoured an association with the Val allele (Glatt et al., 2003; Wonodi et al., 2003; Kremer et al., 
2003; Chen et al., 2004b; Sanders et al., 2005). Two recent meta-analyses found minimal or no 
evidence for an association between the COMTVal158Met polymorphism and schizophrenia (Fan et al., 
2005; Munafo et al., 2005), comparable to a recent study in two large samples (Williams et al., 2005). 
Recent studies have focused on gene-environment interactions involving COMTVal158Met rather than 
genotypic main effects. These studies focused on the Val allele, providing evidence of synergism 
between the Val allele and exposure to cannabis in the causation of psychosis; carriers of the Val allele 
were most likely to exhibit psychotic symptoms and to develop schizophreniform disorder years after 
the initial exposure to cannabis in an epidemiological study (Caspi et al., 2005). Val carriers were also 
found to display more psychotic experiences in reaction to cannabis use in an experimental challenge 
study (Henquet et al., 2006) and an experience-sampling study (Henquet et al., submitted), consistent 
with interaction, although these findings were conditional on prior evidence of psychometric psychosis 
liability in both studies.  
Therefore, rather than a main effect, the influence of COMTVal158Met on behaviour may be better 
understood in terms of gene-environment interactions. Interestingly, a number of studies in general 
population samples suggested that carriers of the Met allele may be differentially affected by the 
environment, by showing larger sensitivity to stress. Oswald and colleagues, for example, found the 
Met allele to be associated with a greater stress hormone response to a physical stressor in 46 healthy 
controls (Oswald et al., 2004). A study of 35 healthy subjects by Smolka and colleagues showed 
greater brain activation in the limbic region to unpleasant stimuli (but not pleasant stimuli) in carriers 
of the Met allele, as measured by fMRI (Smolka et al., 2005). These findings were extended by the 
work of Drabant and colleagues in 100 healthy control subjects, who found a greater limbic reactivity 
in Met carriers using an emotional face processing task. Furthermore, the Met allele was associated 
with excessive hippocampal and prefrontal cortex activity (Drabant et al., 2006). In this study, 
Met/Met subjects also showed greater amygdala-orbitofrontal cortex connectivity that in turn was 
associated with low novelty seeking. In the context of provocative environments (eg stress), this could 
lead to an increased susceptibility for negative mood states (Drabant et al., 2006).  
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These studies suggest that Met carriers may have greater reactivity to situations that provoke negative 
affective states. This is in keeping with findings from the general population that the Met allele is 
associated with a propensity to anxiety (Enoch et al., 2003; Olsson et al., 2005; Stein et al., 2005; 
Mathew et al., 1980), reduced extraversion (Reuter and Hennig, 2005; Stein et al., 2005) and reduced 
novelty seeking (Reuter and Hennig, 2005; Tsai et al., 2004; Benjamin et al., 2000). 
The findings connecting the Met allele to stress-responsivity are relevant to schizophrenia, as 
increased stress-sensitivity was found to be present not only in patients diagnosed with schizophrenia, 
but also in their relatives in an experience sampling study (Myin-Germeys et al., 2001). In addition, 
experience sampling studies also found that increased stress-sensitivity in schizophrenia is associated 
with increases in both affective and psychotic responses (Myin-Germeys et al., 2001; Myin-Germeys 
et al., 2005a) in both patients and their first degree relatives.  
It can thus be hypothesized that the Val and Met allele are both, albeit differentially, implied in the 
development of psychopathology through divergent interactions with specific environmental stimuli. 
Whereas the Val allele may interact with cannabis in shaping the risk for psychotic disorder as shown 
previously (Henquet et al., submitted; Caspi et al., 2005; Henquet et al., 2006), the Met allele may be 
specifically associated with stress-sensitivity in terms of affective and psychotic responses to small 
stressors in the flow of daily life.   
The Experience Sampling Method (Myin-Germeys et al., 2001), a self-assessment technique that is 
used to assess context, thoughts, affect and symptoms in the flow of daily life, can be used to 
investigate these hypothesized gene-environment interactions in a momentary, ‘real-world’ design. 
Using this method, the current study aimed to evaluate the relationship between sensitivity to stress 
and the COMTVal158Met polymorphism in a sample of  31 patients with a clinical diagnosis of psychotic 
disorder and 25 nonpsychotic controls. The aim of the current study was to investigate the hypothesis 
that the Met allele would moderate affective responses to stressful events in daily life both in patients 
and control subjects. In addition, since stress also elicited psychotic reactions in patients, it was 
hypothesized that the Met allele would also moderate the effects of stress on psychotic symptoms in 
patients with a psychotic disorder but not in the control group.  
Of note, this same sample has been previously shown to have an interaction between the Val allele and 
cannabis use in their effect on psychotic symptoms (Henquet et al., submitted). 
 
Materials and methods 
Sample
Thirty-one cannabis users with a clinical diagnosis of psychotic disorder according to DSM-IV criteria 
and 25 nonpsychotic cannabis users were recruited through inpatient and outpatient mental health 
service facilities in South-Limburg, The Netherlands, or were recruited from the general population as 
described previously (Henquet et al., 2006; Henquet et al., submitted). The diagnosis of patients was 
assessed according to the Research Diagnostic Criteria (RDC) using the OPCRIT computer program 
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(McGuffin et al., 1991). Patients had diagnoses of schizophrenia (n=6), schizoaffective disorder 
(n=23) and psychosis not otherwise specified (n=2). 
Subjects attended a briefing session during which a complete description of the study was provided 
and written informed consent was obtained. In addition, past and current psychiatric illness and past 
and current substance use were assessed. Given the focus of the study by Henquet and colleagues on 
the effects of cannabis use on psychosis according to genotype (Henquet et al., submitted), the 
following exclusion criteria were applied in order to reduce possible confounding by the use of other 
substances, and to minimize health risks: alcohol use in excess of 5 units per day; use of illicit drugs 
(other than cannabis) during the 6 consecutive days of the study; respiratory, cardiovascular or 
neurological disease. Pregnant women were also excluded. A positive family history for psychosis was 
a further exclusion criterion for the control group. The study was carried out in accordance with the 
World Medical Association’s Declaration of Helsinki (Edinburgh modification, 2000) and was 
approved by the local Medical Ethics Committee.  
COMTVal158Met genotyping  
Buccal mucosa was obtained from all the individuals by brushing of a large surface inside both cheeks 
by means of a cotton swab. DNA was extracted using a BuccalAmp DNA Extraction Kit. 
COMTVal158Met genotype was assayed by polymerase chain reaction (PCR) and enzymatic digestion 
with NlaIII followed by Acrylamide gel electrophoresis as described by Daniels and colleagues 
(Daniels et al., 1996).  
Experience Sampling Method (ESM) 
The Experience Sampling Method (ESM) has been described in previous reports (Myin-Germeys et 
al., 2001; Myin-Germeys et al., 2005a; Myin-Germeys et al., 2005b). It is a self-assessment technique 
that is used to assess current context, thoughts, mood and symptoms in the flow of daily life. Subjects 
are provided a wrist-watch and a set of booklets (one booklet for each day). At random moments, the 
watch emits a ‘beep’, after which subjects are asked to report their current context, thoughts, 
appraisals and mood. In the current study, the watch emitted a beep 12 times a day, during 6 
consecutive days. Beeps occurred at random, between 7.30 am and 0.30 pm. Self-assessments were 
rated on a 7-point Likert scale.  
  
The ESM procedure was explained to the subjects during an initial briefing session, and a practice 
form was filled in to confirm that subjects were able to understand the 7-point Likert scale format. 
Subjects were asked to complete their reports immediately after the beep and to record the time at 
which they completed their report, in order to minimize memory distortions. For reasons of reliability 
and validity as described in detail before (Delespaul, 1995), all reports completed more than 15 
minutes after the beep and/or subjects with fewer than 24 reports were excluded from the analysis. In 
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line with earlier reports (Myin-Germeys et al., 2001, Myin-Germeys et al., 2005a), recruited patients 
were clinically remitted. This strategy was chosen because i) the completing and adequacy of the 
reports was assumed to be better in clinically remitted patients and ii) clinically remitted patients were 
assumed to be less likely to quit the study because of paranoid ideas interfering with the research 
protocol. 
 
Measures
As described in previous work, stress reactivity was conceptualized as affective and psychotic 
reactivity to daily life events and minor disturbances in daily life (Henquet et al., submitted; Myin-
Germeys et al., 2001; Myin-Germeys et al., 2002; Myin-Germeys et al., 2005a; Myin-Germeys et al., 
2005b). Measures of stress, affective response, and psychotic symptoms were derived from the 
experience sampling reports as described below. 
 
Assessment of stress 
Stress in the model of ESM (hereafter ‘ESM stress’) was conceptualized as the subjective appraised 
stressfulness of distinct events in the natural flow of daily life. Subjects were asked to report the most 
important event that happened between the current and the previous report, and to rate this event on a 
7-point scale (-3: very unpleasant; 0: neutral; 3: very pleasant). ESM stress was linearly defined with 
most stress being related to the ‘unpleasant’ side of the continuum and least stress being associated 
with the ‘pleasant’ side of the continuum. In order to allow high scores to reflect high ESM Stress, 
responses were recoded (-3: very pleasant; 0: neutral; 3: very unpleasant). 
 
Assessment of psychosis 
Psychotic experiences were assessed with 9 ESM items rated on 7-point Likert scales (1: not at all; 7: 
very). To allow self-reported assessments, these 9 items included aspects of the mental state that 
subjects are aware of and that are directly associated with psychotic experiences such as delusions and 
hallucinations. These 9 items were: ‘auditory hallucinations’, ‘visual hallucinations’, ‘preoccupation’, 
‘suspicion’, ‘feeling unreal’, ‘feeling controlled’, ‘difficulty of expressing thoughts’, ‘racing thoughts’ 
and ‘fear of losing control’. As previous reports have shown that subjects with hallucinatory 
experiences can distinguish between hearing real voices and auditory hallucinations (Delespaul, 1995; 
Escher et al., 2002), the presence of hallucinations was asked directly (“Do you hear voices?”,  “Do 
you see things that others cannot see?”). Guided by a previous paper addressing the presence of 
psychotic symptoms using ESM (Myin-Germeys et al., 2005a), the presence of delusions was assessed 
with the use of items that assess aspects of mental states that are directly related to delusional ideation 
in psychosis. These were: ‘preoccupation’, ‘suspicion’, ‘feeling unreal’ and ‘feeling controlled’. 
Finally, three items were added that are related to psychosis in general. These were: “I have difficulty 
expressing my thoughts”, “My thoughts are racing” and “I am afraid to lose control”. The sum of these 
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nine items formed the variable ‘ ESM psychosis’ (Cronbach’s Į = 0.77). A sumscore was preferred 
over other approaches (eg using the highest symptom score as measure for psychosis) because the 
ESM psychosis measure had to allow to pick up subtle fluctuations in psychotic symptomatology 
reactive to small, daily life stressors; a score that ranges from 9 to 63 (as in a sumscore) is more likely 
to allow this than a score that only ranges from 1 to 7 (as in the highest psychotic symptom score). 
Furthermore, the use of a sumscore was chosen because of its consistency with previous ESM studies 
that examined psychotic reactivity to daily life stressors (Myin-Germeys et al., 2005a; Myin-Germeys 
et al., 2005b). 
 
Factor analysis of these 9 psychosis items yielded two factors with eigenvalues greater than 1. The 
first factor loaded high on the items that assessed hallucinations and consisted of the mean of the items 
‘auditory hallucinations’ and ‘visual hallucinations’ (‘ESM hallucinations’; Cronbach’s Į = 0.70). The 
second factor loaded high on items that were intended to assess delusions or thought disorder, and 
consisted of the mean of the items ‘preoccupation’, ‘suspicion’, ‘feeling controlled’, ‘racing thoughts’, 
‘feeling unreal’, ‘fear of losing control’ and ‘difficulty expressing thoughts’ (‘ESM delusions’; 
Cronbach’s Į = 0.76).  
 
Assessment of affect 
The affective states reported after each beep were assessed with 9 mood-related items, that were rated 
on 7-point Likert scales (1: not at all; 7: very). In line with previous reports (Myin-Germeys et al., 
2001; Myin-Germeys et al., 2002), affective states were expressed as ‘positive affect’ and ‘negative 
affect’. The items ‘happy’, ‘cheerful’, ‘relaxed’, and ‘satisfied’ formed the positive affect scale (PA), 
(Cronbach’s alpha=0.85); the items ‘down’, ‘guilty’, ‘insecure’, ‘lonely’ and ‘anxious’ formed the 
negative affect scale (NA), (Cronbach’s alpha=0.80). As there was no a priori hypothesis regarding 
PA, only the results with regard to NA are shown. 
 
Statistical analyses 
ESM data are hierarchically structured: multiple observations (level 1) are nested within subjects 
(level 2). Since observations from the same subject are more similar than observations from other 
subjects, conventional regression techniques are not suited for analyzing ESM data. Therefore, 
multilevel linear random regression was used, hereby taking into account the variance components at 
two levels (ESM-beep level and subject level) (Goldstein, 1987). 
As it is also necessary to correct for autocorrelation of data in a time-series like the ESM data, data 
were analyzed with the XTREGAR module in Stata (StataCorp, 2005), that takes the possibility of 
autocorrelation into account. The ȕ is the fixed regression coefficient, and can be interpreted in the 
same fashion as the parameters of unilevel regression coefficients. In order to test the hypothesis that 
COMTVal158Met genotype moderates the psychotic response to daily life stress, multilevel linear random 
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regression analyses were conducted with ESM psychosis, ESM delusions and ESM hallucinations as 
the respective dependent variables, COMTVal158Met genotype (0= Val/Val; 1=Val/Met; 2=Met/Met) and 
ESM stress as independent variables, as well as their interaction term. Similarly, in order to test the 
hypothesis that COMTVal158Met genotype moderates the affective response to daily life stress, a 
multilevel linear random regression was performed with negative affect as the respective dependent 
variable, and COMTVal158Met genotype and ESM stress as independent variables, as well as their 
interaction term. As the current study was performed in a sample of cannabis users (Henquet et al., 
submitted), ESM cannabis use was included in the analyses as a time-dependent covariate. 
Antipsychotic use was included in the analyses as a time-independent covariate. Furthermore, use of 
sedative medication related to perceived stress as indicated by the subject (‘ESM stress’), was 
included in the analyses as a time-dependent potential confounder. Both benzodiazepines and first-
generation, sedative antipsychotics that were not prescribed on a daily basis were defined as ‘sedative 
medication’. 
In order to estimate effect sizes for each genotype separately, the appropriate linear combinations were 
calculated from the interaction terms using the STATA LINCOM routine, after fitting the 
stressXgenotype interaction term with genotype as two dummy variables, using Val/Val as reference 
category. Main effects and interactions were assessed by Wald test (Clayton and Hills, 1993). As there 
was no a priori hypothesis regarding the type of psychotic symptoms related to the hypothesized gene-
stress interaction, the results were corrected for multiple testing using the Simes’ correction, which in 
the case of correlated outcomes represents an improvement over the Bonferroni procedure (Simes, 
1986). According to the Simes’ procedure, observed p-values greater than Simes’ p-values are 
considered statistically non-significant. Simes’ p-values are shown for p-values below 0.05. Since it 
was hypothesized that the increased responses to stress associated with Met would differ between 
patients and controls, stratified analyses were conducted.  
 
Results 
Subjects
All subjects had used cannabis in the past 12 months with a frequency of use of once a day or more in 
84% of subjects. No illicit drugs other than cannabis were used during the study. In the patient group, 
7 patients were taking typical antipsychotics, 12 were taking atypical antipsychotics and 12 were not 
taking antipsychotic medication. There were no differences between patients and controls with regard 
to frequency of cannabis use, age at onset of cannabis use, gender or living situation, but patients were 
significantly older and had less education (table 1). Patients had significantly more ESM 
symptomatology, but did not experience more ESM stress. The number of completed ESM reports did 
not significantly differ between patients and controls (table 1). Of all ESM moments, cannabis use was 
reported in 40.6%. The use of sedative medication was not confined to patients, but patients were 
much more likely to use sedative medication (t= -4.0, p<0.001). 
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COMTVal158Met genotype 
The COMTVal158Met genotype distribution was in Hardy-Weinberg equilibrium for both patients and 
controls, with the Met/Met genotype being present in 14.3% of subjects (n=8; 5 patients (16.1%); 3 
controls (12.0%)), Val/Met in 55.4% (n=31; 18 patients (58.1%); 13 controls (52.0%)) and Val/Val in 
30.4% (n=17; 8 patients (25.8%); 9 controls (36.0%)). Genotype was not associated with sex, ESM 
cannabis use, ESM psychosis, ESM hallucinations, ESM delusions or ESM stress, but there was a 
significant main effect of genotype on NA (table 2).  
 
Models for NA in patients and controls 
The main effect of genotype on NA was significant in controls (ȕ= 0.27, 95% CI 0.03- 0.51, p=0.03), 
but failed to reach significance in patients, although the relationship was directionally similar (ȕ= 0.37, 
95% CI –0.02- 0.76, p=0.07), with subjects of the Met/Met genotype having the highest NA scores in 
both groups (Table III). ESM stress had a significant main effect on NA in the total group (ȕ= 0.03, 
95% CI 0.02- 0.04, p<0.001). Stratified analyses revealed that this effect was also significant for 
patients, but just failed to reach significance for controls (table 3).  
A significant interaction effect was found for COMTVal158Met genotype and ESM stress in the model of 
NA for patients (interaction Ȥ2=7.4, p=0.02) but not for controls (interaction Ȥ2=3.8, p=0.15), 
indicating that COMTVal158Met genotype moderated the affective response to ESM stress in patients 
only. The Met/Met patients reported a larger increase in NA in reaction to ESM stress than the patients 
of the other genotypes (table 3). Although the interaction between COMTVal158Met genotype and ESM 
stress in the model of NA was only statistically significant for patients, the fit of the model improved 
in both groups after the addition of the interaction term (table 3).  
Models for ESM psychosis in patients and controls 
In the patient group, ESM stress was significantly associated with the ESM psychosis measure 
(ȕ=0.18, 95% CI: 0.05-0.32, p<0.01; table 4). ESM stress was not associated with the ESM psychosis 
measure in controls (table 4). In the model of ESM psychosis, a significant interaction was apparent 
for patients between COMTVal158Met genotype and ESM stress (interaction Ȥ2=11.6, p<0.01; < Simes’p 
of 0.016), indicating that in patients, the psychotic response to ESM stress was moderated by 
COMTVal158Met genotype. The Met/Met patients showed a significantly greater increase in psychotic 
experiences in reaction to ESM stress than the patients of the Val/Met or Val/Val genotype (table 4). 
Similar results were also found for ESM delusions (interaction Ȥ2=12.4, p<0.01; < Simes’p of 0.033), 
but not for ESM hallucinations (interaction Ȥ2=4.9, p=0.08). As expected, there was no interaction 
between COMTVal158Met genotype and ESM stress in the model of ESM psychosis in controls 
(interaction Ȥ2=3.3, p=0.20).
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Discussion 
Findings
The current study aimed to test two main hypotheses. First, it was hypothesized that the Met allele 
would moderate the effects of stress on negative affect in healthy controls as well as in patients with a 
psychotic disorder. This hypothesis was only partly supported, as a significant interaction effect for 
COMTVal158Met genotype and ESM stress in the model of NA was found for patients but not for 
controls. Nevertheless, the fit of the model improved in both groups after the addition of the 
interaction term, suggesting that a lack of power may explain the lack of significant interaction in the 
controls group. As hypothesized, the Met/Met patients reported a larger increase in NA in reaction to 
ESM stress than the patients of the other genotypes.  
Second, it was hypothesized that the Met allele would moderate the effects of stress on psychotic 
symptoms in patients only. In the model of ESM psychosis, a significant interaction between 
COMTVal158Met genotype and ESM stress was indeed apparent for patients, indicating that the psychotic 
response to ESM stress was also moderated by COMTVal158Met genotype in patients. Again, the 
Met/Met patients showed a significantly greater increase in psychotic experiences in reaction to ESM 
stress than the patients of the Val/Met or Val/Val genotype. Similar results were also found for ESM 
delusions, but not for ESM hallucinations, probably because of a relative scarcity of hallucinations in 
the patient group (table 1). As hypothesized, there was no evidence for an interaction between 
COMTVal158Met genotype and ESM stress in the model of ESM psychosis in the controls group. 
ESM stress had a significant main effect on NA and on ESM psychosis in patients but not in controls. 
These findings suggest that patients with psychosis react more strongly to stress, showing an increase 
in psychotic and affective symptoms. Interestingly, the model containing ESM stress, genotype and 
their interaction term predicted the symptomatic response clearly better than the main model only 
containing ESM stress, indicating the importance of taking gene-environment interaction into account 
in explaining transitions in momentary symptomatology in psychosis. The observation that the 
interaction between ESM stress and COMTVal158Met  was only present in patients is in line with findings 
regarding the interaction between the COMTVal158Met Val allele and cannabis use, where the cannabis X 
genotype interaction was dependent on a pre-existing liability to psychosis (Henquet et al., submitted; 
Henquet et al., 2006). Given these findings, it can be hypothesized that the Met allele can be a causal 
factor not only for depression and bipolar disorder as shown by Mandelli and colleagues (Mandelli et 
al., 2006), but also for psychosis, specifically in subjects with a pre-existing liability to psychosis.  
Whereas the effect of genotype on NA in patients was only apparent in interaction with ESM stress, a 
significant main effect of genotype on NA was found in controls. Since the effect of ESM stress on 
measures of symptomatology was only shown in patients, it is unclear whether the effect of genotype 
on NA in the controls group was independent of ESM stress, or alternatively, whether the perceived 
stress for controls during the ESM registration was insufficient to provoke and detect these kind of 
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gene-environment interactions. The observation that the fit and statistical significance of the model 
containing the interaction term was clearly better than the fit of the main effect model (table 3) could 
be in line with  the latter possibility. 
 
COMTVal158Met polymorphism and emotional processing 
These findings support the hypothesized role of the COMTVal158Met polymorphism in sensitivity to 
stress in the patients with a psychotic disorder and its possible contribution to symptomatology in the 
general population, and are in line with previous findings connecting the Met allele with sensitivity to 
stress. The findings support the involvement of the COMTVal158Met polymorphism in the emotional 
processing of environmental stimuli, with Met carriers experiencing more difficulties. The tonic-
phasic dopamine model may provide an underlying biological rationale for COMTVal158Met interactions 
with the environment. According to this model, the enzyme containing Val favours reduction in tonic 
dopamine but increases in phasic dopamine. A milieu characterized by predominance of phasic over 
tonic dopamine may give rise to reduced cognitive stability, but increased cognitive flexibility. For the 
enzyme containing Met, the opposite would hold (Blasi et al., 2005; Stefanis et al., 2005; Nolan et al., 
2004; Bruder et al., 2005; Rosa et al., 2004). It has been suggested that cognitive stability in Met 
carriers would be adaptive in circumstances where holding information is demanded (eg working 
memory), but dysfunctional in circumstances where rapid adjustments to changing external stimuli are 
required (Bilder et al., 2004; Tunbridge et al., 2006). The lack of an allele dosage effect in the current 
study, meaning that the Val/Met individuals clustered with Val/Val individuals rather than being 
intermediate between homozygote groups, is interesting in this regard, and supports the idea that 
excessive cognitive stability, that is only present in subjects with two Met alleles, could be problematic 
in these circumstances. The current study is the first to demonstrate the relevance of these emotional 
processing difficulties in Met carriers for psychopathological symptoms such as psychosis and 
negative affect. It extends the findings of Mandelli and colleagues, who showed that the Met allele was 
associated with depression following adverse life events in a large sample of patients with major 
depression and bipolar disorder (Mandelli et al., 2006). 
 
COMTVal158Met polymorphism and psychosis 
The current findings also add evidence to the theoretical framework that links dopamine to the 
development of psychosis through aberrant salience (Kapur, 2003; Kapur, 2004), in the sense that a 
part of the ‘dopamine system’ (the COMTVal158Met polymorphism, that regulates breakdown of 
intrasynaptic dopamine) was shown to moderate the psychotic response to daily life stressors. These 
daily life stressors were shown to interact with COMTVal158Met genotype to increase momentary 
delusional ideas, which indeed suggests some kind of attribution of aberrant salience to these daily life 
stressors and, given the interaction with COMTVal158Met genotype, also suggests a role for dopamine in 
the development of this aberrant salience. The current results also suggest that the attribution of 
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aberrant salience is not ‘context-independent’, as hypothesized by Kapur and colleagues, but rather 
that the more stressful these daily life stressors are perceived, the greater the chance that they are being 
interpreted in a ‘context-inappropriate’, delusional way. Interestingly, COMT has its effect primarily 
in the prefrontal cortex, whereas aberrant salience is considered to occur through excess striatal 
dopamine. Future research will have to investigate this issue more specifically. 
Strengths and caveats 
First, a major strength of the current study is the use of the Experience Sampling Method for the 
assessment of a gene-environment interaction between the COMTVal158Met polymorphism and the 
responsivity to stress. This method allows gathering insight in the course of symptoms and the 
influence of genes and environmental stimuli in a momentary, ‘real-world’ design. The use of the 
Experience Sampling Method facilitated the test of the hypothesis that both the COMTVal158Met Val and 
Met allele differentially moderated the psychotic response to different specific environmental stimuli. 
Although this finding needs to be replicated, the confirmation of this hypothesis by the current data 
clearly provides greater insight in the role of the COMTVal158Met polymorphism in the occurrence and 
course of psychopathological symptoms. In future research, the Experience Sampling Method could 
also provide an attractive paradigm to study the influence of several other candidate genes, including 
gene-gene and gene-environment interactions.  
A second strength of  the current study is that it was specifically performed in a sample in which it was 
previously shown that the Val allele moderated the psychotic response to cannabis (Henquet et al., 
submitted). In this study on the same sample as that of the current study, subjects with the Val/Val 
genotype, but not those with one or more Met alleles, showed an increase in hallucinations after 
cannabis exposure, that was conditional on prior evidence of psychometric psychosis liability. These 
findings allowed the test of the hypothesis that within an identical sample, both the COMTVal158Met Val 
and Met allele moderate differential vulnerabilities in interaction with specific environmental factors.  
However, apart from being a strength of the current study by allowing to directly test this hypothesis, 
the approach of testing COMTVal158Met moderation of stress reactivity in severe cannabis smokers also 
represents the main limitation of the current study, as it obviously limits the generalizibility of our 
findings. Although limited data are available, cannabis use has been suggested to result in increased 
synaptic dopamine activity, at least as a short term effect (Voruganti et al., 2001). Furthermore, 
chronic cannabis use was found to induce a prefrontal hypodopaminergic state (Eldreth et al., 2004) 
and desensitization of CB1 receptors (Sim-Selley, 2003). Therefore, a replication of our findings in a 
sample of subjects abstinent of any drug use is needed. 
A second limitation is the cross-sectional nature of the analyses, which makes it impossible to 
establish causal relationships. Therefore it is impossible to determine whether stress measures 
influenced affect or psychotic symptoms, or whether affect and psychotic symptoms influenced the 
subjective appraisal of stress. However, either explanation has clinical relevance. A third limitation is 
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the unequal use of sedative medication in patients and controls, which could have biased the results, as 
could the use of antipsychotic medication in patients. However, the therapeutic effect of these drugs is 
intended to be stress-reducing and antipsychotic. This implies that if the current results are indeed 
biased by the unequal intake of these drugs in patients and controls, the bias is most likely to reduce 
the results towards the null rather than to create spurious results.   
In conclusion, the current results provide evidence for a gene-environment interaction between 
COMTVal158Met genotype and stressful events in the flow of daily life in patients with psychosis and 
comorbid cannabis abuse, with Met/Met patients showing the largest increase in psychotic experiences 
as well as NA in reaction to ESM stress. The findings of this study need replication in samples 
abstinent of any drug use in order to confirm these gene-stress interactions. 
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Table 1. Sociodemographic characteristics and descriptives. 
 Patients  Controls t, p 
Age (SD) 36.2 (9.6) 26.1 (6.6) t= -4.3, p<0.001 
Gender (male/female) 23/8 22/3 t= -1.3, p=0.20 
Education (n=58) 
Elementary school 
Secondary school 
Higher education 
 
5 
21 
2 
 
3 
11 
11 
t=  2.6, p=0.01 
Living situation (n=61) 
Alone 
With partner 
With parents or family 
Protected housing 
 
15 
6 
5 
5 
 
12 
5 
8 
0 
t= -0.6, p=0.57 
Frequency of cannabis use* 
1-2 times per week 
3-4 times per week 
one time per day 
more than 1 time per day 
 
2 
2 
5 
22 
 
0 
5 
3 
17 
t= -0.15, p=0.88 
Age of onset cannabis use 18.3 (6.9) 16.0 (1.8) t= -1.6, p=0.11 
Number of ESM reports 41.9 (1.9) 44.2 (2.1) t= 0.8, p=0.43 
ESM psychosis 17.5 (7.6) 12.9 (4.3) t= -2.7, p=0.01 
ESM delusions 2.2 (1.0) 1.6 (0.6) t= -2.5, p=0.02 
ESM hallucinations 1.3 (0.7) 1.0 (0.1) t= -2.5, p=0.02 
ESM stress -1.3 (1.8) -1.5 (1.6) t= -1.1, p=0.28 
ESM positive affect 4.5 (1.3) 5.1 (1.2) t= 2.1, p=0.04 
ESM negative affect 1.7 (1.0) 1.3 (0.7) t= -2.3, p=0.03 
 *over the last year 
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Table 2. Sociodemographic characteristics and Experience Sampling Method (ESM) measures by genotype 
 
 Val/Val  Val/Met Met/Met P 
Age (SD) 32.2 (8.4) 31.3 (10.4) 27.7 (8.2) 0.26 
Sex (M/F) 16/3 24/8 8/2 0.67 
Number of ESM reports (SD) 42.7 (8.5) 47.1 (10.8) 44.5 (8.2) 0.45 
ESM cannabis use* 48.8% 36.7% 39.7% 0.25 
ESM psychosis (SD) 14.9 (6.3) 15.6 (7.0) 14.8 (6.2) 0.79 
ESM delusions (SD) 1.8 (0.9) 1.9 (0.9) 1.8 (0.8) 0.95 
ESM hallucinations (SD) 1.1 (0.4) 1.1 (0.6) 1.3 (0.6) 0.23 
ESM stress (SD) -1.5 (1.6) -1.4 (1.8) -1.1 (1.7) 0.21 
ESM negative affect (SD) 1.3 (0.5) 1.6 (0.9) 1.8 (1.0) 0.03 
 
 
*percentage of ESM moments where cannabis use is reported 
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Table 3. Effect sizes and fit of different models# including ESM stress and COMT genotype on Negative Affect. 
In the composite models, only genotype effect sizes are displayed. 
 
Model Patients Controls 
 Effect size 
(ȕ, p)(SE) 
Model fit 
(Wald Ȥ2; p) 
Effect size 
(ȕ, p)(SE) 
Model fit 
(Wald Ȥ2; p) 
 
‘ESM stress only’ 
 
0.04; p<0.001 (0.01) 
 
25.3; p<0.001 
 
0.01; p=0.07 (0.01) 
 
9.1; p=0.06 
 
‘Genotype only’ 
Val/Val 
Val/Met 
Met/Met 
 
 
0.00* 
0.55; p=0.07 (0.30) 
0.68; p=0.09 (0.40) 
 
7.3; p=0.30 
 
 
0.00* 
0.07; p=0.66 (0.16) 
0.69; p<0.01 (0.24) 
 
13.7; p=0.02 
 
 
‘Genotype+ESM stress’ 
 
 
 
26.6; p<0.001 
 
 
 
17.6; p<0.01 
Val/Val 
Val/Met 
Met/Met 
 
‘Genotype*ESM stress’ 
Val/Val 
Val/Met 
Met/Met 
0.05; p<0.001 (0.01) 
0.57; p=0.05 (0.29) 
0.74; p=0.05 (0.39) 
 
 
0.05; p=0.13 (0.03) 
0.03; p<0.01 (0.01) 
0.12; p<0.001 (0.03) 
 
 
 
 
35.1; p<0.001 
0.01; p=0.32 (0.01) 
0.07; p=0.65 (0.15) 
0.73; p=0.001 (0.22) 
 
 
0.01; p=0.49 (0.02) 
0.00; p=0.92 (0.01) 
0.08; p=0.04 (0.04) 
 
 
 
 
21.2; p<0.01 
 
* Val/Val is the reference category  
# The Wald Ȥ2’s and their statistical significance can be used to compare the fit of the models.The reported effect 
sizes are relative effect sizes as compared to the Val/Val reference category, that can only be interpreted within a 
given model and not across models. Models were adjusted for the following confounders: cannabis use, use of 
sedative medication and antipsychotic use. 
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Table 4. Effect sizes and fit of different models# including ESM stress and COMT genotype on ESM psychosis. 
In the composite models, only genotype effect sizes are displayed. 
 
Model Patients Controls 
 Effect size 
(ȕ, p)(SE) 
Model fit 
(Wald Ȥ2; p) 
Effect size 
(ȕ, p)(SE) 
Model fit 
(Wald Ȥ2; p) 
 
‘ESM stress only’ 
 
0.18; p=0<0.01 
(0.07) 
 
10.5; p=0.06 
 
-0.03; p=0.52 (0.05) 
 
2.8; p=0.59 
 
‘Genotype only’ 
Val/Val 
Val/Met 
Met/Met 
 
 
0.00* 
1.83; p=0.47 (2.51) 
2.87; p=0.39 (3.34) 
 
1.5; p=0.96 
 
 
0.00* 
-0.45; p=0.74 (1.36) 
-2.26; p=0.28 (2.10) 
 
4.5; p=0.47 
 
 
‘Genotype+ESM stress’ 
 
 
 
5.1; p=0.65 
 
 
 
6.6; p=0.36 
Val/Val 
Val/Met 
Met/Met 
 
‘Genotype*ESM stress’ 
Val/Val 
Val/Met 
Met/Met 
0.15; p=0.07 (0.08) 
1.99; p=0.44 (2.57) 
3.11; p=0.37 (3.45) 
 
 
0.25; p=0.30 (0.24) 
0.01; p=0.95 (0.09) 
0.77; p<0.001 (0.21)
 
 
 
 
16.7; p=0.05 
-0.12; p=0.05 (0.06) 
-0.56; p=0.68 (1.36) 
-2.41; p=0.25 (2.08) 
 
 
-0.11, p=0.27 (0.10) 
-0.08, p=0.32 (0.08) 
-0.56, p=0.03 (0.25) 
 
 
 
 
10.1; p=0.26 
 
*Val/Val is the reference category 
# The Wald Ȥ2’s and their statistical significance can be used to compare the fit of the models.The reported effect 
sizes are relative effect sizes as compared to the Val/Val reference category, that can only be interpreted within a 
given model and not across models. Models were adjusted for the following confounders: cannabis use, use of 
sedative medication and antipsychotic use. 
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Abstract  
Objectives: Psychotic patients with COMTVal158Met Met alleles were recently found to display more 
intense psychotic and affective responses to daily life stressors. We aimed to test the hypothesis that 
the Met allele is implicated in the development of affective and psychotic symptomatology in subjects 
genetically at risk for schizophrenia, by testing if first-degree relatives of patients with schizophrenia 
who share a Met allele have greater concordance of symptomatology than relatives not sharing a Met 
allele. Methods: Relatives (n=38) were arranged in as many genetically related pairs as possible 
(n=26), and Met-sharing between Index Subject (IS) and Related Subject (RS) was assessed. 
Psychopathology was assessed with the Brief Psychiatric Rating Scale (BPRS) total score. Results: 
Multilevel regression revealed an interaction between RS BPRS score and Met-sharing in the model of 
IS BPRS score (interaction Ȥ2= 3.46, p=0.06). Stratified analyses revealed that IS-RS total BPRS 
scores were significantly associated in case of Met-sharing (B= 0.53, 95% CI: 0.20-0.87, p=0.002), but 
were not when there was no Met-sharing. Conclusion: These findings support the hypothesis that the 
Met allele may be involved in the causation of psychopathology, at least in populations with a genetic 
predisposition to psychosis. 
 
Keywords: COMT, schizophrenia, psychosis, affective symptoms 
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Introduction 
A Val158Met functional polymorphism in the Catechol-O-Methyltransferase (COMT) gene has 
received much attention in recent psychiatric research, because of a 40% reduction of dopamine 
catabolism in individuals homozygous for the Met variant. Much of the research on this polymorphism 
was focused on psychosis, as dopamine is considered as one of the key neurotransmitters in the 
pathophysiology of psychosis (Kapur, 2004; Kapur, 2003) and because of its genomic localization in 
the 22q11 region,  a region which is deleted in the velo-cardial-facial syndrome, of which the 
psychiatric presentation resembles the clinical syndrome of schizophrenia (Shprintzen et al., 1992; 
Bassett et al., 2003). The results of studies examining COMTVal158Met as a specific risk gene for 
schizophrenia, however, have shown great inconsistency. Earlier studies found an association of 
schizophrenia with the Met allele (Park et al., 2002; Ohmori et al., 1998; Kotler et al., 1999), while the 
latest evidence favors an association with the Val allele (Glatt et al., 2003; Wonodi et al., 2003; 
Kremer et al., 2003; Chen et al., 2004; Sanders et al., 2005). Two recent meta-analyses found minimal 
or no evidence for an association between COMTVal158Met and schizophrenia (Fan et al., 2005; Munafo
et al., 2005), as did a recent study using two large samples (Williams et al., 2005). 
An interesting approach to overcome the problems associated with simple gene-disorder association 
analyses in large samples is the use of smaller samples consisting of pairs of relatives, in order to 
study the association between allele sharing and a certain illness, or alternatively, the influence of a 
candidate polymorphism on continuous or dichotomous measures of psychopathology. This widely 
used approach allows to examine the potential causal role of genetic polymorphisms (Sham, 1998), by 
testing whether sharing of a polymorphism among relatives is associated with greater levels of sharing 
of continuous or dichotomous measures of psychopathology. Comparable methods have already been 
productively applied in schizophrenia (eg (Kohn et al., 2004; Schwab et al., 1997; Gill et al., 1996). 
A current hypothesis in the literature with regard to the functional implications of COMTVal158Met is the 
‘Warrior versus Worrier’ hypothesis, that states that in the general population, Val alleles may be 
associated with an advantage in the processing of aversive stimuli (Warrior strategy), while Met alleles 
may be associated with an advantage in memory and attention tasks (Worrier strategy) (Stein et al., 
2006). Under conditions of increased dopamine release (eg, stress, administration of dopamine 
agonists), individuals with Val alleles may have improved dopaminergic transmission and better 
performance, whereas individuals with Met alleles may have less efficient neurotransmission and 
worse performance (Stein et al., 2006; Tunbridge et al., 2006; Bilder et al., 2004; Mattay et al., 2003). 
Interestingly, the Val allele has also been associated with reduced brain volume and worse cognition in 
patients with schizophrenia (Mata et al., 2006; Ohnishi et al., 2005) and in subjects at high risk for 
schizophrenia (McIntosh et al., 2006), whereas the Met allele has been associated with increased 
sensitivity to stress in patients with psychosis, both in terms of the psychotic as well as the affective 
response to daily life stressors (van Winkel et al., 2007). These findings seem to be in keeping with the 
‘Warrior versus Worrier’ hypothesis, and also with evidence suggesting that sensitivity to stress and 
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cognitive impairments may act through different pathways in the formation of psychotic symptoms 
(Myin-Germeys et al., 2002). In patients with schizophrenia, sensitivity to stress has been associated 
with increases in psychotic symptoms in reaction to daily life stressors (Myin-Germeys et al., 2005), 
and also with increases in affective symptoms (Myin-Germeys et al., 2001). Furthermore, the 
development of depressed mood was found to increase the risk for psychosis in individuals at risk, for 
example in individuals who report hallucinatory experiences (Krabbendam et al., 2005; Krabbendam 
and van Os, 2005; Hanssen et al., 2005). Given these findings, it is attractive to hypothesize that the 
Met allele is involved in the causation of symptomatology in individuals with a genetic predisposition 
for psychosis, and that this symptomatology is not restricted to psychotic symptoms, but also includes 
affective and anxious symptoms. 
An interesting population to study this hypothesis are healthy relatives of patients with schizophrenia, 
since on the one hand they have been found to display schizotypic symptomatology directly related to 
the symptomatology in their relative with schizophrenia (Mata et al., 2000), but on the other hand are 
not treated with dopamine agonists. Moreover, the interpretation of data is not troubled by the 
possibility of reverse causality as it is in patients with schizophrenia. 
Thus, if the Met allele is implicated in the vulnerability to develop psychotic, affective and anxious 
symptoms in subjects with a predisposition to psychosis, then healthy relatives of patients with 
schizophrenia sharing the Met allele should have greater levels of concordance of a range of 
(subclinical) psychopathological symptoms including anxiety, mood symptoms and psychotic 
symptoms than relatives not sharing the Met allele. The current study aimed to test this hypothesis in a 
sample of 38 healthy relatives of patients with schizophrenia. 
 
Methods 
Sample
First-degree relatives of patients with a clinical diagnosis of schizophrenia were asked to participate in 
the present study. They were recruited via the catchment area Community Mental Health Centre in the 
city of Llodio, which their relative with schizophrenia was attending. Llodio is a village with a 
population of 19.000 inhabitants in the rural province of Avala in the Basque region of Spain. All first-
degree relatives were in good mental health. The study was approved by the local ethics committee 
and all subjects provided written informed consent. The level of psychopathology was assessed with 
the Brief Psychiatric Rating Scale (Lukoff et al., 1986). This is a 24-item scale that was chosen 
because it includes a broad range of affective as well as psychotic and psychosis-related symptoms. 
Since the study was performed in healthy relatives with a relatively low expected level of mood and 
psychotic symptomatology, the total BPRS score was used as measure for the level of 
psychopathology, in order to optimize variability in scores between subjects. 
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COMT genotyping
Genomic DNA was extracted by standard procedures. COMTVal158Met was genotyped using a 5'-
nuclease assay on an ABI-PRISM 7700 Sequence Detection System (Applied Biosystems, Foster 
City-CA, USA). Flanking amplification primers (5'-TCGTGGACGCCGTGATTCAGG-3' and 5'-
AGGTCTGACAACGGGTCAGGC-3') and two fluorescent probes [5'-6FAM-CGCTGGCGTGAAG-
3' (Val) and 5'-TET-TTTCGCTGGCATGAA-3' (Met)] were designed using PrimerExpress v.2.0 
software (Applied Biosystems) and reactions were performed using the Taqman® Universal PCR 
master mix (Applied Biosystems) following the manufacturer's instructions.  All assays were run in 
duplicate and alleles were called by the SDS v.1.9.1 software (Applied Biosystems) using pre-
sequenced DNA samples homozygous for either the Val or Met alleles as standards.  
 
Statistical analyses 
The subjects were arranged in as many unique genetically related pairs as possible, resulting in sib-sib, 
father-sib and mother-sib pairs. For every pair, it was assessed whether subjects shared a Met allele 
(sharing of Met allele = ‘1’; no sharing of Met allele = ‘0’; ‘no Met-sharing’ as reference category). 
Since the data were hierarchically structured, with individuals being clustered within families, 
standard errors were corrected for familial clustering using multilevel random regression analysis 
(Goldstein, 1987). Data were analyzed with the XTREG module in Stata (StataCorp, 2005). The 
regression analysis was conducted with the BPRS score of the first subject of the pair (Index Subject: 
IS) as the dependent variable, the BPRS score of the second subject (Related Subject: RS), Met-
sharing and the interaction as independent variables. From the model containing the interaction term, 
stratified effects were calculated by applying the appropriate linear combinations using the STATA 
LINCOM routine.  
 
Results 
The sample consisted of 38 first-degree relatives pertaining to 17 families (table 1). The 38 relatives 
could be arranged in 26 genetically related pairs: 14 mother-sib, 6 father-sib and 6 sib-sib pairs. Their 
mean total BPRS score was 26.4 (range 24-35; SD 2.9).  
 
There was no main effect of COMTVal158Met genotype on BPRS score (B= -1.50, 95% CI: -6.95- 0.84, 
p=0.18). Multilevel random regression revealed a suggestive interaction effect between RS BPRS 
score and Met-sharing in the model of IS BPRS score (interaction Ȥ2= 3.46, p=0.06). Stratified 
analyses revealed that when IS and RS shared at least one Met allele, their BPRS scores were 
significantly associated (B= 0.53, 95% CI: 0.20-0.87, p=0.002), whereas the IS-RS BPRS scores were 
not associated if there was no Met-sharing (B= -0.54, 95% CI: -1.62-0.54, p=0.33). 
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Discussion 
The current study found evidence that healthy relatives of patients with schizophrenia who share a Met 
allele have greater levels of concordance of subclinical psychiatric symptomatology than relatives not 
sharing a Met allele. These findings support the hypothesis that the Met allele may be involved in the 
causation of psychopathology, at least in populations with an increased risk for psychiatric illness. 
This is in line with a study by Mandelli and colleagues (Mandelli et al., 2006), who found that the Met 
allele was associated with first-onset depressive disorder following exposure to a major life event in a 
large sample of patients with depression or bipolar disorder. 
The current study did not differentiate between subclinical psychotic symptomatology and affective 
symptomatology, as the sample was too small to allow for this differentiation, certainly when taking 
the low total BPRS scores in these healthy relatives into account. Nevertheless, a recent study in 
patients with psychotic disorder (van Winkel et al., 2007) revealed that the Met allele moderated both 
the psychotic and the affective reaction to daily life stressors, with Met/Met subjects displaying the 
strongest reactivity. These findings, as well as the findings of the current study, support the hypothesis 
that the Met allele may be associated with a relatively broad vulnerability to develop psychiatric 
symptomatology including mood symptoms and anxiety (Stein et al., 2006), and indicate that the Met 
allele may also be involved in the causation of psychosis in subjects with an increased genetic risk.  
The neurobiological mechanism underlying this vulnerability is much debated. A possible 
neurobiological mechanism can be found in the inverted-U shape of the functional response curve to 
increasing dopamine signalling in the prefrontal cortex (Mattay et al., 2003), meaning that dopamine 
could impact on prefrontal function in such way that the response is optimized within a narrow range 
of dopamine activity, with too little or too much dopamine having a relatively deleterious effect. Thus, 
under conditions of increased dopamine release (eg, stress), individuals with Val alleles may have 
improved dopaminergic transmission and better cognitive performance, whereas individuals with Met 
alleles may have less efficient neurotransmission and worse cognitive performance. Recent evidence 
suggests that this could not only be reflected in worsening cognitive performance in Met subjects 
under conditions of increased dopamine release, induced by amphetamine administration (Mattay et 
al., 2003), but also in an increased risk for methamphetamine-induced psychosis (Suzuki et al., 2006).  
However, other researchers have pointed to the possible role of the tonic-phasic dopamine model 
(Tunbridge et al., 2006; Bilder et al., 2004). According to this model, the enzyme containing Val 
favours reduction in tonic dopamine but increases in phasic dopamine. A predominance of phasic over 
tonic dopamine may give rise to reduced cognitive stability, but increased cognitive flexibility. For the 
enzyme containing Met, the opposite would be true (Blasi et al., 2005; Stefanis et al., 2005; Nolan et 
al., 2004; Bruder et al., 2005; Rosa et al., 2004). It has thus been suggested that cognitive stability in 
Met carriers would be adaptive in circumstances where holding information is demanded (eg working 
memory), but dysfunctional in circumstances where rapid adjustments to changing external stimuli are 
required (Bilder et al., 2004; Tunbridge et al., 2006), possibly leading to a ruminative, worrisome 
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coping style. This, in turn, could explain the greater stress-sensitivity found in patients with psychosis 
with the Met/Met genotype (van Winkel et al., 2007), and the greater response to negatively 
connotated stimuli in healthy Met carriers, in terms of prefrontal, hippocampal and limbic neural 
activation (Drabant et al., 2006; Smolka et al., 2005). More research is certainly needed in order to 
fully understand the nature of the interactions between COMTVal158Met and environmental factors such 
as daily life stressors, adversive life events, cannabis- and amphetamine abuse and the etiopathological 
mechanism underlying these complex gene-environment interactions.  
The current study also has some limitations. The sample was relatively small, and subjects had low 
levels of symptomatology as measured by the total BPRS score. Therefore, it was not possible to 
differentiate between subclinical psychotic and subclinical affective/anxious symptomatology in these 
subjects. Furthermore, the current study did not evaluate the neurobiological mechanism underlying 
these findings, and did not evaluate the cognitive coping styles that could possibly mediate the 
influence of COMTVal158Met on symptomatology. Future research will have to address these issues more 
specifically.  
In conclusion, the current study found evidence that healthy relatives of patients with schizophrenia 
who share a Met allele have greater levels of concordance of subclinical psychiatric symptomatology 
than relatives not sharing a Met allele. These findings support the hypothesis that the Met allele may 
be involved in the causation of psychopathology, at least in populations with a genetic predisposition 
to psychosis. 
 
Acknowledgments 
This work was supported by an unrestricted grant from Lilly SA, Spain. Inez Myin-Germeys was 
supported by a 2006 NARSAD Young Investigator Award and by the Dutch Medical Council (VENI 
& VIDI grant). 
 
 
 
 
 88 
 Table 1. Demographic and genetic variables. 
 
 
 
 Subjects (n=38) 
Male sex (n, %) 14 (36%) 
Years of full-time education (SD) 10.4 (6.4) 
Age (SD) 50.3 (16.0) 
  
8 (21.1%) 
 16 (42.1%) 
Genotype (n, %) 
Val/Val 
Val/Met 
Met/Met  14 (36.8%) 
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Abstract 
Objective:  to assess the diagnostic properties of two different screening guidelines for the detection 
of diabetes in patients diagnosed with schizophrenia. Methods: Over a two-year period, 415 patients 
with schizophrenia were screened with a full laboratory screening and a 75 g Oral Glucose Tolerance 
Test (OGTT). The sensitivity of two screening strategies was compared to the ‘Gold Standard’: the 
OGTT. The two strategies were: 1) assessing fasting glucose in all patients, as suggested by the 
American Psychiatric Association/American Diabetes Association (APA/ADA) and 2) a screening 
strategy derived from the guidelines of the World Health Organization (WHO) of assessing fasting 
glucose in all patients (step one), and subsequently performing an OGTT in patients with impaired 
fasting glucose (step two).  
Results:  Of the total sample, 6.3% (n=26) met criteria for diabetes, resulting in a mean annual 
incidence of diabetes of 3.15% (6.3% incident cases/2 years). A screening based on the APA/ADA 
guidelines detected diabetes in 12 of the 26 cases (46.2%) identified by the OGTT. The proposed two-
step strategy detected 25 out of 26 cases (96.2%). Conclusion: The data suggest a high incidence of 
diabetes in patients diagnosed with schizophrenia. However, the guidelines to detect diabetes as 
proposed by the APA/ADA, did not sufficiently detect diabetes in this specific high risk group. The 
alternative two-step strategy was able to detect the vast majority of diabetes cases and should therefore 
be considered in the clinical routine of screening and monitoring patients with schizophrenia. 
 
Key words: Schizophrenia, Diabetes, Metabolic Syndrome, Physical Health 
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Introduction 
In recent years, there has been a growing interest in the occurrence of medical co-morbidity in patients 
diagnosed with schizophrenia (Goldman, 1999; Jones et al., 2004; Lambert et al., 2003; Marder et al., 
2004). This is certainly the case for diabetes, as numerous case reports and some retrospective cohort 
studies provided evidence for an increased risk of diabetes in patients diagnosed with schizophrenia, 
or more broadly, in patients treated with atypical antipsychotics (Henderson et al., 2005a; Caro et al., 
2002; Citrome and Jaffe, 2003; Gianfrancesco et al., 2003; Hedenmalm et al., 2002; Henderson, 2002; 
Lindenmayer et al., 2003; Melkersson and Dahl, 2004; Newcomer et al., 2002; Carlson et al., 2006). 
Given this amount of evidence, there is a large consensus that patients treated with atypical 
antipsychotics are at high risk of developing diabetes, specifically diabetes type 2 (Lean and Pajonk, 
2003). Schizophrenic patients treated with antipsychotics indeed display many risk factors for diabetes 
type 2 such as a sedentary lifestyle, overweight and unhealthy dietary habits. In addition to these risk 
factors, all atypical antipsychotics are to some degree associated with weight gain, although their 
liability to induce weight gain varies from relatively low  to relatively high, depending on the 
individual drug. Furthermore, antipsychotic drugs may even induce insulin resistance (Bergman and 
Ader, 2005; Henderson et al., 2005b), although insulin resistance was also found in drug-naïve 
patients with schizophrenia (Ryan et al., 2003). Another major health concern in patients with 
schizophrenia is the metabolic syndrome, which comprises abnormalities in glucose metabolism, lipid 
metabolism, body weight/fat distibution and blood pressure. The metabolic syndrome is present in as 
much as 40% of patients diagnosed with schizophrenia, and its presence significantly increases the 
risk for diabetes and other glucose abnormalities (De Hert et al., 2006a; Basu et al., 2004; Cohn et al., 
2004; Heiskanen et al., 2003; McEvoy et al., 2005; De Hert et al., 2006b).   
A recent American consensus conference proposed much awaited guidelines to screen and monitor 
patients treated with an atypical antipsychotic (American Diabetes Association and American 
Psychiatric Association, 2004). Importantly, the consensus conference also acknowledged the need to 
acquire additional data in order to further improve screening and treatment guidelines. This is 
especially relevant because of two reasons. First, preliminary evidence suggests that the use of the 
proposed guidelines may result in an underdiagnosis of diabetes and other glucose abnormalities in 
high risk groups, when compared to the ‘gold standard’ of the Oral Glucose Tolerance Test (OGTT) 
(De Hert et al., 2006a; Adam and Tarigan, 2004; Botas et al., 2003). Second, early detection of 
glucose abnormalities in patients diagnosed with schizophrenia could well be of eminent importance, 
as prediabetic abnormalities and even frank diabetes are shown to be potentially reversible in this 
specific population, at least in cases in which the onset of diabetes was most likely related to 
antipsychotic treatment (Ananth et al., 2002; Rigalleau et al., 2000; Peuskens et al., 2004; De Hert et 
al., 2007).   
However, the standard use of an OGTT as a screening instrument in all patients treated with 
antipsychotics may not be an achievable goal in all treatment settings. Therefore, a two-step strategy 
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derived from the guidelines of the World Health Organization (WHO) (World Health Organization, 
1999) was developed, that could serve as an alternative for the standard use of an OGTT in patients 
treated with antipsychotics.  
The current study reports on the baseline data of a cohort of 415 prospectively monitored 
schizophrenic patients treated with antipsychotics. The aim of the current study was twofold: first, to 
assess metabolic abnormalities in a large sample of patients diagnosed with schizophrenia; second, to 
assess the sensitivity of two different screening guidelines for the detection of diabetes. These two 
strategies were: 1) assessing fasting glucose in all patients, as suggested by the American Psychiatric 
Association/American Diabetes Association (APA/ADA) consensus guidelines and 2) the screening 
strategy derived from the guidelines of the WHO of assessing fasting glucose in all patients (step one), 
and subsequently performing an OGTT in patients with impaired fasting glucose (IFG)(step two).  
In line with the previous literature on screening for diabetes in the general population (Botas et al., 
2003; Adam and Tarigan, 2004; Hilton et al., 2002; Tai et al., 2000; Cheng et al., 2006), it was 
hypothesized that the use of the consensus screening guidelines, but not the use of the two-step 
strategy, would result in a large underdiagnosis of diabetes and other glucose abnormalities in the 
present sample of patients diagnosed with schizophrenia. 
 
Methods 
Over a two-year period, both inpatients (73.7%) and outpatients (26.3%) with a diagnosis of 
schizophrenia or schizoaffective disorder who were in contact with the services of the University 
Centre St. Jozef (Kortenberg, Belgium), were asked to participate in the present study. All included 
patients were on stable medication treatment for at least three months and were not diagnosed with 
diabetes mellitus prior to the baseline screening. All patients were informed about the purpose of the 
study and provided written informed consent. The study was approved by an ethical committee. 
The baseline screening consisted of a full laboratory screening including fasting insulin and a 75 g 
Oral Glucose Tolerance Test (OGTT). For the OGTT, patients were instructed to fast overnight and 
were observed by a nurse during the OGTT, in order to ensure the reliability of the test results. All 
laboratory analyses were performed in the same laboratory. For the diagnosis of diabetes and impaired 
glucose tolerance, the ADA criteria were used (Expert Committee on the Diagnosis and Classification 
of Diabetes Mellitus, 2003), meaning that diabetes was defined as a fasting glucose level > 125 mg/dl 
and/or a 2-hour post-glucose load > 199 mg/dl. Prediabetes was defined as impaired fasting glucose 
(IFG: fasting glucose level 100-125 mg/dl) and/or impaired glucose tolerance (IGT: 2-hour post-
glucose load 140-199 mg/dl). Insulin resistance was assessed using fasting plasma glucose and insulin 
levels and a homeostatic model (HOMA-IR). Glycosylated hemoglobin (HbA1c) levels were assessed 
in diabetic patients. For all patients that were identified with a glucose level that met the criteria for 
diabetes, a new OGTT was performed within two weeks to confirm the diagnosis. To assess the 
diagnostic properties of two different screening strategies, the diabetes cases identified by means of 
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the OGTT were used as the ‘gold standard’ for comparison. The two strategies were: 1) assessing 
fasting glucose in all patients, as suggested by the APA/ADA and 2) a screening strategy derived from 
the guidelines of the WHO (World Health Organization, 1999). The WHO guidelines suggest the use 
of an OGTT in patients presenting with fasting glucose above 109 mg/dl. Following the lower 
diagnostic fasting glucose levels recommended by the ADA (Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus, 2003), we modified this WHO strategy to the use of an OGTT in 
patients presenting with a fasting glucose level above 100 mg/dl (further referred to as impaired 
fasting glucose or IFG). 
The presence of the metabolic syndrome was assessed using the adapted National Cholesterol 
Education Program – Adult Treatment Panel III (ATP-III) criteria (Expert Panel on Detection and 
Evaluation of Treatment of High Blood Cholesterol in Adults, 2001; Grundy et al., 2005). This is a 
recent commentary on the original ATP-III criteria, that proposes to use a fasting glucose limit of 100 
instead of 110 mg/dl and to include drug treatment for hypertension, hyperlipidemia and 
hyperglycemia as criteria for the metabolic syndrome. Descriptive statistics were applied for basic 
demographic and clinical characteristics. An analysis of variance was done to evaluate the influence of 
the metabolic syndrome on measures of the OGTT.  
 
Results 
Subjects
The mean age of the patients was 34.7 years (SD=11.3), and they had been ill for a mean of 10.8 years 
(SD=10.2). The majority of the sample was male (67%) and 99% were Belgian natives and of 
Caucasian descent. The mean Global Assessment of Functioning (GAF) score was 60.6 (SD=9.1). 
Patients had been admitted a mean of 5.1 times (SD=4.5), with the mean age of first admission being 
23.9 years (SD=6.6). Of all patients, 68% were smokers, and many patients had a family history of 
diabetes (31.1%), dyslipidaemia (34.7%) or cardiovascular disorders (47.5%). 
All patients but 2 patients were treated with antipsychotic medication at the moment of assessment. 
First-generation antipsychotics were used by 19.3% (n=80) of patients, second-generation 
antipsychotics by 91.1% (n=378). The majority of patients were on monotherapy (84.1%, n=349), with 
90.0% of this group receiving a second-generation antipsychotic and 10.0% a first-generation 
antipsychotic (table 1). Patients received a mean of 3.2 (SD=2.0) different medications. Antipsychotics 
were combined with anticholinergics (16.1%), antidepressants (38.3%), benzodiazepines (35.7%), 
mood stabilisers (21.2%) and non-psychoactive medications (40.9%). Of the non-psychoactive 
medications, 24.4% were related to metabolic disturbances, with 7 patients (1.7%) taking a statin 
(3.5% of all non-psychoactive medications) and 42 patients (10.1%) taking antihypertensive 
medication (20.9% of all non-psychoactive medications). 
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Metabolic abnormalities 
Only a minority of patients had a normal body mass index (BMI) (47.2%). Overweight (BMI 25-30) 
was present in 34.2% of patients, an additional 18.6% even had a BMI of more than 30. The mean 
BMI was 25.8 (SD=5.0). An increased waist circumference (> 102 cm for men, > 88 cm for women) 
was present in 36.1% of patients. Female patients were more likely than male patients to be 
overweight or obese and to have an increased waist circumference (Ȥ2=30.6, p<.0.0001). Lipid 
abnormalities were also highly prevalent: 47.9% had elevated total cholesterol (> 190 mg/dl), 41.2% 
elevated triglycerides (>150 mg/dl), 28.9% low high-density lipoprotein (HDL; men: < 40 mg/dl; 
women: < 50 mg/dl) and 45.1% elevated low-density lipoprotein (LDL; >115 mg/dl).  
In the total sample, 6.3% (n=26) met criteria for diabetes. Since the inclusion and screening of patients 
were performed over a period of two years, this results in a mean annual incidence of diabetes of 
3.15% (6.3% incident cases/2 years). Of the patients meeting criteria for diabetes, 12 (46.2%) met the 
criterion of fasting glucose >125 mg/dl, 18 (69.2%) met the criterion of glucose >199 mg/dl at 120 
min in the OGTT, and 4 (15.4%) met both these criteria. All 26 diabetes cases had another OGTT 
within two weeks, that confirmed the diagnosis in all patients. IFG was present in another 79 patients 
(19.0%). IGT was present in 53 patients (12.8%), of whom 31 (58.5% of all IGT cases) had a normal 
fasting glucose. Prediabetic abnormalities, defined as IFG and/or IGT, were present in 97 patients in 
total (table 2). The prevalence of diabetes and pre-diabetic abnormalities was significantly higher in 
the patients treated with clozapine (Ȥ2 =23.87, df 4, p<.0001) (table 3), and the use of clozapine was 
significantly associated with the presence of glucose abnormalities (Ȥ2 =13.15, df 1, p<.001; controlled 
for the possible confounders age, gender and BMI). 
The metabolic syndrome was present in 30.6% of patients. Its prevalence was significantly higher in 
diabetic subjects (84.6%) compared to patients with prediabetic abnormalities (51.1%) and patients 
without glucose abnormalities (18.8%). Patients with the metabolic syndrome were more likely to 
meet criteria for diabetes or prediabetic abnormalities (table 4).  
As expected, all parameters evaluated in the OGTT (glucose and insulin values fasting, at 30 minutes, 
at 60 minutes and at 120 minutes) as well as HOMA-IR and HbA1c levels were significantly higher in 
patients with the metabolic syndrome (p<.0001). Similar highly significant differences were found on 
all fasting serum lipid values and calculated lipid risk factors for cardiovascular disease (cholesterol, 
triglycerides, HDL, LDL, total cholesterol/HDL and LDL/HDL) (p<.0001). There were no significant 
differences between antipsychotics for any of the metabolic parameters. 
 
Diagnostic properties of the screening guidelines 
In a screening based on the APA/ADA guidelines, 12 of the 26 diabetes cases (46.2%) were identified, 
as they had a fasting glucose that was higher than 125 mg/dl, and 79 patients (19.0%) showed IFG.  
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When compared to the consensus screening strategy of fasting glucose alone, the screening according 
to the WHO-derived guidelines resulted in the detection of an extra 13 diabetes cases (25 of 26 or 
96.2% of all diabetes cases).  
Thus, the difference between the two strategies was most striking with regard to the number of missed 
diabetes cases or ‘false negatives’ (3.8% for the WHO-derived guidelines against 53.8% for the 
APA/ADA guidelines), resulting in a lower sensitivity for the APA/ADA guidelines. The number 
needed to diagnose (NND), which is the expression of how many tests one has to do in order to get 1 
correct test result (either negative or positive), was much higher in the consensus screening. Ideally, 
NND equals 1, which means that every test gave a correct result. The sensitivity, specificity, 
percentage of  false negatives and NND of the two strategies compared to the ‘gold standard’ are 
shown in table 5. 
 
Discussion 
The present study, which describes the baseline data of 415 patients, is the largest study as of today, 
using an OGTT to assess glucose abnormalities in patients treated with antipsychotics. A screening 
based on the consensus guidelines showed that diabetes was present in 12 patients (2.9%), and 
impaired fasting glucose in another 79 patients (19.0%). However, in line with our hypothesis, these 
cases represented only 46.2% of diabetes cases and 69.3% of prediabetes cases (IGT and/or IFG) of 
the cases identified by means of an OGTT. In total, 6.3% (n=26) met criteria for diabetes, resulting in 
a mean annual incidence of diabetes of 3.15% (6.3% incident cases/2 years).  
These data confirm that metabolic abnormalities are highly prevalent in a relatively young sample of 
schizophrenic patients treated with antipsychotics. Compared to the estimated prevalence of diabetes 
in the Belgian general population, the prevalence in this sample is about double (Walckiers et al., 
1992; Hortulanus-Beck et al., 1990). Two large scale naturalistic studies however revealed that the 
screening and diagnosis of these abnormalities in patients treated with antipsychotics still have not 
become routine practice, and that therefore, these abnormalities frequently remain untreated (Wampers 
et al., 2004; Hanssens et al., 2006).   
Moreover, one has to take into account that all patients who were screened were not diagnosed with 
diabetes prior to this baseline screening, so that the diagnosed cases are newly detected or incidence 
cases. As the screening was performed over the period of two years, the current data suggest a mean 
annual incidence of diabetes of  3.15% (6.3% incident cases/2 years). One could argue that at the start 
of an extensive screening program, there is a possibility that in addition to new cases, already existing 
but previously undiagnosed cases are detected. However, before the start of the current screening 
program, subjects were regularly screened with fasting plasma glucose assessments as a part of clinical 
routine, and none of the included subjects had diabetes according to these assessments. Therefore, the 
newly detected cases most likely indeed represent incidence cases. This interpretation is being 
strengthened by a sensitivity analysis for the 250 patients for whom data on the first year of follow-up 
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were already available. Of these 250 patients, 10 (4.0%) were diagnosed with diabetes at the baseline 
screening. Of the remaining 240 patients (that did not have diabetes at baseline), another 10 developed 
diabetes during the first year of follow-up (4.17%), indicating that the rate reported on the whole 
sample (3.15%) is not likely to be an overestimation of the actual incidence rate. Furthermore, the 
reported incidence rate is in line with other incidence rates in patients treated with antipsychotics that 
ranged from 4.4% to 6.9% (Leslie and Rosenheck, 2004; Miller et al., 2005; Lambert et al., 2006), 
although the methods that were used to derive incidence rates in these studies were less extensive and 
the screening was performed in other regions, which makes a comparison across studies difficult. 
The data of the current study suggest that, even when screened according to the APA/ADA guidelines, 
53.8% of patients with diabetes would not have been recognized and thus, would not have been 
adequately treated. This is in line with previous research (Adam and Tarigan, 2004; Botas et al., 2003; 
Hilton et al., 2002; Tai et al., 2000), and underscores the need for a more thorough screening in high-
risk populations. Clearly, schizophrenic patients treated with antipsychotics ought to be considered at 
a very high risk of developing diabetes (Lean and Pajonk, 2003), as was convincingly shown by the 
current data. The results of the present study also suggest that the use of OGTT’s to screen and 
monitor glucose abnormalities in this high risk population should be encouraged. This is especially so 
since it has been shown that patients with postload hyperglycemia are at risk for cardiovascular 
morbidity, even in the absence of impairments in fasting glucose (DECODE Study Group; on behalf 
of the European Diabetes Epidemiology Group), which further underscores the usefulness of the 
OGTT. 
However, since the use of OGTT’s as the standard screening instrument may not be an achievable 
practice in all treatment settings due to concerns of inconvenience and high cost (Lorenzo et al., 2003; 
Stern et al., 2002), the diagnostic properties of an alternative, two-step strategy was assessed. The 
WHO-derived two-step strategy of performing an OGTT in patients with IFG detected 96.2% of 
diabetes cases. The loss of sensitivity that is inherent to a two-step strategy, as one tries to identify a 
certain risk group within a larger sample, was limited to 3.8% or 1 diabetes case that had a fasting 
glucose <100 mg/dl. This limited loss of sensitivity resulted in a superior sensitivity and NND when 
compared to the APA/ADA consensus guidelines, suggesting that the two-step strategy would provide 
a substantial improvement over the currently used APA/ADA consensus screening guidelines.  
To our knowledge, the cost-effectiveness of this two-step strategy has not been investigated before. 
Nevertheless, a study by the CDC Diabetes Cost-Effectiveness Study Group (CDC Diabetes Cost-
Effectiveness Study Group, 1998) revealed that screening for diabetes type 2 is especially cost-
effective when done in subgroups at high risk for developing diabetes and in younger patients, 
resulting in a reduction of lifetime complications such as end-stage renal disease, blindness and lower 
extremity amputations. Since the population of patients diagnosed with schizophrenia fits both the 
characteristics of relatively young age and high risk for diabetes, this suggests that a more extensive 
screening in this specific population could be cost-effective and would result in a limitation of lifetime 
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major complications and an increase in Quality-Adjusted-Life-Years (QALY’s) (CDC Diabetes Cost-
Effectiveness Study Group, 1998). Preliminary evidence (Ananth et al., 2002; Rigalleau et al., 2000; 
Peuskens et al., 2004) even suggests that in those cases where there is a rapid onset of diabetes 
following the start of antipsychotic medication, screening for diabetes could possibly result in reversal 
of diabetes by allowing a rapid switch to another antipsychotic. These findings provide additional 
arguments to stress the importance of adequately screening and treating diabetes in patients diagnosed 
with schizophrenia, and underscore the potential relevance of a more thorough screening in this 
specific population.  
Although investigating the prevalence of diabetes and prediabetes per drug treatment was not the 
primary aim of the study, these data are interesting, since they give ‘real world’ information on the 
prevalence of glucose abnormalities in a large sample of patients with schizophrenia. Especially for 
clozapine, these real world data support the clinical impression of a higher risk for glucose 
abnormalities, with not even half of the patients treated with clozapine having a normal glucose 
metabolism, and are in line with previous naturalistic studies (Gianfrancesco et al., 2006; Henderson et 
al., 2005a). However, one has to be cautious in interpreting the possible causality of the high 
prevalence of glucose abnormalities, which is especially true for the antipsychotic drugs other than 
clozapine. Indeed, the explanation for the high prevalence of glucose abnormalities in patients with 
schizophrenia and schizoaffective disorder probably is multifactorial, since in addition to the possible 
iatrogenic influence of antipsychotic medication, schizophrenic patients also display many risk factors 
for diabetes such as bad dietary habits, lack of exercise and obesity. Furthermore, it is difficult to draw 
firm conclusions regarding the causality of the reported glucose abnormalities because of the relatively 
low number of patients per treatment group and the impossibility to control for other factors such as 
dietary habits and exercise.  
In addition to diabetes, there was a high prevalence of the metabolic syndrome, which is in line with 
earlier reports (Basu et al., 2004; Cohn et al., 2004; De Hert et al., 2006b; McEvoy et al., 2005). The 
high prevalence of diabetes and other metabolic abnormalities including the metabolic syndrome may 
in part explain the high mortality rates in this population (Brown, 1997; Joukamaa et al., 2001), and 
especially why 50% of the excess mortality in this population is caused by cardiovascular disease 
(Osby et al., 2000). 
The current study also has some limitations. First, it is a cross-sectional study and therefore the 
adequacy of the current screening guidelines can not be assessed in a longitudinal fashion. It is 
possible that some diabetes or prediabetes cases would have been detected with a fasting glucose test 
in a follow-up screening. Second, this study was restricted to one site, indicating that the interpretation 
of the incidence and prevalence rates of metabolic abnormalities needs to be done with caution, since 
large regional differences in metabolic parameters have been reported in the literature (Ford et al., 
2005). Third, although this is the largest study as of today that used the OGTT to evaluate the different 
screening strategies (n=415), the number of patients with both schizophrenia or schizoaffective 
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disorder and diabetes is relatively low (n=26), meaning that the interpretation of these results needs to 
be done with caution. On the other hand, the findings of the current study are in line with previous 
literature on screening methods for diabetes in the general population. Moreover, the relatively low 
number of patients with diabetes in the current study is the consequence of the fact that both 
schizophrenia and diabetes have a relatively low prevalence. In order to collect larger numbers of 
patients with schizophrenia and diabetes to evaluate these screening guidelines, even larger, multi-site 
studies need to be conducted. As of today, no such studies have been undertaken, probably because of 
the enormous cost of doing OGTT’s in 1000 or more patients.   
In conclusion, metabolic abnormalities are highly prevalent in schizophrenic patients treated with 
antipsychotics. The importance of actively screening for these abnormalities needs to be emphasized 
and, by consequence, the widespread use of adequate screening guidelines is crucial. However, the 
guidelines as proposed by the APA/ADA(American Diabetes Association and American Psychiatric 
Association, 2004) did not sufficiently detect diabetes in this specific high risk group. In contrast, the 
alternative two-step strategy was able to detect the vast majority of diabetes cases and should therefore 
be considered in the clinical routine of screening and monitoring patients with schizophrenia. 
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Table 1. Antipsychotic (AP) treatment 
 
Antipsychotic treatment  % (n) 
Only first generation* 8.4 % (35) 
Only second generation* 80.2% (333) 
Combination of FGA# and SGA$ 10.8% (45) 
  
Only 1 antipsychotic 84.1 % (349) 
First-generation AP 10.0% (35) 
Second generation AP 90.0% (314) 
  
Second generation AP 91.1% (378) 
Second generation 
(N= 400 prescriptions) 
 
Amisulpride (n=32) 7.7% 
Aripiprazole (n=4) 1.0% 
Clozapine (n=74) 17.8% 
Risperidone (n=98) 23.6% 
Quetiapine (n=53) 12.8% 
Olanzapine (n=139) 33.5% 
 
#FGA=first generation antipsychotic; $SGA=second generation antipsychotic 
*within-class combinations (FGA-FGA or SGA-SGA) included 
 
Table 2. Overlap of glucose abnormalities identified by means of fasting glucose (column) and by means of the 
120-min glucose in the OGTT (row) in 415 patients diagnosed with schizophrenia. 
 
 
Nl fasting glucose 
(<100 mg/dl) 
IFG 
(100<126 mg/dl) 
Diabetes 
(126 mg/dl) All 
Normal OGTT  
(glucose120min<140 mg/dl) 
292 (70.4%) 48 (11.6%) 4 (1.0%) 344 (82.9%) 
IGT 
(glucose120min140<200mg/dl) 31 (7.5%) 18 (4.3%) 4 (1.0%) 53 (12.8%) 
Diabetes  
(glucose120min200 mg/dl) 1 (0.2%) 13 (3.1%) 4 (1.0%) 18 (4.3%) 
All 324 (78.1%) 79 (19.0%) 12 (2.9%) 415 (100%) 
 
This table describes the overlap between the fasting glucose results and the OGTT results. For example: 18 
subjects meet the 120 minutes OGTT criterion for diabetes, 12 subjects meet the fasting glucose criterion for 
diabetes. Of these 12, 4 also meet the 120 minutes OGTT criterion. Thus, the total amount of patients with 
diabetes is 18 (OGTT criterion) + 12 (fasting glucose criterion) – 4 (subjects that meet both criteria) = 26.
 106
Table 3. Glucose abnormalities in relation to antipsychotic treatment 
 
 
Diabetes 
 (n=26) 
Prediabetes 
(n=97) 
Normal values 
(n=292) 
Only FGA (n=35) 8.6% (3) 25.7% (9) 65.7% (23) 
Combination FGA + SGA (n=45) 2.2% (1) 28.9% (13) 68.9% (31) 
Combination SGA (n=19) 5.3% (1) 21.0% (4) 73.7% (14) 
    
Only 1 SGA (n=314) 6.7% (21) 22.6% (71) 70.7% (222) 
Amisulpride (n=26) 0% (0) 3.9% (1) 96.1% (25) 
Aripiprazole (n=3) 0% (0) 0% (0) 100% (3) 
Clozapine (n=54) 9.3% (5) 42.6% (23) 48.1% (26) 
Risperidone (n=75) 6.6% (5) 22.7% (17) 70.7% (53) 
Quetiapine (n=44) 11.4% (5) 9.1% (4) 79.5% (35) 
Olanzapine (n=112) 5.4% (6) 23.2% (26) 71.4% (80) 
 
 
 
Table 4. Glucose abnormalities in relationship with the metabolic syndrome* 
 
 Normal values Pre diabetes Diabetes Total P# 
No 82.3% (237) 16.3%  (47) 1.4%  (4) 69.4%  (288) 0.0001 
Yes 43.3% (55) 39.4%  (50) 17.3%  (22) 30.6%  (127)  
 
*Criteria are: 1)waist circumference >102 (male subjects)/ >88 (female subjects); 2)blood pressure  130/85 or 
treatment with antihypertensive medication; 3) HDL <40 mg/dl (male subjects)/ <50 mg/dl (female subjects) or 
treatment with antihyperlipidemic medication; 4) triglycerides  150 mg/dl or treatment with antihyperlipidemic 
medication; 5) fasting glucose 100 mg/dl or treatment with antihyperglycemic medication. The metabolic 
syndrome is present if at least 3 criteria are met. 
#ANOVA
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Table 5. Diagnostic properties of the different screening strategies for diabetes 
 
Screening strategy Baseline 
assessment 
Subsequent 
OGTT 
Sensitivity 
(a) 
Specificity 
(b)# 
False 
negatives (c) 
Number needed to 
diagnose (NND) (d) 
 
‘Gold Standard’* 
 
Weight (BMI) 
Waist 
circumference 
Blood pressure 
Fasting glucose 
Fasting lipids 
+ 
OGTT 
 
 
Not applicable 
 
100.0% 
 
100.0% 
 
0% 
 
1 
APA/ADA 
consensus 
guidelines 
 
Weight (BMI) 
Waist 
circumference 
Blood pressure 
Fasting glucose 
Fasting lipids 
 
No 46.2% 100.0% 53.8% 2.16 
Two-step Strategy  Weight (BMI) 
Waist 
circumference 
Blood pressure 
Fasting glucose 
Fasting lipids 
In patients with 
IFG (n=79) 
96.2% 100.0% 3.8% 1.04 
 
(a) Sensitivity: the probability of an individual with the condition having a positive test (true positives divided by true 
positives plus false negatives) 
(b) Specificity: the probability of an individual without the condition having a negative test (true negatives divided by false 
positives plus true negatives) 
(c) False negatives: undiagnosed or ‘missed’ diabetes cases 
(d) Number needed to diagnose: the expression of how many tests one has to do in order to get 1 correct test result (either 
negative or positive). Ideally, NND equals 1, which means that every test gave a correct result. 
*The ‘Gold Standard’ is defined as being 100% specific and sensitive 
#There were no false positives, since 1) the diagnosis of diabetes is defined by abnormal glycemic levels (fasting or at 120 
minutes in the OGTT) and 2) all values that were above the diabetes diagnosis threshold were double-checked and confirmed 
in all cases. As there were no false positives, the specificity by definition is 100% for all strategies. 
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Abstract 
Objective: to investigate 3-month changes in glucose metabolism in a naturalistic sample of patients 
with schizophrenia newly started on or switched to specific atypical antipsychotic medication. 
Methods: 183 patients were evaluated before initiation and 3 months after with a 75gr glucose load 
Oral Glucose Tolerance Test (OGTT). Results: 8 patients developed new-onset diabetes within 3 
months (4.4%). Initiation of clozapine resulted in a significantly higher risk for new-onset glucose 
abnormalities than initiation of aripiprazole (odds ratio 67.29, 95% CI: 5.23 – 866.49). Significant 
drug X time interactions were found for all OGTT glucose assessments (fasting: F(5, 177) = 6.79, p < 
.0001, 30 minutes: F(5, 177) = 3.89, p = .0023, 60 minutes: F(5, 177) = 5.03, p = .0002, 120 minutes: 
F(5, 177) = 3.78, p = .0028), with the evolution of glucose levels being significantly worse in patients 
initiated on clozapine (fasting, 30 minutes, 60 minutes), olanzapine (fasting, 60 minutes, 120 minutes) 
and quetiapine (fasting, 60 minutes) than in patients initiated on aripiprazole (p<.05). Clozapine was 
also significantly more deleterious than risperidone and amisulpride for fasting glucose changes 
(p<.05). Type of initiation (start or switch) did not affect any of the metabolic parameters. 
Conclusions: the incidence of new-onset glucose abnormalities including diabetes in the first 3 
months after newly starting or switching of atypical antipsychotic medication is high and may be 
markedly influenced by type of prescribed antipsychotic. The importance of accurately screening for 
new-onset glucose abnormalities after initiation of an atypical antipsychotic is emphasized. 
 
Key words: Schizophrenia, Diabetes, Metabolic Syndrome, Physical Health 
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Introduction 
High prevalence rates of diabetes have consistently been reported in patients with schizophrenia 
(Cohen et al., 2006; De Hert et al., 2006a), with growing evidence suggesting a direct diabetogenic 
effect of atypical antipsychotic medication (De Hert et al., 2006b; Henderson et al., 2005; Newcomer 
and Haupt, 2006; Scheen and De Hert, 2007). Evidence however also suggests that a diagnosis of 
schizophrenia may be a relevant factor for the development of diabetes independently of medication 
effects. Increased central obesity (Thakore et al., 2002), decreased insulin sensitivity (Cohn et al., 
2006), impaired fasting glucose (Ryan et al., 2003) and impaired glucose tolerance (Spelman et al., 
2007) were also shown at increased rates in unmedicated subjects presenting with a first episode of 
psychosis. Furthermore, high prevalence rates of diabetes and cardiovascular morbidity were reported 
in unaffected relatives (Mukherjee et al., 1989; De Hert et al., 2006a; Lamberti et al., 2004; Spelman et 
al., 2007). These findings not only support the high liability to develop diabetes in patients with 
schizophrenia, but also underscore the possible relevance of diagnostic homogeneity. Next to 
medication effects (Newcomer and Haupt, 2006), shared genetic factors could partly underlie reported 
associations (Gough and O'Donovan M, 2005; Bellivier, 2005), although not all studies found 
evidence for insulin resistance in drug-naïve patients (Arranz et al., 2004; Zhang et al., 2004).  
In two diagnostically mixed samples treated with atypical antipsychotics, annual incidence rates of 
new-onset diabetes were 4.7% (Miller et al., 2005) and 6.9% (Lambert et al., 2006a). In a sample 
consisting only of patients with schizophrenia, Leslie and Rosenheck observed an annual incidence 
rate of 4.4% in patients on a stable regimen of antipsychotic treatment (Leslie and Rosenheck, 2004). 
Likewise, in a study using the Oral Glucose Tolerance Test (OGTT), an annual incidence rate of 4.2% 
was found in 240 schizophrenia patients with OGTT-confirmed non-diabetic status at baseline who 
were on stable treatment (van Winkel et al., 2006).  
Whereas these incidence studies only included patients on a stable antipsychotic regimen for at least 3 
months (van Winkel et al., 2006; Leslie and Rosenheck, 2004), information on the exact timing of the 
development of diabetes after initiation of an atypical antipsychotic is scarce. So far, only one study 
addressed this issue (Lambert et al., 2006b), by identifying all new antipsychotic users with 
schizophrenia in the database of the U.S. Veterans Health Administration, and prospectively 
following-up any diagnosis of diabetes or antidiabetic treatment, as recorded in the database. In this 
study, that examined only patients newly initiated on haloperidol, risperidone, olanzapine and 
quetiapine, one year incidence rates of a database diagnosis of diabetes or treatment with antidiabetic 
medication were 2% in patients started on haloperidol, 3.2% in patients with risperidone, 3.3% in 
patients with olanzapine and 3.6% in patients with quetiapine. The available data thus confirm that the 
development of new-onset diabetes represents a major health problem in patients with schizophrenia 
and suggest that the development of new-onset diabetes may occur rather quickly after initiation of an 
atypical antipsychotic. However, there have been no studies that have assessed the early changes in 
glucose metabolism following initiation of atypical antipsychotics in detail by using the OGTT.   
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The aim of the current study was to investigate the early changes in glucose metabolism, including the 
3-month incidence of new-onset diabetes, in a naturalistic sample of patients with schizophrenia with 
OGTT-confirmed non-diabetic status who were initiated on a specific atypical antipsychotic. 
Furthermore, we were interested in differential effects of antipsychotic medication on the evolution of 
glucose metabolism, given the evidence that some antipsychotics, especially clozapine and olanzapine, 
could be more deleterious than others (Newcomer and Haupt, 2006). We hypothesized that substantial 
changes in glucose metabolism would occur within 3 months after initiation of an atypical 
antipsychotic, and that these changes would be most severe in patients initiated on clozapine and 
olanzapine. 
 
Methods 
Study cohort 
At our hospital and affiliate services, all patients treated with antipsychotic medication (AP) are being 
screened and monitored prospectively for metabolic abnormalities. The vast majority of patients are 
part of an extensive clinical metabolic screening and monitoring protocol, which was started in 
November 2003 (van Winkel et al., 2006; De Hert et al., 2006a; De Hert et al., 2006c; De Hert et al., 
2007). The study population is a dynamic, naturalistic cohort. Decisions regarding antipsychotic 
medication are made by the treating psychiatrist and the patient, including dose reduction, dose 
augmentation and switch strategies. These changes are recorded, and patients are monitored for 
metabolic abnormalities by means of laboratory tests, Oral Glucose Tolerance Tests (OGTT) and 
clinical examinations. The baseline characteristics of the first 415 included patients of this dynamic 
cohort that were screened with an OGTT are described in detail elsewhere (van Winkel et al., 2006; 
De Hert et al., 2006a). The sample of the current study was derived from this large, dynamic cohort. 
Patients were included if i) they had a DSM-IV diagnosis of schizophrenia or schizoaffective disorder 
as established by their treating psychiatrist, ii) if they were newly initiated on a specific atypical 
antipsychotic, meaning they did not take any antipsychotic medication and were then newly started on 
a specific atypical antipsychotic (‘starters’) or were switched from an other antipsychotic and newly 
initiated on a specific atypical antipsychotic with complete discontinuation of the previous 
antipsychotic within 3 weeks (‘switchers’) and iii) did not have diabetes before initiation of the 
specific atypical antipsychotic as confirmed with an OGTT. As one of the aims of the study was to 
assess differential medication effects on glucose metabolism, patients for whom the initiated atypical 
antipsychotic was added to existing antipsychotic medication (‘add-on’, or ‘antipsychotic 
polypharmacy’) were excluded from the analyses.  The study was approved by an ethical committee 
and all patients gave written informed consent. 
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Metabolic screening 
Patients were evaluated 2 times with a full metabolic screening, which included a 75gr glucose load 
OGTT after an overnight fast: at baseline before the initiation of the atypical antipsychotic and 3 
months after initiation of the new antipsychotic drug.  Insulin resistance (HOMA-IR) was assessed 
using fasting plasma glucose and insulin levels and a homeostatic model (Matthews et al., 1985). 
For the diagnosis of diabetes and prediabetic abnormalities the American Diabetes Association criteria 
were used: diabetes (fasting plasma glucose > 125 mg/dl and/or 2-h OGTT plasma glucose > 199 
mg/dl), Impaired fasting glucose (IFG; 100-125 mg/dl) and Impaired Glucose Tolerance (IGT, glucose 
140-199 mg/dl at 2 hours in the OGTT) (American Diabetes Association, 2006).  
 
Statistical analyses 
Descriptive statistics were computed for the basic demographic and clinical variables as well as for the 
variables relevant for the evaluation of metabolic abnormalities. Differences between treatment groups 
at baseline were evaluated through one-way analysis of variance (ANOVA). The influence of known 
diabetes risk factors and type of medication on the occurrence of glucose abnormalities (diabetes + 
pre-diabetes) was modelled through logistic regression in patients without glucose abnormalities at 
baseline (n=153). Known risk factors for diabetes, as measured at baseline, were included in the model 
(fasting glucose, glucose at 120 minutes in the OGTT, Body Mass Index (BMI), a family history of 
diabetes, High Density Lipoprotein (HDL) cholesterol blood level, Low Density Lipoprotein (LDL) 
cholesterol blood level, HDL/LDL ratio and triglycerides blood level) (American Diabetes 
Association, 2006). Drug (6) X time (2) repeated measures ANOVAs were performed to evaluate 
changes in glucose and insulin levels and in HOMA-IR as a function of antipsychotic medication over 
the follow-up period. Pairwise comparisons between antipsychotic treatment groups were evaluated 
through Tukey’s studentized range test at an alpha level of .05.  
 
Results 
Subjects
In 220 patients a specific atypical antipsychotic was newly initiated. Of these, 12 were diagnosed with 
diabetes at the OGTT that was performed before initiation. As one of the aims of the current study was 
to examine the incidence of new-onset diabetes, these patients were excluded from the analyses. Of the 
remaining 208 subjects, the initiated atypical antipsychotic was added to existing antipsychotic 
medication in 25 patients (‘add-on’, or ‘antipsychotic polypharmacy’). The 25 patients with 
polypharmacy were also excluded in order to be able to reliably assess differential medication effects, 
resulting in a final sample of 183 patients. Of these 183, 126 were not treated with antipsychotic 
medication before study entry because they were drug-naïve first-episode patients (n = 22) or because 
of non-compliance with their previous treatment (n = 104). Duration of non-compliance was not 
recorded. The remaining 57 patients were treated with antipsychotic medication (20 with risperidone, 
 118
18 with olanzapine, 6 with amisulpride, 5 with a typical antipsychotic, 4 with quetiapine, 3 with 
clozapine and 1 with bifeprunox) and were switched to the specific atypical medication under study. 
No significant differences in age, sex, Clinical Global Impression (CGI), Global Assessment of 
Functioning (GAF) score and number of different medications were found between starters and 
switchers, but starters did have a significantly shorter duration of illness (F(1, 181) = 4.51, p = .0350) 
and a significantly lower mean BMI (F(1, 181) = 16.42, p < .0001). 
Olanzapine was initiated in 50 patients (27.3%), risperidone in 48 patients (26.2%), quetiapine in 24 
patients (13.1%), aripiprazole in 22 patients (12.0%), clozapine in 21 patients (11.5%) and amisulpride 
in 18 patients (9.8%). Anticholinergic medication was prescribed in 13.7% of patients, antidepressants 
in 32.8%, benzodiazepines in 33.9%, mood stabilizers in 23.0%, antihypertensive medication in 10.4% 
and statins in 1.1%. No significant differences in age, duration of illness, Global Assessment of 
Functioning (GAF) score or Clinical Global Impression (CGI) were found for the different 
antipsychotic treatment groups, but there was a significant main effect of BMI (F(5, 147) = 3.28, p = 
.0078), although only the contrast between patients initiated on aripiprazole and on olanzapine reached 
significance, with patients initiated on aripiprazole having a significantly higher baseline BMI than 
patients treated with olanzapine (p < .05). 
Patients had DSM-IV diagnoses of schizophrenia (76.0%) and schizoaffective disorder (24.0%). Their 
mean age was 33.7 years (SD=11.6), and they had been ill for a mean of 7.5 years (SD=9.4). The 
majority of the sample was male (60.7%). Many patients had a family history of diabetes (31.2%), 
dyslipidaemia (37.7%) or cardiovascular disorders (50.8%).  
 
Incidence of new-onset diabetes 
8 patients developed diabetes within 3 months after the start of the atypical antipsychotic, resulting in 
a 3-month incidence rate of 4.4% (8/183). Patients with new-onset diabetes were initiated on clozapine 
(2 of the 21 treated patients, 9.5%), olanzapine (4 of the 50 treated patients, 8.0%), quetiapine (1 of the 
24 treated patients, 4.2%) and risperidone (1 of the 48 treated patients, 2.1%), whereas no new cases 
developed in the group treated with aripiprazole and amisulpride. Of the 8 new-onset diabetes cases, 2 
already had IFG at baseline, 1 had IGT at baseline, 2 had both IFG and IGT, indicating that 16.7% of 
patients with prediabetic abnormalities developed diabetes (table 1). The remaining 3 had no glucose 
abnormalities at baseline (table 1). Prediabetic abnormalities regressed in 12 patients (40% of patients 
with pre-existing glucose abnormalities), mainly in patients initiated on aripiprazole, whereas 
prediabetic abnormalities developed in 29 patients (18.9% of normoglycemic patients), mainly in 
patients initiated on clozapine and olanzapine  (table 1).  
 
Three-month evolution of glucose, weight and insulin 
The repeated measures drug (6) X time (2) ANOVA on glucose and insulin levels and HOMA-IR 
revealed significant main effects of time on glucose at 120 min (F(1, 177) = 4.76, p = .0304) and 
 119
insulin at 60 min (F(1, 177) = 4.38, p = .0378). There were no significant main effects of drug. There 
were no significant differences in the evolution of any of the metabolic parameters between switchers 
and starters. 
For fasting glucose, a significant drug X time interaction was observed (F (5, 177) = 6.79, p < .0001) 
(table 2). Patients initiated on clozapine had a significantly greater increase of fasting glucose than 
patients initiated on risperidone, aripiprazole or amisulpride (p < .05). Fasting glucose changes in 
patients initiated on aripiprazole differed significantly from changes observed in patients on 
olanzapine or quetiapine (p < .05).  The drug X time interaction for glucose at 30 min also reached 
significance (F(5, 177) = 3.89, p = .0023), with decreased levels in patients initiated on aripiprazole 
significantly different from increased levels in patients on clozapine. There was a significant drug X 
time interaction for glucose at 60 minutes (F(5, 177) = 5.03, p = .0002) with a decrease in patients on 
aripiprazole significantly different from increases in patients on clozapine, olanzapine and quetiapine 
(p < .05). Finally, we observed a significant drug X time interaction for glucose at 120 min (F(5, 177) 
= 3.78, p = .0028) with decreases in patients on aripiprazole significantly different from increases in 
patients treated with olanzapine (p < .05).  
A significant drug X time interaction was also found for BMI (F(5, 177) = 43.60, p < .0001) and waist 
circumference (F(5, 177) = 26.03, p < .0001) (table 2). For waist circumference, the decrease in 
patients initiated on aripiprazole was significantly different from increases in patients initiated on 
olanzapine, quetiapine, risperidone and amisulpride (p < .05) but not from increases in patients 
initiated on clozapine. For BMI, the decrease in patients initiated on aripiprazole was significantly 
different from increases in patients treated with any of the other atypicals (p < .05). The increase of 
both waist circumference and BMI in patients initiated on olanzapine was significantly larger than in 
patients initiated on risperidone (p < .05). There were no significant drug X time interactions for 
insulin measures and HOMA-IR (table 2). 
   
Prediction of new-onset glucose abnormalities  
At baseline, 153 patients were normoglycemic, both in the fasting state and after the glucose load. The 
logistic regression model predicting the incidence of any new-onset glucose abnormality (IFG, IGT, 
diabetes) based on type of antipsychotic agent and known diabetic risk factors was significant (Ȥ2 (14) 
= 42.26, p < .0001). Baseline glucose at 120 min (Ȥ2 (1) = 4.61, p = .0318) and type of antipsychotic 
(Ȥ2 (5) =18.40, p =.0025) were significantly associated with new-onset glucose abnormalities. None of 
the known risk factors for diabetes were associated with new-onset glucose abnormalities, although 
the effect of age just failed to reach significance (Ȥ2 (1) = 3.79, p = .0515). Type of initiation (start or 
switch) did not significantly predict new-onset glucose abnormalities (Ȥ2 (1) = 0.32, p = .5704). 
Higher baseline values for glucose at 120 min slightly increased the risk for the development of 
glucose abnormalities (OR = 1.023, 95% CI: 1.003-1.044). A post-hoc analysis failed to find an 
association between weight change over the 3-month period and new-onset glucose abnormalities (Ȥ2 
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(1) = .27, p = .604), nor did including weight change in the predictive model change the significant 
associations with type of antipsychotic medication (Ȥ2 (5) = 17.31, p = .0039) and baseline glucose at 
120 min in the OGTT (Ȥ2 (1) = 4.81, p = .0284). 
Patients treated with clozapine had a significantly higher risk of developing glucose abnormalities at 3 
months follow-up as compared to patients on aripiprazole (odds ratio (OR)= 67.29, 95% CI: 5.23 – 
866.49). The risk of developing new-onset glucose abnormalities in patients on olanzapine, 
risperidone, amisulpride, and quetiapine did not significantly differ from the risk for patients on 
aripiprazole.  
 
Discussion 
Findings  
To our knowledge, this is the first study to examine the incidence of new-onset diabetes and early 
changes in glucose metabolism in patients with schizophrenia who were initiated on a specific atypical 
antipsychotic, by means of the OGTT. A 3-month incidence rate of new-onset diabetes of 4.4% was 
found. Most patients with new-onset diabetes already had baseline prediabetic abnormalities (5/8, 
62.5%), although a substantial number did not (3/8, 37.5%). Initiation of clozapine resulted in a 
significantly higher risk of developing glucose abnormalities at 3-months follow-up as compared to 
patients on aripiprazole. There were significant drug X time interactions for all glucose assessments in 
the OGTT (fasting, 30 min, 60 min, 120 min), with the evolution of glucose levels being significantly 
worse in patients treated with clozapine (fasting, 30 min, 60 min), olanzapine (fasting, 60 min, 120 
min) and quetiapine (fasting, 60 min) than in patients treated with aripiprazole. Clozapine was also 
significantly worse than risperidone and amisulpride at the fasting glucose assessment (p<.05). Type 
of initiation (start or switch) did not affect the evolution of any of the metabolic parameters. 
Interestingly, the development of new-onset glucose abnormalities was not associated with BMI or 
weight change over the 3-month follow-up period. 
 
Incidence
As a 10-year OGTT study in a European general population sample of 837 subjects aged between 40 
and 79 in the village of Bruneck (Italy) revealed a yearly incidence rate of 0.72% (Bonora et al., 
2004), a 3-month incidence of new-onset diabetes of 4.4% in a representative sample of patients with 
schizophrenia with a mean age of 34 years is disturbingly high. This supports the claim that compared 
to the general population, patients with schizophrenia treated with atypical antipsychotics are at a 
considerably increased risk to develop diabetes (De Hert et al., 2006a), although it needs to be noted 
that the reasons for this increased risk are likely multifactorial, including differences in known risk 
factors such as BMI and dietary habits. Compared to the 1-year incidence rate of 4.2% reported in the 
identically screened sample of 240 patients that was on stable medication (van Winkel et al., 2006), 
the current 3-month 4.4% incidence rate is strikingly similar, despite a much shorter follow-up period. 
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This suggests that the chance of developing diabetes is especially high in the first months after 
initiation of antipsychotic medication, which underscores the importance of accurately screening for 
new-onset glucose abnormalities after the initiation of an atypical antipsychotic (De Nayer et al., 2005; 
Newcomer, 2006). Indeed, our data convincingly show that even patients without abnormalities at 
baseline can develop prediabetic abnormalities and even frank diabetes within a 3-month period.
  
Compared to the only other study so far in patients with schizophrenia who were newly started on a 
second-generation antipsychotic (Lambert et al., 2006b), the current 3-month incidence rate of 4.4% is 
higher than the reported 1-year incidence rates of  3.2% in patients started on risperidone, 3.3% in 
patients started on olanzapine and 3.6% in patients started on quetiapine. However, this was an 
epidemiological study that used the Veterans Health Administration database to identify new users of 
atypical antipsychotics and to assess the incidence of new-onset diabetes. This also represents the 
main limitation of the latter study, as convincing evidence exists that a large proportion of incident 
diabetes cases remain undiagnosed for years (Samuels et al., 2006), making it likely that the reported 
incidence rates are an underestimation of the actual incidence rates. In contrast, the diagnostic 
accuracy of the current study is very high, as new-onset diabetes was assessed by means of the ‘Gold 
Standard’: the OGTT. However, whereas the study by Lambert and colleagues had a sample of 15.767 
patients (Lambert et al., 2006b), our study only included 183 patients. Given the low incidence rates 
typically reported for diabetes, this is a relatively low number.  
  
Risk factors for new onset glucose abnormalities and differential medication effects 
The finding that clozapine was significantly associated with new-onset glucose abnormalities is in line 
with earlier evidence, with naturalistic studies finding glucose abnormalities in more than half of 
patients on stable clozapine treatment for at least 3 months (van Winkel et al., 2006) and even frank 
diabetes in almost half of clozapine-treated patients after 10 years of treatment (Henderson et al., 
2005). The available data also suggest that aripiprazole is safer in this regard (De Hert et al., 2007), 
which was confirmed by the finding that the evolution of OGTT glucose levels was significantly better 
in patients initiated on aripiprazole than in patients initiated on clozapine, olanzapine and quetiapine. 
Interestingly, none of the known risk factors for diabetes were associated with the development of 
new-onset glucose abnormalities, although the effect of age just failed to reach significance. A post-
hoc analysis also failed to find an association between weight change over the 3-month period and 
new-onset glucose abnormalities, nor did including weight change in the predictive model change the 
significant associations with type of antipsychotic medication and baseline glucose at 120 min in the 
OGTT.  
The absence of significant associations between known risk factors and glucose abnormalities is in 
contrast to our research on patients on stable medication (van Winkel et al., 2006), where age and BMI 
were significantly associated with glucose abnormalities. First, this supports the importance of 
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differential antipsychotic medication effects in the development of new-onset glucose abnormalities in 
patients with schizophrenia. Second, although speculative, it may also suggest two possible 
mechanisms for the development of new-onset diabetes in patients treated with antipsychotic 
medication: a slower onset related to weight gain, leading to insulin resistance and gradual beta-cell 
decompensation (Haupt et al., 2007),  and a quick onset more directly related to antipsychotic 
treatment effects, possibly via a specific effect on beta-cell function, where the influence of known 
risk factors is much less prominent. This claim is supported by the finding that the latter type may be 
reversible following a medication switch to aripiprazole (De Hert et al., 2006b), or amisulpride (De 
Hert et al., 2005). These findings also suggest that certain antipsychotic medications, especially 
clozapine, should be considered as medication that can induce diabetes (American Diabetes 
Association, 2006).   
Next to type of antipsychotic medication, glucose level at 120 minutes in the OGTT was the only 
significant predictor of subsequent glucose abnormalities, which further underscores the usefulness of 
the OGTT in patients treated with atypical antipsychotics as reported earlier (van Winkel et al., 2006; 
De Hert et al., 2006d; Cohen et al., 2006), certainly when taking into account that IGT (Qiao et al., 
2003), but not IFG (Rijkelijkhuizen et al., 2007), was shown to be associated with increased 
cardiovascular mortality in the absence of diabetes in the general population. 
 
Limitations
The current study also has some limitations. As previously stated, the sample was relatively small to 
assess the low incidence rates typically reported for diabetes. This is especially true for differences 
between atypical antipsychotics, although the demonstrated differences are in line with previous 
research. Furthermore, the current study is a naturalistic study, meaning that there was no random 
allocation of antipsychotic medication. It is thus likely that patients’ and caregivers’ views of 
anticipated metabolic side-effects have influenced their choice for an antipsychotic. Although we have 
tried to minimize such influence by controlling for known diabetes risk factors, it is still possible that 
this has biased our results to some extent. Nevertheless, the data provide ‘real-world’ evidence that a 
significant proportion of a representative, naturalistic sample of patients with schizophrenia develops 
new-onset diabetes and prediabetic abnormalities within 3 months after initiation of a second-
generation antipsychotic, which is of major clinical significance. The importance of accurately 
screening for diabetes in patients with schizophrenia therefore needs to be stressed.  
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Table 1. Three-month glucose abnormalities in a naturalistic sample of patients with schizophrenia who were 
normoglycemic (n=153) and prediabetic (IFG and/or IGT; n=30) at baseline. 
 
NORMOGLYCEMIC PATIENTS 
(n=153) 
 
PREDIABETIC PATIENTS 
(n=30) 
 
No abnormality 121 (79.1%) No abnormality 12 (40.0%) 
IFG and/or IGT 29 (18.9%) IFG and/or IGT 13 (43.3%) 
Diabetes 3 (2.0%) Diabetes 5 (16.7%) 
 
Amisulpride (n=14) 
  
Amisulpride (n=4) 
 
No abnormality 12 (85.7%) No abnormality 2 (50.0%) 
IFG and/or IGT 2 (14.3%) IFG and/or IGT 2 (50.0%) 
Diabetes 0 (0.0%) Diabetes 0 (0.0%) 
 
Aripiprazole (n=17) 
  
Aripiprazole (n=5) 
 
No abnormality 16 (94.1%) No abnormality 5 (100.0%) 
IFG and/or IGT 1 (5.9%) IFG and/or IGT 0 (0.0%) 
Diabetes 0 (0.0%) Diabetes 0 (0.0%) 
 
Clozapine (n=18) 
  
Clozapine (n=3) 
 
No abnormality 8 (44.4%) No abnormality 0 (0.0%) 
IFG and/or IGT 9 (50.0%) IFG and/or IGT 2 (66.7%) 
Diabetes 1 (5.6%) Diabetes 1 (33.3%) 
 
Olanzapine (n=39) 
  
Olanzapine (n=11) 
 
No abnormality 31 (79.5%) No abnormality 3 (27.3%) 
IFG and/or IGT 8 (20.5%) IFG and/or IGT 4 (36.4%) 
Diabetes 0 (0.0%) Diabetes 4 (36.4%) 
 
Quetiapine (n=23) 
  
Quetiapine (n=1) 
 
No abnormality 17 (73.9%) No abnormality 1 (100.0%) 
IFG and/or IGT 5 (21.7%) IFG and/or IGT 0 (0.0%) 
Diabetes 1 (4.4%) Diabetes 0 (0.0%) 
 
Risperidone (n=42) 
  
Risperidone (n=6) 
 
No abnormality 37 (88.1%) No abnormality 1 (16.7%) 
IFG and/or IGT 4 (9.5%) IFG and/or IGT 5 (83.3%) 
Diabetes 1 (2.4%) Diabetes 0 (0.0%) 
 
IFG: Impaired Fasting Glucose (fasting glucose 100-125 mg/dl)  
IGT: Impaired Glucose Tolerance (glucose 140-199 mg/dl at 2 hours in the OGTT)
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Abstract 
Objective: The presence of metabolic abnormalities is an important risk factor for cardiovascular disease and 
diabetes. There are limited data on the prevalence of the metabolic abnormalities in disorders other than 
schizophrenia in which antipsychotic medication is part of routine treatment. Methods: Sixty consecutive 
patients with bipolar disorder at our university psychiatric hospital and affiliate services were entered in an 
extensive prospective metabolic study including an oral glucose tolerance test. The prevalence of the 
metabolic syndrome was assessed based on the National Cholesterol Education Program Adult Treatment 
Protocol criteria (ATP III), the adapted ATP-III criteria using a fasting glucose threshold of 100mg/dl,  and 
the recently proposed criteria from the International Diabetes Federation (IDF). Results: The analysis of 60 
patients showed a prevalence of the metabolic syndrome of 16.7% (ATP-III), 18.3% (adapted ATP-III) and 
30.0% (IDF), respectively. 6.7% of the patients met criteria for diabetes and 23.3% for prediabetic 
abnormalities. Conclusion: The metabolic syndrome and glucose abnormalities are highly prevalent among 
patients with bipolar disorder. They represent an important risk for cardiovascular and metabolic disorders. 
Assessment of the presence and monitoring of metabolic abnormalities and its associated risks should be part 
of the clinical management of patients with bipolar disorder. 
 
Key words: Bipolar disorder, Metabolic Syndrome, Diabetes, Physical Health 
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Introduction 
Since the introduction of second generation antipsychotics and their association with metabolic abnormalities, 
there has been a rise of interest into the occurrence of metabolic abnormalities in patients treated with these 
drugs, although the main focus of research was on patients diagnosed with schizophrenia (Jin et al., 2004; 
Allison and Casey, 2001; Meyer and Koro, 2004). The issue of abnormalities in glucose metabolism has 
received most attention (Jin et al., 2002; Jin et al., 2004; Haupt and Newcomer, 2001; Scheen and De Hert, 
2005; Newcomer, 2005; De Nayer et al., 2005; De Hert et al., 2006a).  
Next to diabetes, there has been a surge of interest into other medical conditions such as cardiovascular 
morbidity, abnormal lipid metabolism and obesity that also have a serious impact on the physical health. In 
patients with schizophrenia, recent research has demonstrated a prevalence of 40 to 50% of the metabolic 
syndrome, which comprises abnormalities in glucose metabolism, lipid metabolism, obesity and blood 
pressure (Heiskanen et al., 2003; Basu et al., 2004; De Hert et al., 2006b).  
In contrast to patients diagnosed with schizophrenia, research on metabolic abnormalities in patients with 
bipolar disorder has been relatively scarce. Three retrospective chart reviews of patients with bipolar disorder 
(Lilliker, 1980; Cassidy et al., 1999; Regenold et al., 2002), one of which also investigated diabetes 
prevalence in patients with schizoaffective disorder and schizophrenia (Regenold et al., 2002), found evidence 
for an increased prevalence of diabetes in these patients, when compared to the general population. It has been 
previously shown, however, that a large proportion of diabetes cases remain undetected when patients are not 
actively screened for these abnormalities (van Winkel et al., 2006; Taylor et al., 2005; Sernyak et al., 2005; 
De Hert et al., 2006c), which implicates that the actual prevalence of diabetes in patients with bipolar disorder 
could even be higher than the rates reported in these studies.  
With respect to the metabolic syndrome, a study by Fagiolini and colleagues evaluated the prevalence of the 
metabolic syndrome in 171 patients with bipolar disorder, and found a prevalence of 30%, using ATP III 
criteria (Fagiolini et al., 2005). Furthermore, there is convincing evidence for an increased prevalence of 
obesity in bipolar patients (Elmslie et al., 2000; McElroy et al., 2002; Fagiolini et al., 2002; Fagiolini et al., 
2003), and possibly also for different dietary habits, with bipolar patients consuming more sugars and 
carbohydrates than controls (Elmslie et al., 2001). These data clearly show the relevance of investigating 
metabolic abnormalities in patients with bipolar disorder.  
To our knowledge, no study has specifically addressed the prevalence of metabolic abnormalities in bipolar 
patients with a comprehensive metabolic screening using an oral glucose tolerance test. The aim of the current 
study was to investigate the prevalence of metabolic abnormalities and the metabolic syndrome in a sample of 
60 patients with bipolar disorder.  
 
Methods 
At the University Psychiatric Center Katholieke Universiteit Leuven in Kortenberg (Belgium) and its affiliate 
services, according to international guidelines, patients treated with antipsychotic medication are being asked 
to participate in an extensive screening and prospective follow-up study of metabolic parameters. The vast 
majority of patients treated with antipsychotic medication and in follow-up in our hospital or its affiliate 
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services are part of this extensive metabolic study, which was started in November 2003. This screening 
program was described extensively elsewhere (De Hert et al., 2007; van Winkel et al., 2006; De Hert et al., 
2006b; De Hert et al., 2006c; De Hert et al., 2006d). In short, the study population is a dynamic, naturalistic 
cohort. Referral by the treating psychiatrist for metabolic screening and monitoring is a clinical routine in our 
hospital and its affiliate services, certainly for hospitalized patients and to a lesser extent for ambulatory 
patients. Although no systematic data are being recorded on patients who refuse this monitoring, the clinical 
experience learns that very few patients do so. Decisions regarding medication are made by the treating 
psychiatrist together with the patient, including dose reduction, dose augmentation, and switch strategies. 
These changes are recorded and patients are being monitored by means of laboratory tests, Oral Glucose 
Tolerance Tests and clinical examinations. The baseline characteristics of the first 430 patients with 
schizophrenia or schizoaffective disorder of this cohort were previously reported (De Hert et al., 2006b). The 
current study describes the baseline characteristics of the first 60 patients with bipolar disorder. As the 
diagnosis is a clinical diagnosis recorded by the treating psychiatrist, and no structured diagnostic interview 
was done, it was not possible to distinguish bipolar I and bipolar II patients.  
At baseline, patients received a full fasting laboratory screening, clinical measurements and an ECG. A 75gr 
glucose load Oral Glucose Tolerance Test (OGTT) was performed in all patients. Patients were initiated on an 
overnight fast and were monitored during the OGTT. All laboratory analyses were performed in the same 
laboratory.  
The presence of the metabolic syndrome was assessed using the ATP-III criteria, the adapted ATP-III criteria 
(fasting glucose criterion of 100 instead of 110mg/dl, plus including treatment for hypertension, -lipidemia 
and –glycemia as criteria) and the recent IDF criteria (for overview see table 4) (Expert Panel on Detection 
and Evaluation of Treatment of High Blood Cholesterol in Adults, 2001; Grundy et al., 2005; IDF, 2005). For 
the diagnosis of diabetes and prediabetic abnormalities, we used the criteria of the American Diabetes 
Association (Impaired fasting glucose (IFG): fasting glucose 100-125 mg/dl and Impaired Glucose Tolerance 
(IGT), glucose 140-199 mg/dl at 2 hours in the OGTT) (American Diabetes Association, 2006). Patients were 
not known with diabetes prior to the baseline metabolic screening.  
Descriptive statistics were computed for the basic demographic and clinical variables as well as for the 
variables relevant for the evaluation of metabolic abnormalities. The influence of the presence/absence of the 
metabolic syndrome and the presence/absence of glucose abnormalities on continuous variables was assessed 
by means of an independent samples t-test. The association between categorical variables was evaluated by a 
chi-square test. The study was approved by an ethical committee and all patients gave written informed 
consent.  
 
Results 
Subjects
The mean age of the patients was 45.3 years (std 13.0) and the mean duration of illness was 9.4 years (std 
10.9). Of these patients, 26 were male (43.3%), and all patients were caucasians. All subjects completed the 
assessments. The majority of patients was able to live independently in the community (n=55, or 91.7%) and 
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17 patients also had a job (28.3%). There was a high prevalence of family history for cardiovascular and 
metabolic disorders (table 1). The majority of patients had a normal weight, and obesity was only present in 5 
patients (8.3%). Except for 7 patients, all patients were treated with antipsychotic medication. The most 
frequently used antipsychotics were olanzapine and quetiapine (table 2). On average, patients received 3.2 (std 
1.5) different medications. Next to antipsychotic medication, patients were treated with anticholinergics (5%), 
antidepressants (46.5%) and benzodiazepines (35.0%). Thirty patients received mood stabilisers: 20 patients 
received valproic acid, 10 lithium, 3 lamotrigine and 1 carbamazapine (4 patients took 2 mood stabilizers). 
Twenty patients took not-psychoactive medication, which was relevant for metabolic disturbances in 9 
patients, who all took antihypertensive medication. Except for these 9 patients, no other patients were known 
with hypertension prior to the baseline screening; similarly, no patients were known with diabetes or lipid 
disorders prior to the baseline screening.  
 
Metabolic abnormalities 
The prevalence of the metabolic syndrome according to the different definitions is shown in table 3.  There 
was no significant difference in the prevalence of the metabolic syndrome according to sex, although female 
patients were significantly more likely to meet the increased waist criterion according either to ATP-III (Ȥ2 
=4.67, p<.0307) or IDF criteria (Ȥ2 =5.98, p<.0144). Abnormal lipid values were frequently observed: 35 
patients (58.3%) had elevated cholesterol, 31 patients (51.7%) elevated LDL cholesterol, 16 (26.7%) elevated 
triglycerides and 13 (21.7%) low HDL cholesterol, with all of these elevated measures being uncovered for 
the first time. Patients meeting criteria for the metabolic syndrome were significantly more likely to take a 
second-generation antipsychotic, except for patients meeting criteria for the metabolic syndrome according to 
the IDF definition (ATP III: 7 of 10 patients, Ȥ2 =9.4, p<.01; adapted ATP III: 8 of 11 patients, Ȥ2 =8.1, 
p=.0175; IDF: 16 of 18 patients, Ȥ2 =2.4, p=.31). Patients with the metabolic syndrome were significantly 
more likely to be overweight or obese than patients that did not meet criteria for the metabolic syndrome 
(ATP III: 8 of 10 patients, Ȥ2 =17.3, p<.001; adapted ATP III: 9 of 11 patients, Ȥ2 =21.4, p<.0001; IDF: 10 of 
18 patients, Ȥ2 =12.2, p<.01).  
According to ADA criteria, 4 patients (6.7%) met criteria for diabetes and another 14 (23.3%) met criteria for 
prediabetes (14 IFG, of whom 9 also had IGT). Of the patients with diabetes, 3 were treated with quetiapine 
and 1 with quetiapine combined with olanzapine. Two of the patients who met criteria for diabetes were not 
treated with a mood stabilizer, the other two were treated with lithium. Patients with diabetes were 
significantly older than patients without diabetes (F(1, 58)=4.9, p=.0314). Similarly, patients that met criteria 
for the metabolic syndrome, regardless of the definition applied, were significantly older than patients not 
meeting criteria for the metabolic syndrome (ATP III: F(1, 58)=14.5, p<.001; adapted ATP III: F(1, 58)=10.8, 
p<.01; IDF: F(1, 58)=4.3, p=.0422). Of the patients with prediabetic abnormalities, 3 were treated with 
risperidone, 2 with clozapine, 3 with quetiapine, 5 with olanzapine and 1 without antipsychotic medication 
(who took two mood stabilizers and an antidepressant). Patients with the metabolic syndrome were more 
likely to meet criteria for diabetes or prediabetic abnormalities in all definitions applied (table 4). Patients 
with the metabolic syndrome according to the IDF criteria were more likely to have a family history of 
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diabetes (Ȥ2 =4.9, p=.0269), but this was not found for patients meeting criteria for the metabolic syndrome 
according to the ATP III or adapted ATP III criteria, or for patients that met criteria for diabetes. Likewise, the 
presence of a family history of lipid disorders or cardiovascular disease was not significantly different in 
patients with or without diabetes, or in patients with or without the metabolic syndrome for all definitions 
applied.  
 
Discussion 
To our knowledge, this is the first non-retrospective study to directly assess the prevalence of diabetes in 
patients with bipolar disorder, by the use of an OGTT. Furthermore, the metabolic syndrome and other 
metabolic abnormalities were assessed. High rates of diabetes, the metabolic syndrome and metabolic 
abnormalities were found. These results confirm the high prevalence of the metabolic syndrome in patients 
with bipolar disorder, reaching as much as twice the prevalence of the general Belgian population matched for 
age (Rietzschel et al., 2005). The prevalence of diabetes in the current sample was 3 times higher than the rate 
of drug-treated diabetes in the general population (Walckiers et al., 1992). Therefore, these data clearly 
demonstrate the need for screening for the metabolic syndrome and diabetes, not only in patients diagnosed 
with schizophrenia, as suggested in the literature (Marder et al., 2004; De Hert et al., 2006a; De Nayer et al., 
2005; van Winkel et al., 2006), but also in patients with bipolar disorder, or at least those who are being 
treated with second generation antipsychotics. The importance of such screening is underlined by the rates of 
newly detected and previously untreated hypertension in 33% of patients and hypercholesterolemia in 58% of 
patients, which is in line with high rates of non-treatment in patients with schizophrenia (Nasrallah, 2006).   
Despite these increased prevalence rates when compared to the general population, the prevalence of the 
metabolic syndrome in the current sample of bipolar patients was considerably lower than the prevalence 
reported by Fagiolini and colleagues (Fagiolini et al., 2005). These differences in prevalence rates are likely to 
be due to life style differences in the European versus the American population, but to our knowledge, no 
study has specifically handled this issue. Nevertheless, estimates of the metabolic syndrome in the general 
population have consistently been lower for European than for US populations (Ferreira et al., 2005; 
Boulogne and Vantyghem, 2004; Hu et al., 2004; Ford et al., 2004; Ford et al., 2002).  
When compared to patients with schizophrenia or schizoaffective disorder (De Hert et al., 2006b), the 
prevalence of the metabolic syndrome appears lower in the bipolar patient group. Interestingly, rates of 
glucose abnormalities were as high in bipolar patients as in schizophrenia patients (van Winkel et al., 2006), 
as was the presence of a family history of cardiovascular complications, diabetes and lipid disorders (De Hert 
et al., 2006e). The current results suggest that patients with bipolar disorder are also at high risk to develop 
metabolic abnormalities, and thus, that the increased risk for the development of these abnormalities is not 
limited to patients with schizophrenia. Interestingly, the current results suggest that the development of the 
metabolic abnormalities is only moderately associated with weight, since of the current sample, 43 of the 60 
patients had a normal weight (body mass index between 20 and 25) and only 5 patients met criteria for obesity 
(body mass index above 30). An other interesting finding is the finding that female patients were more likely 
to have increased waist circumference in the current study, which is in line with studies in patients with 
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schizophrenia (De Hert et al., 2006b; McEvoy et al., 2005). Unfortunately, the sample size did not permit to 
investigate the liability to develop metabolic abnormalities according to the individual antipsychotic drugs. 
The current study also has some limitations. First and most importantly, the current sample of patients with 
bipolar disorder is relatively small. Furthermore, it consisted mainly of patients that were treated with a 
second generation antipsychotic (almost 90%), and may thus not be representative for bipolar patients in 
general. Second, it is a cross-sectional study. We intent to follow-up this cohort prospectively, in order to 
assess metabolic changes during the course of the illness and in function of antipsychotic regimes. Third, we 
failed to include other parameters, such as dietary habits, physical activity level and psychopathological 
profile. Fourth, patient recruitment was restricted to one site, which could have influenced our results, since 
large regional differences in the prevalence of metabolic abnormalities have been reported, at least in the US 
(Ford et al., 2005). Future research should address these issues more specifically, in large, multi-site samples 
and with prospective study designs.   
In conclusion, our data confirm the high prevalence of metabolic abnormalities, and especially glucose 
metabolism disturbances, for a European population of patients with bipolar disorder. Caregivers should 
carefully monitor and treat metabolic abnormalities in these patients.  
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Table 1 
Clinical and demographic data. 
 All 
Age 45.3 (± 13.0) 
Sex  
Female 56.7% (34) 
Male 43.3% (26) 
GAF 58.7 (± 8.7) 
Age first admission 35.9 (± 12.3) 
N admissions 3.3 (± 2.5) 
Duration of illness 9.4 (± 10.9) 
Number of different drugs 3.2 (± 1.5) 
BMI 24.4 (± 4.2) 
BMI segmentation  
Normal (20-25 kg/m2) 70% (42) 
Overweight (25-30 kg/m2) 21.7% (13) 
Obese (>30 kg/m2) 8.3% (5) 
Living situation  
Sheltered housing 3.3 % (2) 
With family 20 % (12) 
Partner 35% (21) 
Alone 36.7% (22) 
Residential facility 5% (3) 
Occupation  
Work 28.3% (17) 
Sheltered work 0% (0) 
Study/training 3.3% (2) 
None 68.3% (41) 
Family history of CVD 40% (24) 
Family history of diabetes 30% (18) 
Family history of lipid disorder 30% (18) 
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Table 2 
Medication characteristics. 
 % (n) 
Anticholinergic 5.0% (3) 
Benzodiazepine 35.0% (21) 
Antidepressant 46.6% (28) 
Mood stabiliser* 50% (30) 
Valproate 66.7% (20) 
Lithium 33.3% (10) 
Lamotrigine 10.0% (3) 
Carbamazepine 3.3% (1) 
  
No antipsychotic 11.7% (7) 
Only first generation 0% (0) 
Only second generation 78.3% (47) 
Combination 10% (6) 
  
Second generation antipsychotic 88.3% (53) 
Second generation  
Aripiprazole 1.9% (1) 
Clozapine 3.7% (2) 
Risperidone 20.4% (11) 
Quetiapine 31.5% (17) 
Amisulpride 1.8% (1) 
Olanzapine 40.7% (22) 
No medication 0% (0) 
 
*4 patients combine two mood stabilizers
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Table 3 
Metabolic syndrome criteria prevalence. 
 
All (n=60) 
% (n) 
Male (n=26) 
% (n) 
Female (n=34) 
% (n) 
P 
ATP-III* 16.7% (10) 19.2 % (5) 17.6% (5) ns 
Criteria:     
Waist (M>102, F>88) 30.0% (18) 15.4% (4) 41.4% (14) 0.03 
Blood pressure  ( 130/85) 48.3% (29) 61.5% (16) 38.2% (13) ns 
HDL (M<40 mg/dl, F<50 mg/dl) 21.7% (13) 19.2% (5) 23.5% (8) ns 
Triglycerides ( 150 mg/dl) 26.7% (16) 38.4% (10) 17.6% (6) ns 
Glucose (110 mg/dl) 13.3% (8) 15.1% (4) 11.8% (4) ns 
     
Adapted ATP-III* 18.3% (11) 19.2% (5) 17.6% (6) ns 
Criteria:     
Waist (M>102, F>88) 30.0% (18) 15.4% (4) 41.4% (14) 0.03 
Blood pressure  ( 130/85)*** 48.3% (29) 61.5% (16) 38.2% (13) ns 
HDL (M<40 mg/dl, F<50 mg/dl) 21.7% (13) 19.2% (5) 23.5% (8) ns 
Triglycerides ( 150 mg/dl) 26.7% (16) 38.4% (10) 17.6% (6) ns 
Glucose ( 100 mg/dl)**** 28.3% (17) 23.1% (6) 32.4% (11) ns 
     
IDF** 30.0% (18) 34.6% (9) 26.5% (9) ns 
Criteria:     
Waist (M  94, F  80) 60.0% (36) 30.6% (11) 69.4% (25) 0.01 
Blood pressure ( 130/85) 48.3% (29) 61.5% (16) 38.2% (13) ns 
HDL (M<40 mg/dl, F<50 mg/dl) 21.7% (13) 19.2% (5) 23.5% (8) ns 
Triglycerides ( 150 mg/dl) 26.7% (16) 38.4% (10) 17.6% (6) ns 
Glucose (100 mg/dl) 28.3% (17) 23.1% (6) 32.4% (11) ns 
 
*Metabolic syndrome if 3 of 5 criteria are met. 
**Metabolic syndrome if 2 criteria AND the waist criterion are met (waist is obligatory). 
***Or if treated with antihypertensive medication. 
****Or if treated with insulin or glucose-lowering medication. 
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Table 4 
The prevalence of glucose abnormalities depending on the absence (‘No’) or presence (‘Yes’) of the metabolic syndrome according to 
the different definitions. 
 
Normal values 
% (n) 
Pre diabetes 
% (n) 
Diabetes 
% (n) 
Total 
% (n) 
P 
ATP-III     <0.001 
No 78% (39) 20% (10) 2%  (1) 83.3%  (50)  
Yes 30% (3) 40% (4) 30%  (3) 16.7%  (10)  
      
Adapted ATP-III      <0.001 
No 79.6% (39) 18.4%  (9) 2%  (1) 81.7%  (49)  
Yes 27.3% (3) 45.4%  (5) 27.3%  (3) 18.3%  (11)  
      
IDF     <0.001 
No 83.3%  (35) 16.7%  (7) 0%  (0) 70%  (42)  
Yes 38.9% (7) 38.9%  (7) 22.2%  (4) 30%  (18)  
      
Total 70%  (42) 23.3%  (14) 6.7%  (4)   
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Chapter 9 
DISCUSSION
 
Endophenotypes for schizophrenia research 
Schizophrenia is a complex disorder, with genes and environmental factors likely to interact in its etiology, 
hereby complicating the search for causative genes.  In an effort to reveal susceptibility genes, schizophrenia 
research has therefore turned to the endophenotype strategy, as endophenotypes are thought to reflect the 
actions of genes predisposing an individual to a disorder, even in the absence of diagnosable pathology. The 
underlying assumption is that individual endophenotypes are determined by fewer genes than the more 
complex and etiologically heterogeneous phenotype of schizophrenia, and that investigating endophenotypic 
outcomes would thus reduce the complexity of genetic analyses.  
The advantage of the endophenotype strategy over straightforward gene-disorder association strategies is 
illustrated best by the example of COMTVal158Met . Several findings make COMT a plausible candidate gene for 
schizophrenia: it is implicated in the catabolism of dopamine and contains a functional polymorphism that 
directly affects catabolic enzyme function (Chen et al., 2004). Furthermore, it maps to the 22q11 region that 
has been identified as one of three loci that had the highest likelihood of harbouring schizophrenia-risk genes 
in a meta-analysis of genome-wide linkage scans (Badner and Gershon, 2002) and is deleted in the velo-
cardial-facial syndrome, of which the psychiatric presentation resembles the clinical syndrome of 
schizophrenia (Shprintzen et al., 1992; Bassett et al., 2003). Despite this evidence pointing towards a role of 
COMTVal158Met in the etiology of schizophrenia, two meta-analyses disappointingly found minimal or no 
evidence for an association between the COMTVal158Met polymorphism and schizophrenia (Fan et al., 2005; 
Munafo et al., 2005), as did a study in two large samples (Williams et al., 2005). 
However, by using an endophenotypic approach, recent studies have suggested a role of COMTVal158Met in 
(candidate) endophenotypes for schizophrenia such as P50 gating (Lu et al., 2007), schizotypy (Smyrnis et al., 
2007; Schurhoff et al., 2007) and stress-sensitivity (chapter 4), which underscores the usefulness of 
endophenotypic rather than disorder outcomes.  
This thesis aimed to explore clinical and genetic correlates of three candidate endophenotypes for 
schizophrenia, ie cognitive impairments, stress-sensitivity and metabolic disturbances. These endophenotypes 
were chosen because of their direct impact on treatment and outcome compared to other, more subtle 
endophenotypic markers.  
 
Cognition for genetic research in schizophrenia 
Cognition as an endophenotype for schizophrenia 
Cognitive impairments are well established endophenotypic markers for schizophrenia (Gould and Gottesman, 
2005; Gottesman and Gould, 2003; Snitz et al., 2006), for several reasons: because of their biological 
plausibility in the etiology of schizophrenia; because a meta-analysis revealed relatively large cognitive 
impairments in memory, attention and executive functioning and moderate impairments in vocabulary and 
145
visual perceptive skills in 7420 patients with schizophrenia compared to 5865 controls (Heinrichs and 
Zakzanis, 1998); and because these cognitive impairments were also found, to a lesser degree, in first-degree 
relatives of patients with schizophrenia (Finkelstein et al., 1997; Gold, 2004). These findings show that 
cognitive impairments are associated with the illness (criterion 1 of the endophenotype concept as described 
in chapter 1), that these traits are presumably heritable (criterion 2), cosegregate with the illness within 
families (criterion 4) and are also found in a higher rate in unaffected relatives than in the general population 
(criterion 5).  
However, this thesis suggested cognitive impairments may not be as stable, or ‘state-independent’ (criterion 
3), as previously thought. Evidence suggests significant intellectual decline preceding the first episode of 
psychosis (Rabinowitz et al., 2000), especially in subjects wither higher premorbid capacities (chapter 2). In 
those patients, catching up of cognitive function may take place later in the course of the illness, whereas 
those with the most severe premorbid impairments remain stable (chapter 2). 
The cognitive instability around the first episode of psychosis in subjects with higher premorbid capacities 
makes the use of cognitive impairments as endophenotypic markers in these subjects potentially problematic, 
as cognitive assessments in this time-period may reflect illness-related, state-dependent characteristics rather 
than stable, endophenotypic traits suitable for genetic analyses.  
 Nevertheless, the global stability of cognitive measures from premorbid level up to at least ten years into the 
illness suggests that cognition could be a useful endophenotypic trait for genetic analyses, which is 
underscored by the finding that cognitive measures were able to differentiate between patients with a more 
neurodevelopmental and a more reactive profile (chapter 2) and had a direct relationship with functional 
outcome, cross-sectionally as well as prospectively (chapter 3), but only when premorbid or cognitive 
measures in patients with a certain illness duration were used. 
Other points of consideration also need to be addressed. First, the type of cognitive test may be important 
when assessing cognition as an endophenotype. Estimates of heritability are particularly high for IQ measures 
(Wright et al., 2001), but recent evidence suggest that the often used Wisconsin Card Sorting Test may not be 
an ideal marker for cognitive heritability (Kremen et al., 2007). Second, the use of cognitive impairments as 
endophenotypic measures for schizophrenia within families assumes developmental equivalence; however, 
cognitive tests may not measure the same cognitive domain in children or older adults, and the heritability of 
cognitive skills likely destabilizes after the age of 50 (Kaprio and Koskenvuo, 2002). This illustrates the 
importance of carefully choosing the most adequate age range, balancing sample size and test- equivalence.  
 
The use of subtypes for genetic analyses 
Chapter 2 showed that cognitive measures, more specifically estimated premorbid IQ, could be used to 
distinguish patients with a more ‘neurodevelopmental’ and a more ‘reactive’ expression of the illness. 
Differences in clinical presentation between these patients have lead some researchers to put forward the 
concept of the ‘deficit syndrome’ consisting of patients with enduring, idiopathic negative symptoms 
(Kirkpatrick et al., 2001). The ‘deficit syndrome’ is suggested to identify individuals with a more 
homogeneous expression of the illness, or even a separate illness category (Kirkpatrick et al., 2001), although 
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the latter is in disagreement with a recent taxometric study on patients with schizophrenic and non-
schizophrenic psychotic disorders (Cuesta et al., 2007). It has been suggested that genetic association analyses 
in these patients could prove to be productive (Hallmayer et al., 2005), but genetic studies so far have failed to 
find positive, ‘deficit’-specific associations with candidate genes such as COMT, neuregulin, DTNBP1 
(dysbindin), G72/G30, RGS4 and PIP5K2A (Bakker et al., 2007; Wonodi et al., 2006; Bakker et al., 2004). 
Although selection of specific subsamples within a certain clinical syndrome could be productive for the 
identification of disease genes, the importance of environmental factors in the expression or non-expression of 
psychosis in at-risk persons and the continuous rather than dichotomous distribution of positive, negative and 
desorganisation symptom domains of psychosis (Cuesta et al., 2007) could hamper the applicability of this 
approach for schizophrenia. Furthermore, this approach demands large samples of patients given the necessity 
to compare two patient samples (‘deficit’ versus ‘non-deficit’ patients). Studying endophenotypic outcomes in 
a more homogeneous ‘deficit’ sample would also reduce variability and thus the sensitivity of genetic 
analyses, making it unfavorable to study endophenotypic outcomes in homogeneous samples such as patients 
with the ‘deficit syndrome’ (Szatmari et al., 2007).  
 
Stress-sensitivity as endophenotypic marker for schizophrenia 
Stress-sensitivity: endophenotype? 
Stress-sensitivity was only recently put forward as a possible endophenotype for psychosis (Lataster et al., 
2007). A large body of evidence suggests a role of stress in the etiology of psychosis (Bebbington et al., 1993; 
Bebbington et al., 1996; Carr et al., 2000; Bebbington and Kuipers, 1994; Butzlaff and Hooley, 1998; Brown 
et al., 1972), making a possible role of stress-sensitivity biologically plausible. Quantification of stress-
sensitivity by using ESM allowed to show that patients with schizophrenia are more stress-sensitive than 
controls, with first-degree relatives scoring intermediate (Myin-Germeys et al., 2001; Myin-Germeys et al., 
2005). These studies also found evidence for state-independency, as they investigated stress-sensitivity in 
remitted patients. Furthermore, evidence was found for cosegregation within families (Lataster et al., 
submitted). These findings show that stress-sensitivity is associated with the illness (criterion 1), that it is 
presumably heritable (criterion 2), that it is state-independent (criterion 3), that it cosegregates with the illness 
within families (criterion 4) and is also found in a higher rate in unaffected relatives than in the general 
population (criterion 5). These findings suggest that stress-sensitivity is indeed a useful endophenotype for 
schizophrenia. 
Nevertheless, some issues need to be considered. Although stress-sensitivity was present in remitted patients, 
which suggests state-independency, there have been no studies that have specifically assessed the stability of 
stress-sensitivity over longer periods of time. Concerns of within-person trait-stability, developmental 
equivalence and test-retest reliability therefore are concerns that need to be addressed.  
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Genes for stress-sensitivity in psychosis  
This thesis was the first to show genetic moderation of stress-sensitivity in patients with psychosis, more 
specifically by COMTVal158Met (chapter 4), and also suggested that COMTVal158Met could have a relevant 
etiological role in the formation of psychotic and affective symptoms in at-risk persons (chapter 5).  
These findings suggest that stress-sensitivity may be an important intermediate factor in gene-to-disorder 
pathways, that could play a crucial role in the development of both affective as well as psychotic 
symptomatology. Given the considerable overlap between affective and psychotic disorders in terms of 
genetic risk (Craddock et al., 2006; Cardno et al., 2002) and clinical comorbidity (Murray et al., 2004), 
understanding the role of stress-sensitivity in the formation of symptoms and its genetic underpinning could 
prove to be a large step forward in our understanding of the etiology of these disorders.  
Of interest in this regard is a recent study in subjects with a varying degree of susceptibility to depression that 
investigated the influence of COMTVal158Met on endocrine and subjective responses to a psychological stress 
task, showing an increased subjective response to psychological stress with increased Met loading in both 
healthy and depressed subjects, but a stronger endocrine response in controls with increased Met loading only 
(Jabbi et al., 2007a). These results do not only suggest that Met alleles are involved in subjective appraisals on 
situations that evoke negative affective states (ie stress-sensitivity), but the dissociation between subjective 
and endocrine responses to psychological stress in depressed subjects also suggests that it is in interaction 
with altered HPA axis functioning that this could lead to depression, although the issue of reverse causality 
needs to be addressed in future studies.  
Further candidate genes for stress-sensitivity were reported by the same group, showing that next to 
COMTVal158Met,  polymorphic variations in genes coding for serotonin transporter (SERTPR), monoamine 
oxidase A (MAOA) as well as sex differences influence the regulation of hypothalamic-pituitary-adrenal 
(HPA)-axis response to acute psychological and endocrine challenges in subjects with a varying degree of 
susceptibility to depression (Jabbi et al., 2007b). Similar results were reported in a mixed sample of patients 
with depression and bipolar disorder, where both COMTVal158Met and SERTPR were associated with the 
development of depression in reaction to life stressors in the preceding year, and significant interaction 
between COMTVal158Met and SERTPR was also found (Mandelli et al., 2006). 
Other interesting polymorphisms include a variable number tandem repeat in the dopamine transporter gene 
(DAT VNTR), given its role in dopamine reuptake, and a Val66Met polymorphism of Brain-Derived-
Neurotrophic-Factor (BDNF), as there is growing evidence that stress decreases the expression of BDNF in 
limbic structures involved in affective regulation (Duman and Monteggia, 2006).  
 
Metabolic disturbances for schizophrenia research 
Metabolic disturbances as endophenotype?
Differential effects of antipsychotic treatment, as were also shown in this thesis (chapters 6 and 7), complicate 
the applicabilility of metabolic disturbances as a candidate endophenotype for schizophrenia. Therefore, this 
thesis focused on basic clinical questions, such as investigation of guidelines (chapter 6), incidence of new-
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onset diabetes (chapters 6 and 7) and assessment of prevalence of metabolic disturbances in bipolar disorder 
(chapter 8), which confirmed the major clinical importance of these abnormalities. 
Despite its questionable use for genetic research on schizophrenia, findings that metabolic disturbances are 
also consistently higher in unmedicated first-episode patients (Thakore et al., 2002; Cohn et al., 2006; Ryan et 
al., 2003; Spelman et al., 2007) and non-affected relatives (Mukherjee et al., 1989; De Hert et al., 2006; 
Lamberti et al., 2004) however confirm that these abnormalities are also present in the absence of 
antipsychotic medication and can thus be seen as biological markers of schizophrenia and possibly also 
bipolar disorder. The biological plausibility of metabolic disturbances as intermediate factors in gene-to-
disorder pathways of psychosis is however far from clear.  
A first clue on a possible biological mechanism relating metabolic disturbances and psychosis comes from a 
metabolic profiling study of cerebrospinal fluid (CSF) in 82 patients with psychosis, of whom 54 were first-
episode, drug-naïve patients, and 70 healthy controls (Holmes et al., 2006). This study showed a significantly 
elevated concentration of glucose (and decreased concentrations of acetate and lactate) in the CSF of first-
episode, drug-naïve patients compared to healthy controls, whereas serum glucose levels showed no 
difference, suggesting a brain-specific elevation of glucose levels in first-episode, drug-naïve patients. Short-
term treatment for an average of about 9 days with atypical medication resulted in normalization of the CSF 
metabolic profile in 58% of these first-episode patients, whereas no normalization occurred in patients that 
were only treated with antipsychotic medication after their second psychotic episode, although it has to be 
noted that this was a very small group (n=7). Nevertheless, these data may suggest that brain-specific 
alterations in glucoregulation could be involved in the etiology and response to treatment of psychosis, and 
align with a postmortem brain tissue study (Prabakaran et al., 2004), that demonstrated significant alterations 
of pathways relating to glucoregulation and mitochondrial functioning in patients with schizophrenia. 
Although these findings demonstrate that pathways of glucoregulation could be relevant for the etiology of 
schizophrenia, findings from this thesis suggest that its peripheral correlates, ie metabolic abnormalities, can 
not be considered as stable, ‘endophenotypic’ traits suited for genetic analyses aiming to investigate 
etiological mechanisms for schizophrenia, given the large and differential impact of atypical antipsychotics on 
prevalence and incidence rates of metabolic abnormalities, as was demonstrated in chapters 6 and 7. 
Furthermore, the increase of metabolic abnormalities with age (developmental unequivalence) and the 
possibility of familial aggregation caused by non-genetic factors such as social class, lifestyle and dietary 
habits make the use of metabolic abnormalities as endophenotypic measures unfavorable.  
 
Strategies for research on metabolic abnormalities in schizophrenia
Despite the conclusion that the use of metabolic abnormalities as endophenotypic measures is unfavorable, 
findings that suggest that brain-specific glucodysregulation could be involved in the etiology of schizophrenia 
imply that this area certainly merits further research. A potentially productive strategy could be to combine 
basic clinical research on metabolic abnormalities, such as examination of guidelines and assessment of risk 
factors for the development of metabolic abnormalities such as differential medication effects, dietary 
measures and life style changes, with fundamental research focusing on mechanisms that can be assumed to 
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be more proximal to the supposedly etiologically relevant effects of glucodysregulation than the peripheral 
metabolic abnormalities themselves. These studies could also more specifically address the question whether 
the increased rates of metabolic abnormalities in patients and unaffected relatives is under genetic control or is 
the result of shared environmental factors such as social class, lifestyle and dietary habits.    
Furthermore, future studies could focus on interactions between drugs and susceptibility genes for metabolic 
disturbances or schizophrenia, ie pharmacogenetic studies. Studying interactions between metabolic genes and 
antipsychotics could give important answers to who is at risk for developing metabolic abnormalities, whereas 
studying interactions between schizophrenia susceptibility genes and antipsychotics could also guide the 
search for possibly shared etiological mechanisms between metabolic disturbances and schizophrenia. These 
type of studies could also provide a step forward in predicting the risk to develop metabolic abnormalities and 
could thus may be helpful in guiding treatment choices in the future. Studies investigating these kind of gene-
drug interactions, for example, have found significant associations between a Leptin G2548A polymorphism 
and clozapine-induced weight gain (Zhang et al., 2007) and between a 5-HT2C receptor C759T 
polymorphism and antipsychotic-induced weight gain (Ryu et al., 2007). 
 
Are reported associations specific for schizophrenia? 
The use of endophenotypes provides a potentially powerful approach in the search for schizophrenia 
susceptibility genes. As stated previously, the underlying assumption is that individual endophenotypes are 
determined by fewer genes than the more complex and etiologically heterogeneous phenotype of 
schizophrenia, and that investigating endophenotypic outcomes would thus reduce the complexity of genetic 
analyses. In other words, the rationale of the endophenotypic approach is to reduce complexity in order to 
increase sensitivity of genetic analyses.  
Broadening the subject of genetic analyses to endophenotypes may however lead to loss of specificity. For 
example, increased stress-sensitivity (Myin-Germeys et al., 2003) has also been shown in bipolar disorder and 
major depression, and associations between COMTVal158Met and affective regulation have also been shown in 
the general population (Drabant et al., 2006; Smolka et al., 2005).  
This could indicate that the role of specific genes may be similar for patients with schizophrenia or affective 
disorders as for the general population, which can be considered as insufficient evidence to support a specific 
role of this particular gene in the etiology of schizophrenia. Study designs that assess genetic moderation of 
subclinical symptomatology in subjects at risk may help to clarify whether reported genetic associations could 
indeed be relevant for the etiology of the disorder. For instance, this thesis suggested that COMTVal158Met is 
associated with stress-sensitivity in patients with psychosis (chapter 4), and that this could be a relevant 
mechanism for the development of psychotic and affective symptomatology in an at-risk population (chapter 
5).  
Furthermore, the role of specific genes may be quantatively rather than qualitatively different for patients with 
schizophrenia versus patients with affective disorders or subjects from the general population. For instance, in 
the earlier reported comparative study on stress-sensitivity in subjects with diagnoses of non-affective 
psychosis, bipolar disorder, major depression and healthy subjects, significant quantitative differences 
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between groups were found for the degree of stress-sensitivity, with subjects with a diagnosis of non-affective 
psychosis being most vulnerable to the effects of daily life stress (Myin-Germeys et al., 2003).  
This indicates that, although stress-sensitivity is likely to be involved in the etiology of psychosis, it is not 
specific for patients with schizophrenia, suggesting that the development of psychopathology does not follow 
diagnostic categories and that general psychopathological mechanisms such as stress-sensitivity may interact 
with other mechanisms to result in specific psychopathology. Thus, quantitative trait differences may only 
become relevant in the presence of specific environments and in interaction with (deficits in) other biological 
mechanisms. For stress-sensitivity, this was supported by the recent study of Jabbi and colleagues (Jabbi et al., 
2007a) who found stronger subjective reactions to a psychological stress task with increased COMTVal158Met 
Met loading in both healthy and depressed subjects (ie stress-sensitivity), but a stronger endocrine response in 
controls with increased Met loading only. These findings indicate that future genetic research will have to 
generate specific hypotheses in order to be able to study and understand the complex actions of genes, their 
interactions with other genes and the environment in the etiology of psychiatric disorders.    
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SUMMARY 
 
The use of endophenotypes is a relatively novel approach to the genetics of complex disorders. For 
schizophrenia, several traits have been proposed as candidate endophenotypes for schizophrenia, yet the use 
of the term endophenotype has broadened over recent years to include traits that are biological markers rather 
than true endophenotypes. Furthermore, several candidate endophenotype have not been evaluated for key 
endophenotype characteristics. This thesis, Evaluation of candidate endophenotypes for schizophrenia, 
evaluates the usefulness of cognition, stress-sensitivity and metabolic disturbances as endophenotypes for 
schizophrenia. 
 
Chapter 1 describes the phenomenology of schizophrenia and the as of yet relatively unsuccesful attempt to 
find genes underlying it. The failure to identify schizophrenia genes through genetic association studies have 
lead to alternative approaches such as studies taking into account gene-environment interaction and 
replacement of the dichotomous disorder-outcome with continuous, ‘endophenotypic’ outcomes. The concept 
of endophenotypes is introduced, as being quantifiable intermediate factors in the genes-to-behaviors 
pathways which make genetic and biological studies for disease categories more manageable. Five criteria 
distinguish endophenotypes from biological markers: 1. they are associated with the illness in the population, 
2. they are heritable, 3. they are state independent, 4. they cosegregate with the ilness within families and 5. an 
endophenotype identified in probands is found in their unaffected relatives at a higher rate than in the general 
population. Based on these criteria and available literature on the three candidate endophenotypes, specific 
research questions are delineated. For cognitive impairments, the aim was to evaluate the course of the global 
cognitive measure IQ in patients who presented with a first episode of psychosis and to investigate possible 
differences in course of IQ resulting from underlying phenotypic heterogeneity. A second aim was to 
investigate the relationship between IQ measures and functional outcome in this sample of first-episode 
patients. For stress-sensitivity, the aim was to evaluate whether COMTVal158Met would moderate the psychotic 
and affective reaction to daily life stressors in a sample of patients with psychosis and controls, and to 
evaluate whether this possible COMTVal158Met moderation could also be a causal mechanism in the 
development of psychosis, by assessing whether unaffected first-degree relatives of patients with 
schizophrenia who share a Met allele have greater concordance of subclinical symptomatology than relatives 
not sharing a Met allele. For metabolic abnormalities, aims were to assess the comparative adequacy of the 
widely used American Psychiatric Association/American Diabetes Association (APA/ADA) screening 
guidelines for detecting diabetes versus a screening guideline derived from the guidelines of the World Health 
Organization (WHO), to evaluate early changes in glucose metabolism after initiation of an atypical 
antipsychotic and to also assess the prevalence of metabolic abnormatlities in a sample of patients diagnosed 
with bipolar disorder. 
  
Following these specific research questions, Chapter 2 described the longitudinal course of IQ in first episode 
patients diagnosed with schizophrenia. After ten years follow-up, there was no evidence for a deterioration of 
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IQ. The hypothesis that estimated premorbid IQ would moderate the course of IQ was confirmed. 
Dichotomization revealed that in the high IQ group, which was hypothesized to reflect the ‘episodic subtype’, 
IQ measures did not remain stable over the follow-up period. A significant deterioration at the first 
hospitalization was seen, followed by an improvement up to premorbid level. In the low IQ group, which was 
hypothesized to reflect the ‘neurodevelopmental subtype’ a stable course of IQ was found. Chapter 3 
assessed the presence of a prospective association between cognition and functional outcome in first episode 
patients with schizophrenia. The presence of a prospective as well as a cross-sectional relationship of the 
global cognitive measure IQ with 10-year functional outcome could be established. However, it was also 
found that assessing associations between cognitive measures at first hospitalization and subsequent 
functional outcome can give inconclusive results due to non-uniform intellectual deterioration from premorbid 
level in the period preceding the first hospitalization. These findings may help to explain the controversy in 
the literature regarding the prospective relationship between cognitive measures and subsequent functional 
outcome between chronic and first episode patients. 
 
In Chapter 4, it was found that patients with psychosis and comorbid cannabis use react more strongly to 
stress than healthy cannabis users, showing an increase in psychotic and affective symptoms. Interestingly, 
there also was evidence for an interaction between stress and  COMTVal158Met genotyped on increases in 
psychotic and affective symptoms, with patients with the Met/Met genotype showing the largest increases in 
symptomatology. These findings indicate the importance of taking gene-environment interaction into account 
in explaining transitions in momentary symptomatology in psychosis. In Chapter 5, we aimed to test the 
hypothesis that the COMTVal158Met Met allele is causally implicated in the development of affective and 
psychotic symptomatology in subjects genetically at risk for schizophrenia, by testing if first-degree relatives 
of patients with schizophrenia who share a Met allele have greater concordance of symptomatology than 
relatives not sharing a Met allele. The results showed that when relatives shared a Met allele, subclinical 
symptomatology showed significant concordance. This was not the case when relatives did not share a Met 
allele, which suggests that the Met allele may be involved in the causation of psychopathology, at least in 
populations with a genetic predisposition to psychosis. 
 
In Chapter 6, the diagnostic properties of two different screening guidelines for the detection of diabetes in 
patients diagnosed with schizophrenia was evaluated: 1) assessing fasting glucose in all patients, as suggested 
by the American Psychiatric Association/American Diabetes Association (APA/ADA) and 2) a screening 
strategy derived from the guidelines of the World Health Organization (WHO) of assessing fasting glucose in 
all patients (step one), and subsequently performing an OGTT in patients with impaired fasting glucose (step 
two).  
The screening based on the APA/ADA guidelines detected less than half of the diabetes cases identified by 
the OGTT, whereas the proposed two-step strategy detected all but 1 diabetes cases. The data also suggested a 
high incidence of diabetes in patients diagnosed with schizophrenia. Chapter 7 investigated the early changes 
in glucose metabolism in a naturalistic sample of patients with schizophrenia newly started on or switched to 
158
specific atypical antipsychotic medication. A significant proportion of these patients (4.4%) developed new-
onset diabetes within 3 months. Initiation of clozapine resulted in a significantly higher risk for new-onset 
glucose abnormalities than initiation of aripiprazole. Furthermore, the evolution of glucose levels was 
significantly worse in patients initiated on clozapine, olanzapine and quetiapine than in patients initiated on 
aripiprazole. Clozapine was also significantly more deleterious than risperidone and amisulpride for fasting 
glucose changes. Type of initiation (start or switch) did not affect any of the metabolic parameters. Chapter 8 
showed that the metabolic syndrome and glucose abnormalities are not only highly prevalent in patients with 
schizophrenia but also in patients with bipolar disorder, implicating that assessment of metabolic 
abnormalities should be also part of the clinical management of patients with bipolar disorder. 
  
Chapter 9 summarizes the evidence for and applicability of cognition, stress-sensitivity and metabolic 
abnormalities as endophenotypes for schizophrenia. The cognitive instability around the first episode of 
psychosis in subjects with higher premorbid capacities makes the use of cognitive impairments as 
endophenotypic markers in these subjects potentially problematic, as cognitive assessments in this time-period 
may reflect illness-related, state-dependent characteristics rather than stable, endophenotypic traits suitable for 
genetic analyses.  
 Nevertheless, the global stability of cognitive measures from premorbid level up to at least ten years into the 
illness suggests that cognition could be a useful endophenotypic trait for genetic analyses, which is 
underscored by the finding that cognitive measures were able to differentiate between patients with a more 
neurodevelopmental and a more reactive profile (chapter 2) and had a direct relationship with functional 
outcome, cross-sectionally as well as prospectively (chapter 3), but only when premorbid or cognitive 
measures in patients with a certain illness duration were used. With regard to stress-sensitivity, findings show 
that it is associated with the illness (criterion 1), that it is presumably heritable (criterion 2), that it is state-
independent (criterion 3), that it cosegregates with the illness within families (criterion 4) and is also found in 
a higher rate in unaffected relatives than in the general population (criterion 5). These findings suggest that 
stress-sensitivity is indeed a useful endophenotype for schizophrenia, although within-person trait-stability, 
developmental equivalence and test-retest reliability are concerns that need to be addressed in future research. 
Furthermore, the findings of this thesis suggest that COMTVal158Met is a viable candidate gene for stress-
sensitivity in psychosis, that could be related to the development of psychotic and affective symptoms in 
subjects with a genetic predisposition. Although available literature has found that pathways of 
glucoregulation could be relevant for the etiology of schizophrenia, findings from this thesis suggest that its 
peripheral correlates, ie metabolic abnormalities, can not be considered as stable, ‘endophenotypic’ traits 
suited for genetic analyses aiming to investigate etiological mechanisms for schizophrenia, given the large and 
differential impact of atypical antipsychotics on prevalence and incidence rates of metabolic abnormalities, as 
was demonstrated in chapters 6 and 7. Furthermore, the increase of metabolic abnormalities with age 
(developmental unequivalence) and the possibility of familial aggregation caused by non-genetic factors such 
as social class, lifestyle and dietary habits make the use of metabolic abnormalities as endophenotypic 
measures unfavorable. The implications of these findings, as well as suggestions for future research are given.  
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SAMENVATTING
 
Schizofrenie is wellicht de meest ernstige psychiatrische stoornis en heeft een hoge mate van erfelijkheid. 
Schizofrenie wordt gekenmerkt door wanen, hallucinaties, verward gedrag, affectvervlakking, verlies van 
initiatief en sociale terugtrekking. Ook affectieve problemen komen veelvuldig voor. Hoewel er 
overeenstemming is over de symptomen die voorkomen bij schizofrenie, is het klinisch beeld van individuele 
patiënten onderling erg verscheiden, hetgeen het zoeken naar causaal betrokken genen bemoeilijkt.  
Het gebruik van endofenotypes is een relatief recente benadering voor de genetica van complexe stoornissen 
zoals schizofrenie. Verschillende kenmerken werden al voorgesteld als kandidaat endofenotypes, hoewel het 
gebruik van de term endofenotype recent ten onrechte uitgebreid werd naar kenmerken die eerder biologische 
markers dan echte endofenotypes zijn. Daarnaast werden verschillende goede kandidaat endofenotypes nog 
onvoldoende onderzocht op essentiële kenmerken van een endofenotype. Deze thesis, Evaluation of candidate 
endophenotypes for schizophrenia, evalueert de toepasbaarheid van cognitie, stressgevoeligheid en metabole 
stoornissen als endofenotypes voor schizofrenie. 
 
Hoofdstuk 1 beschrijft de fenomenologie van schizofrenie en de tot nu toe relatief weinig succesvolle 
pogingen om risicogenen voor deze aandoening te vinden. Doordat de klassieke methodes weinig succes 
kenden werden er alternatieve methodes gezocht, zoals studies die zich richtten op gen-omgevingsinteracties 
en op continue, endofenotypische maten in plaats van op de aan- of afwezigheid van een bepaalde stoornis. 
Het concept endofenotype wordt geïntroduceerd, als zijnde quantificeerbare kenmerken die intermediair zijn 
tussen genen en gedrag. Vijf criteria onderscheiden endofenotypes van gewone biologische markers: 1. ze zijn 
geassocieerd met de ziekte, 2. ze zijn erfelijk, 3. ze zijn onafhankelijk van de fase van de ziekte, 4. ze 
segregeren samen met de ziekte binnen families en 5. endofenotypes worden in gezonde familieleden in 
verhoogde mate gevonden in vergelijking met de algemene bevolking. Gebaseerd op deze criteria en op de 
beschikbare literatuur voor de kandidaat endofenotypes worden vervolgens een aantal specifieke 
onderzoeksvragen geformuleerd. Voor cognitieve stoornissen was het doel om het verloop van IQ als globale 
maat voor cognitie te onderzoeken bij eerste episode patiënten, en met name mogelijke verschillen in het 
verloop van IQ die onderliggend zouden kunnen zijn aan onderliggende fenotypische heterogeniciteit. Een 
tweede doelstelling was om de relatie tussen IQ en outcome te onderzoeken in deze patiëntengroep. Voor 
stressgevoeligheid was het doel om te onderzoeken of een kandidaat genetisch polymorphisme in het COMT 
gen, COMTVal158Met, de psychotische en affectieve reacties op stress in het dagelijkse leven zou modereren bij 
patiënten met psychose en bij gezonde proefpersonen, en of deze mogelijke moderatie ook causaal betrokken 
zou kunnen zijn bij de ontwikkeling van psychose. Voor metabole stoornissen waren de doelstellingen om 
twee verschillende guidelines voor het opsporen van diabetes bij schizofrene patiënten te evalueren. Verder 
waren doelstellingen om de vroege veranderingen na het opstarten van een atypisch antipsychoticum te 
belichten en om ook de prevalentie van metabole stoornissen bij bipolaire patiënten te onderzoeken.    
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Vertrekkende vanuit deze specifieke onderzoeksvragen wordt in Hoofdstuk 2 het longitudinale verloop van 
IQ in eerste episode patiënten beschreven. Na tien jaar opvolging was er geen evidentie voor een afname van 
IQ. De hypothese dat geschat premorbied IQ het verloop van IQ zou modereren werd bevestigd. 
Dichotomizatie maakte duidelijk dat in de groep met het hoogste IQ, die verondersteld werd om het 
‘episodische subtype’ te vertegenwoordigen, IQ niet stabiel bleef gedurende de periode van opvolging. Een 
significante daling van IQ bij de eerste opname werd gevolgd door een verbetering tot op het premorbide 
niveau. Bij de groep met het laagste IQ, die verondersteld werd om het ‘neurodevelopmental subtype’ te 
vertegenwoordigen, werd daarentegen wél een stabiel IQ gemeten. Hoofdstuk 3 onderzocht of er een verband 
was tussen cognitie en outcome bij deze patiënten. De aanwezigheid van zowel een prospectief als een cross-
sectioneel verband tussen IQ en de outcome na 10 jaar kon worden aangetoond. Daarentegen werd opgemerkt 
dat er geen verband was tussen IQ gemeten bij de eerste episode en outcome na tien jaar. Deze bevindingen 
zouden de controverse in de literatuur over een mogelijk prospectief verband tussen cognitie en outcome 
kunnen verklaren. 
 
In Hoofdstuk 4 wordt beschreven dat cannabis gebruikende patiënten met psychose sterker op stress reageren 
dan gezonde cannabis gebruikers. Verder was er ook bewijs voor een interactie tussen stress in het dagelijkse 
leven en COMTVal158Met op psychotische en affectieve symptomen, waarbij patiënten met het Met/Met 
genotype de grootste toename van symptomatologie vertoonden. In Hoofdstuk 5 werd de hypothese getest 
dat het COMTVal158Met Met allel causaal verbonden is met de mogelijke ontwikkeling van affectieve en 
psychotische symptomen bij mensen die een genetisch risico op schizofrenie hadden, namelijk eerstegraads 
familieleden van patiënten met schizofrenie. Wanneer familieleden een Met allel deelden, was er een 
significante concordantie van subklinische symptomatologie. Dit was niet het geval wanneer familieleden 
geen Met allel deelden, wat een mogelijke betrokkenheid van dit allel in het ontstaan van psychopathologie 
suggereert, tenminste bij mensen met een genetische predispositie voor psychose. 
 
In Hoofdstuk 6 worden de diagnostische eigenschappen van twee screenings guidelines voor de opsporing 
van diabetes bij patiënten met schizofrenie met elkaar vergeleken: 1) het bepalen van een nuchtere glycemie 
bij alle patiënten, zoals wordt voorgesteld door de American Psychiatric Association/American Diabetes 
Association (APA/ADA) en 2) een screenings strategie afgeleid van de guidelines van het WHO, namelijk het 
bepalen van een nuchtere glycemie bij alle patiënten (1e stap) en het vervolgens doen van een Orale Glucose 
Tolerantie Test (OGTT) bij patiënten met een verstoorde nuchtere glycemie. (2e stap). De screening gebaseerd 
op de guidelines van de APA/ADA detecteerde diabetes in minder dan de helft van de gevallen die werden 
geïdentificeerd door middel van de OGTT, terwijl de tweestapsstrategie op één na alle gevallen van diabetes 
detecteerde. Ook werd er een hoge incidentie van diabetes gevonden in deze studie. Hoofdstuk 7 belicht de 
vroege veranderingen in glucosemetabolisme bij patiënten bij wie een atypisch antipsychoticum werd 
opgestart. Een behoorlijk percentage van deze patiënten ontwikkelde diabetes binnen de drie maanden na het 
opstarten van het antipsychoticum (4.4%). Het opstarten van clozapine gaf een significant hoger risico op het 
ontwikkelen van diabetes dan aripiprazole. Clozapine, olanzapine en quetiapine hadden ook een significant 
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slechter effect op glucosespiegels dan aripiprazole. Daarnaast was clozapine ook slechter dan risperidone en 
amisulpride met betrekking tot de evolutie van nuchtere glycemie. In Hoofdstuk 8 werd aangetoond dat het 
metabool syndroom en glucose afwijkingen niet alleen vaak voorkomen bij patiënten met schizofrenie maar 
ook bij mensen met bipolaire stoornis, wat betekent dat de evaluatie van deze metabole stoornissen ook 
onderdeel zou moeten zijn van de behandeling van mensen met een bipolaire stoornis.   
 
In Hoofdstuk 9 wordt de evidentie en toepasbaarheid van cognitie, stressgevoeligheid en metabole 
stoornissen als endofenotypes voor schizofrenie samengevat. De cognitieve instabiliteit rondom de eerste 
psychotische episode bij patiënten met een hoger premorbied IQ maakt het gebruik van cognitieve stoornissen 
als endofenotypische markers potentieel problematisch, omdat in tegenstelling tot de vereisten voor een 
endofenotype, cognitie gemeten in deze periode niet stabiel en betrouwbaar is. Dit terwijl cognitie op langere 
termijn, namelijk van voor de ziekte tot tenminste tien jaar na aanvang, juist wél stabiliteit vertoont. Dit 
suggereert dat cognitie wél een goede endofenotypische marker zou kunnen zijn, hetgeen versterkt wordt door 
de bevinding dat cognitieve maten in staat waren om te differentiëren tussen patiënten met een meer 
‘neurodevelopmental’ profiel en patiënten met een meer ‘episodisch’ profiel (Hoofdstuk 2), en ook een direct 
verband vertoonden met outcome, zowel cross-sectioneel als prospectief (Hoofdstuk 3). De bevindingen met 
betrekking tot stressgevoeligheid toonden aan dat stressgevoeligheid geassocieerd is met de ziekte (1e 
criterium), dat het vermoedelijk genetisch is (2e criterium), dat het onafhankelijk is van het stadium van de 
ziekte (3e criterium), dat het met de ziekte cosegregeert binnen getroffen families (4e criterium) en dat het in 
verhoogde mate wordt gevonden in eerstegraads familieleden dan in de algemene bevolking (5e criterium). 
Deze bevindingen suggereren inderdaad dat stressgevoeligheid een goed endofenotype zou kunnen zijn voor 
schizofrenie, hoewel de stabiliteit binnen personen, test - hertest betrouwbaarheid en de invloed van leeftijd 
nog nader onderzoek behoeven. De bevindingen tonen ook aan dat COMTVal158Met mogelijk betrokken is bij 
verhoogde gevoeligheid aan stress en het ontwikkelen van symptomatologie. Hoewel er literatuur is die heeft 
aangetoond dat pathways van glucoregulatie mogelijk relevant zijn voor de etiologie van schizofrenie, tonen 
de bevindingen van deze thesis dat de perifere correlaten hiervan – metabole afwijkingen – geen stabiele, 
‘endofenotypische’ kenmerken zijn die geschikt zijn voor genetische analyses naar schizofrenie, gezien de 
grote en differentiële impact van atypische antipsychotica op prevalentie- en incidentiecijfers van diabetes en 
andere metabole stoornissen, zoals werd aangetoond in hoofdstukken 6 en 7. Daarnaast maakt de toename van 
metabole stoornissen met de leeftijd en de mogelijkheid dat niet-genetische de familiale aggregatie van 
metabole stoornissen veroorzaken het gebruik van metabole stoornissen als endofenotypische maat 
onwenselijk. De implicaties van deze bevindingen, alsmede suggesties voor toekomstig onderzoek worden 
besproken.    
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